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“Nobody ever figures out what life is all about, and it doesn't matter. 
Explore the world. 
Nearly everything is really interesting if you go into it deeply enough.” 
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1.1   The role of computational methods in drug   
discovery 
In the last decades, the applications of computational methods in medicinal 
chemistry have experienced significant changes which have incredibly expanded 
their approaches, and more importantly their objectives.   
Indeed, computational methods were initially focused on the rational design of 
novel improved bioactive molecules. Using both ligand-based and structure-based 
approaches, the in silico studies were primarily focused on parameterizing the 
ligand-receptor binding processes and were substantially aimed at optimizing the 
ligand structure in terms of affinity, potency and selectivity. Usually, these studies 
involved a few dozen of compounds and their primary objective was to extract 
qualitative or (better) quantitative relationships to guide the rational design of novel 
(hopefully improved) derivatives. Not surprisingly, the most utilized and simplest 
way to define such kind of computational studies was “drug design” because all 
their objectives were limited to ligand design and optimization.   
Over time, computational applications felt a rich extension of their objectives and 
one of the clearest examples in this context is represented by the ever increasing 
applications of the in silico tools to optimize the ADME/Tox profile of the novel 
compounds. In fact, the development of computational models to predict 
ADME/Tox parameters is surely older and dates back to the 70s, but only on the 
last decades these approaches are applied in a comprehensive and synergistic way 
and, more importantly, during the early stage of the discovery process, to focus the 
attention only on the most promising derivatives, so limiting the remarkable 
attrition caused by unsuitable pharmacokinetic profiles. In particular, the last two 
decades have seen an incredibly increasing effort spent in developing reliable 
approaches for metabolism prediction, especially as an inappropriate metabolic 
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profile is probably the most impeding attrition cause in drug discovery and 
development. 
In parallel, computational methods are finding successful applications in the 
research phase which precedes the ligand design and which is focused on a detailed 
validation and characterization of the biological target. In this context, in silico 
approaches can be conveniently exploited, for example, to elucidate the mechanism 
of action at an atomic level, to explore the role of secondary/allosteric binding sites 
and to deorphanize new receptors or new binding pockets. Also here, the protein 
modeling techniques are clearly older, but recently they found new avenues with 
the incredibly increasing number of potential targets coming from the “omics” 
disciplines. On these grounds, we can notice that nowadays computational 
approaches can support the drug discovery pipeline in all its phases, starting from 
the target validation, to hit selections, until lead optimization. 
Moreover, the above mentioned “omics” disciplines dictated also a remarkable 
change in the commonly used in silico approaches, or at least in their founding 
philosophy. Indeed and as said above, old analyses usually involved a limited 
number of derivatives and only one ( or at most very few) targets, whereas a typical 
current study can include thousands compounds potentially interacting with many 
targets. This change of paradigm required the development of novel computational 
approaches able to manage such an incredibly huge amount of data. When 
considering the biological (proteins and genes) data analyses, these approaches are 
often referred by using the term of bioinformatics, the development of which 
paralleled in the last few years the advances in all omics techniques. Similarly, the 
huge amount of chemical data coming from these kinds of studies required the 
development of similar computational approaches which thus are defined with the 
overall term of chemoinformatics. 
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1.2   Aim of this PhD project 
During my PhD studies, I had the opportunity to make experience of the three 
principal application areas of computational methods in drug discovery, as I have 
mentioned before, and to divide my efforts between the hit selection phase, as well 
as the target validation one and, finally, the lead optimization and traditional drug-
design studies.  
The first and main object of my project regards the field of metabolism prediction, 
and is based upon the meta-analysis and the corresponding metabolic database, 
called MetaSar, manually collected in a collaborative project involving our 
research group. The aim of this database, the compilation of which required a great 
deal of effort and a long work, is the building of a global predictive algorithm, and 
is perfectly in line with the actual trend in drug discovery which gives increasing 
importance to the metabolic fate of new leads, and thus recommends an earlier 
screening of the hit compounds based on their pharmacokinetic profiles.  
Among the numerous possible secondary applications of MetaSar, one in 
particular, the Proteochemometric modelling (PCM), consists in a predictive 
technique that is at the forefront of the latest modelling techniques, as it perfectly 
fits the growing request of new solutions to deal with big data. In this context, 
MetaSar represents an alternative and still appropriate source of data which enables 
the extension of the fields of application of this predictive technique to a new 
avenue, represented by metabolism prediction. As this methodology is relatively 
novel and based on innovative approaches, Chapter 2 is entirely dedicated to a 
description of the basics of PCM, while the computational details of our application 
to the glucuronidation reactions’ prediction and the obtained results are reported in 
Chapter 3.2 
Always involving the almost unexplored field of glucuronidation reactions on  
which PCM is focused, Chapter 3.3 reports also a second application of 
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computational approaches, represented by homology modelling techniques and MD 
simulations. In detail, the study involves the main isoform of glucuronidation 
enzymes in humans, UGT2B7, and uses Steered Molecular Dynamics (SMD) 
simulations to gain deeper insights on the reaction mechanism of this enzyme, as 
well as to optimize its homology model. 
A proper example of detailed validation and characterization of the biological 
target is given by the study about purinergic receptors, reported in Chapter 4, which 
is aimed at improving the knowledge about this promising and recently discovered 
biological target. In particular, the research regards the identification and 
characterisation of potential allosteric binding pockets for the already reported 
inhibitors, and involves not only standard docking-based modelling techniques but 
also applications of new approaches for binding site predictions (SPILLO-PBSS).  
The canonical computational methods are instead exploited in Chapter 5, which 
regards the muscarinic receptors. Beside the use of already well-known ligand-
based and structure-based approaches aimed at optimizing the ligand design, we 
applied also a novel method for target optimization, which explore the structural 
flexibility of the modelled GPCR structure by generating the so-called 
conformational chimeras. 
In conclusion, the overall aim of the present research project is to explore the 
different fields of the modelling studies by using different and innovative 
techniques, from the first examples to the more recent approaches, to contribute to 
draw the images of the frontiers in the world of chemoinformatics. 
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 2.1   Introduction 
This introductive chapter is aimed at presenting the methodological bases of an 
innovative computational technique, the Proteochemometric modelling (PCM), that 
we utilized in the prediction of the metabolism by UGT enzymes (see Chapter 3.4). 
The other here reported computational studies involved rather conventional 
approaches, and, as such, they do not deserve detailed methodological 
introductions. Therefore, their computational details will be separately described in 
each chapter.   
In this section, we are including two computational strategies which can be 
classified in a hybrid position between traditionally ligand-based and structure-
based approaches. They are mostly oriented towards the ligand space, but, with a 
different importance, they are also focused on the target space. They are both part 
of the wide world of Chemogenomics, and interdisciplinary field which lies in the 
interface of biology, chemistry, and informatics. Chemogenomics defines the 
systematic screening of the whole chemical universe against the whole targets 
universe, with the final aim to identify novel drugs as well as novel targets
1
 (Figure 
2.1).  
The ultimate goal can never be achieved but the realistic purpose is that, along this 
systematic screening, we can increase the chances in the research of compounds 
with significant targets.          
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Figure 2.1:  PCM and QSAR in the Chemogenomics world. 
 
 
 
 
2.2   Quantitative structure-activity relationships (QSAR) 
“Quantitative structure-activity relationships” (QSAR) is a conventional modelling 
technique that interprets the quantitative relationship between the bioactivity of a 
specific molecule and its structure. By using statistical approaches, it models the 
interactions of a group of compounds to a single target, in order to extrapolate the 
bioactivity of novel compounds on that specific target. This approach is founded on 
the principle of congenericity, by which chemicals sharing similar properties also 
share similar targets
2
.  
As QSAR considers just a single target, it has some limitations and drawbacks. 
First of all, to build the predictive model, it requires a good amount of data 
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available for ligands of that specific target, and this is a rare situation, especially 
when dealing with recently identified targets. Furthermore, it has an unsatisfactory 
ability to extrapolate into novel area of chemical space: this means that it is 
difficult to identify new classes of ligands or new binding modes outside the 
training set. Moreover, as traditional QSAR models are built using only compounds 
features, it is not even completely able to describe the interactions between that 
specific target and its ligands
3
. Indeed, the ligand-target interaction depends on the 
reciprocal affinity between chemicals and protein and to better describe this 
interaction it is necessary to take in consideration also the features of the binding 
site
4
. To overcome this drawback, some QSAR studies include also features 
depending on the specific target, such as docking scores or “cross-terms” of ligand 
and target features 
5
. This is the case in which the technique advances towards the 
structure-based approaches.    
 
 
2.3   Proteochemometric modelling (PCM) 
Proteochemometric modelling (PCM) is a computational technique that describes 
both small molecules and targets and combines description from the ligand and the 
biological side of the system within a single predictive algorithm, in order to 
completely model the compound-target interaction space. Thanks to the 
introduction of target descriptors in its data matrices, PCM can be regarded as an 
extension of the classical QSAR modelling and can actually overcome the 
limitations of that conventional technique. It permits to  extrapolate the bioactivity 
of novel compounds on both known targets and yet untested one
3
. 
Generally, the term “target” refers to protein, but it can also refers to protein-
complexes or to gene expression levels of particular cell lines and, conversely, to a 
specific part of the protein target, such as the binding site, enabling distinctions 
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between diverse binding pockets on the same protein, as well as different binding 
modes or protein conformations
5
.  
The relevance of considering more targets is also consistent with the recent 
overcoming of the so-called “one drug one target” paradigm and the demonstration 
that drugs exerts their therapeutic effects by modulating about six targets
6
. Thus, to 
exhaustively understand the effect of a given drug in a biological system, we 
cannot avoid describing the activity of that drug on all its targets. 
Moreover, including more targets in the input matrices of the model, it is possible 
to describe a different selectivity of these targets regarding their ligands. The 
capability to virtually screen selective compounds that are solely active on a single 
member of a subfamily of targets is of particular and increasing interest in the 
contest of drug discovery.   
The interesting advantage of PCM is that the model is able to simultaneously 
describe the interaction between a set of compounds and a set of targets without 
losing the capability to describe the interaction of an individual compound on an 
individual target inside the dataset. Of course, in order to build the best PCM 
model, it is important to have the maximum number of bioactivity data of multiple 
compounds on multiple targets. 
In summary, while QSAR and PCM are based on similar assumptions, PCM can 
benefits from additional information in model training, leading to additional 
results. It permits to outperform conventional QSAR methods and enlarges the 
principle of congenericity: not only compounds with similar features share similar 
targets, but also targets with similar compounds share similar features (Figure 2.2).  
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Figure 2.2: Heat map of ligand target interaction. The interaction between a set of ligand against 
a set of targets is represented in a matrix. The binding activity is calculated as pEC50 and transposed 
in colours according to the legend. Each matrix cell contains the binding activity of a given 
compound on a given target. QSAR models deal with the similarity between ligands and predict 
their activity on one target. On the contrary, traditional bioinformatics techniques deal with 
similarity between targets. PCM models are able to contemporary deal with both ligands and targets 
similarity, and thus they are capable of bioactivity interpolation from known targets to new 
compounds or from known compounds to new targets, and also of bioactivity extrapolation for new 
compounds on new targets.   
 
 
The first example of a predictive model including descriptors of several proteins 
and their ligand has been developed by a research group at the Uppsala University, 
in 2001, and the name “Proteochemometric” has been coined by the same group. It 
concerned the interaction between chimeric peptides and chimeric Melanocortin 
Receptor
7
. Nowadays, although PCM is a relatively new technique, it has already 
been successfully applied to a wide variety of drug targets.  
Among these, the family of G protein coupled receptor (GPCR) has been studied 
by many research groups. Weill and Rognan
8
 created on global GPCR model 
combining several models on class A GPCR and they used it to identify the natural 
receptor ligands in a dataset of 200000 decoys. Bock et al.
9
 built another global 
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model able to identify selective ligands for an orphan GPCR receptor among a 
dataset of 1.9 million data points. Another interesting application is in the field of 
viral proteins, such as HIV Protease, Dengue virus NS3 Protease, Influenza virus A 
and B Neuramidase
10
, in consideration of the high similarity between the mutants, 
even more evident in comparison with the average similarity between multiple 
GPCR families. This is also true for enzyme mutants, and another important topic 
subjected to PCM is the Kinase superfamily and the corresponding inhibitors 
compounds.  
PCM comprises a vast variety of computational tools and can implement different 
Machine Learning models. By exploring the whole range of opportunities it offers, 
and using well curated data so to take full advantage from the technique, it is 
possible to achieve interesting progresses in drug discovery and explore new 
avenues. Among these, we can mention the generation of multitarget or 
multispecies models, the “deorphanization” process of novel emerging targets, the 
integration of phenotypic and toxicity data in predictive models, the design of new 
personalized medicine for antiviral or anticancer therapy based on genotypic 
information
11
.     
Two kinds of PCM models can be implemented, the first based on a regression and 
the second on a classification algorithm. Regression model involves estimating or 
predicting of a response and the output variable are continuous values. Conversely, 
classification aims at identifying group memberships and the output variables are 
class labels.   
In this Thesis, a Proteochemometric technique was applied to MetaSar substrates 
and UGTs enzymes resulting in the first PCM model about the regioselectivity of 
glucuronidation reactions. The study led to the generation of a classification 
algorithm able to predict if a given molecule can be a UGTs substrate or not. 
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2.4   Chemical descriptors 
A chemical descriptor is a numerical value which describes the properties of the 
molecule in order to establish relationships between its structure and its functions. 
Both QSAR and PCM traditionally use them and a large collection of ligand 
descriptors is now available, all aiming at both describing the ligand itself, and 
putting in evidence the differences to one another.  
A brief overview of chemical descriptors currently used in QSAR and PCM model 
will be given, with a particular attention on those applied by the studies described 
in this thesis. 
A first classification of chemical descriptors can be done on the basis of the data 
type, which can be integer values, real numbers or a Boolean variables, when 
indicating whether a specific functional group is present in the ligand or not. 
Another common classification of chemical descriptors relies on the dimensionality 
of the molecular representation from which they are calculated. According to this 
criterion, a ligand descriptor can have zero, one, two, or three dimensions (0D, 1D, 
2D, 3D)
1
. 
OD descriptors are merely derived from the chemical formula, indicating for 
example the occurrence of a particular functional group. 1D descriptors are 
rudimental physicochemical descriptors, such as the atom counts, the bond counts 
and the molecular weight, and are generally simple, computationally very fast and 
easy to interpret. This means also that they are not informative enough to provide a 
satisfactory discriminating power and are particularly affected by possible 
overfitting of the data. Thus, they should be used always in combination with other, 
more informative, descriptors. 
2D descriptors are computed from the graphical two-dimensional representation of 
the molecule caught by the SMILES, which allows a precise definition of the 
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atomic connectivity. The connectivity is the bonds’ pattern connecting the atoms of 
a given molecule, and, from it, a molecule can be easily dissected into constitutive 
fragments. This kind of dissection allows the calculation of all physicochemical 
descriptors, which have a constitutive/additive character by which their values can 
be computed as a sum of fragmental increments. These physicochemical 
descriptors include, among the others, the Virtual LogP, which is a calculation of 
the octanol-water partition coefficient, namely a measure of the molecular 
lipophilicity. Topological molecular descriptors are calculated based on the 
molecular graphs (in a graph, the atoms form the nodes and the bonds correspond 
to the edges), and include bond properties, atomic properties and inner atom 
distances between the functional groups. In the 2D Circular Fingerprints and in 
other kind of fingerprints, the molecular 2D structure is transformed into a 
numerical string.  
2D descriptors are frequently used both in traditional QSAR model and in PCM, 
since they can catch fairly well the properties of the chemicals and the differences 
among them, in order to establish a direct relationship between structure and 
function. They also have the advantage to be quickly calculated and modelled, even 
when dealing with large datasets
12
. 
3D descriptors are derived from the three-dimensional representation of the 
chemicals. They overcome the typical limitations due to the insufficiently 
informative two-dimensional characterization, while clearly having other 
drawbacks. The calculation process can be time-consuming and it does not  derive 
directly from the three-dimensional representation of the molecule
13
. Indeed, 
alignment-based 3D compound descriptors require superimposition in 3D space of 
the chemicals in their bioactive conformation, a step that can introduce more noise 
than functional information and requires the active conformation of the ligand to be 
known. This problem is overcome by the Grid Independent descriptors (GRINDs), 
which are calculated starting from a set of molecular interaction fields. These 
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descriptors are computed in such a way as to remain highly relevant for describing 
biological properties of chemicals while being alignment-independent, chemically 
interpretable and easy to derive
14
.  
 
 
2.4.1   Extended-Connectivity Fingerprints  
Extended-Connectivity Fingerprints (ECFPs) are an important class of topological 
2D fingerprints for molecular characterization, developed at the “University Of San 
Diego”, California, in 2000. They were originally designed to assist the structure 
searching in chemical databases, and later largely applied to a wide range of 
applications, including similarity searching and structure-activity relationships. The 
first application of ECFPs was in the area of high-throughput screening (HTS), as a 
tool to evaluate the results, analysing false positive and false negative hits. 
Furthermore, ECFPs were frequently applied in ligand-based virtual screening 
studies, in order to distinguish between actives and inactives. Among their most 
relevant advantages, we can mention the wide range of different molecular features 
that they are able to catch, the capacity to represent either the presence or the 
absence of functionalities ˗ both crucial for analysing molecular activity˗ and the 
rapidity of computational time required to calculate them
15
. Another crucial 
peculiarity of ECFPs is that they don’t use a set of substructure-based keys, as 
happened for many other kinds of fingerprints, such as MACCS. Since they are not 
defined a priori, they can represent novel structural classes. 
The generation process of ECFPs consists of three subsequent steps. First of all, all 
the non-hydrogen atoms of the input molecule are considered individually and an 
initial integer identifier is assigned to each of them, according to various atom 
properties (e.g., atomic number, connection, count, etc.). The set of such local atom 
properties is an important configuration parameter that can be variously 
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customized. After that, these initial integer identifiers are modified combining them 
with identifiers that capture the neighbourhood around each atom, with circular 
subsequent iterations having an increasing diameter, until a value that can be 
customized. Finally, in the third step, eventual duplicates are removed, defining as 
a duplicate an identifier of an equivalent atomic neighbourhood.  
This process results in the first kind of ECFPs representation: the list of Integer 
Identifiers. This representation consists in strings of different length made up by a 
list of integer numbers, each of them describing a specific circular atomic 
neighbourhood in the molecule. This varying-length string can also be interpreted 
as a virtual bit string, in which each position accounts for the presence or the 
absence of a specific substructural feature (Figure 2.3).  
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Illustration of the generation of integer identifiers by effect of iterative updating for a 
selected atom in a sample molecule.    (Reproduced from docs.chemaxon.com) 
 
 
A second kind of ECFPs representation is the Fixed-length bit string, which is 
obtained by "folding" the underlying virtual bit string into a much shorter bit string 
of specified length. This binary representation has numerous advantages that render 
it the first choice in QSAR and PCM models: compared to the identifier list, the 
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binary string reduces the required storage and, most of all, its specific length, 
which is another parameter customizable, allows their use by Machine Learning 
techniques and by similarity analysis. On the other hand, more than one different 
substructural feature could be represented in the same bit position, resulting in 
collisions and loss of pieces of information. Furthermore, the interpretability of the 
bits is partially compromised and the process to go back to the specific circular 
atom neighbourhood which generates the specific bit is not direct (Figure 2.4).  
 
 
 
Figure 2.4: Generation of the fixed-length bit string from the list of Integer Identifier.           
(Reproduced from docs.chemaxon.com) 
 
 
 
2.4.2   EigenSpectrum Shape Fingerprints  
EigenSpectrum Shape Fingerprints (ESshape3) are a quite new kind of fingerprints 
belonging to the class of the shape-based descriptors. Instead of describing 
molecules as a set of atoms in a two-dimensional space, as the other 2D 
fingerprints do, they consider molecules into a three-dimensional contest, as having 
a volume and a surface. Since the drug-target interaction rely to the shape 
complementariness of the ligand to the active site, this kind of descriptors permit to 
add relevant information to the model
16
.  
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ESsape3D are implemented in the Molecular Operating Environment software 
(MOE)
17
, and are fixed-length string of integer values. The generation process 
starts with the individuation of the heavy atoms in the input molecule and the 
calculation of the Euclidean distance matrix for each pair of them
18
. The matrix 
affords a pattern characteristic of the molecular shape, which is thereafter encoded 
as a fingerprint
19
. The process consists in the calculation of the eigenvalues from 
the distance matrix, and then the signed square roots of these eigenvalues are 
smoothened by a Gaussian function and stored in a histogram with 122 bins 
containing values between -30 and +30.   
However, the accuracy of shape-based descriptors is limited because of the lack of 
electrostatic properties, which are relevant as well as the steric properties to 
characterize the ligand-protein complementary.  
 
 
2.4.3   3DAPfp and 3DXfp 
The research group of Professor Jean-Luis Raymond, from the “University of 
Berne”, designed a new type of 3D-atom pair fingerprints, called 3DAPfp and 
3DXfp
20
. These descriptors belong to the class of topological descriptors and are an 
extension in the three-dimensional space of the two-dimensional topological atom 
pair fingerprints APfp and Xfp, developed by the same group. 
APfp and Xfp count the number of atom pairs at increasing topological distances, 
through the shortest path. They are designed following a concept originally 
reported by Carhart et al
21
 and are computed from 2D structure only. Nevertheless, 
they are found to correlate with molecular shape and able to encode 3D-features of 
molecules, in various enrichment studies
22
.  
The new 3D descriptors are a simplification of the 3D-atom pair fingerprints 
developed by Sheridan et al
23
, whom calculation is more time consuming. 3DAPfp 
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and 3DXfp are designed to represent the actual 3D-shape more closely than the 2D 
corresponding one to distinguish among different stereoisomers of the same 
molecule. 3DAPfp is a 16-bit descriptor that treats all heavy atoms equally, while 
3DXfp is a 80-bit descriptor that considers different atom categories, such as 
hydrophobic atoms, H-bond donors, H-bond acceptors and others.  
 
 
2.5   Protein descriptors  
A protein descriptor can be just one descriptor referred to the whole protein, 
characterizing one of its general properties, as well as the presence of a specific 
domain, or a list of descriptors referring to the sequence of amino acids. In both 
cases, considering the large dimension of the protein in comparison to the ligand, a 
selection of a subset of the protein, usually the binding pocket would be 
recommended. The collection of available protein descriptors is wide and can be 
grouped into different subclasses, among which the following descriptors are the 
ones typically used in PCM studies.  
The first protein descriptors exploited in PCM models are the binary protein 
descriptors, where each column corresponds to a specific domain or to a key 
residue in the protein, and each binary value encodes the presence or the absence of 
that particular element. These descriptors are computationally fast and, in 
comparison with sequential descriptors, they often have more satisfactory 
performances, but also less interpretable capabilities and more limits in 
extrapolation 
3
.    
While binary descriptors encoded only one-dimensional properties of the protein, 
some 3D protein descriptors have been developed by different research groups, 
both for the full protein
24
, and for a specific region
25
. The performances of this kind 
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of descriptors in PCM are quite good but their use is limited to those cases in which 
a diverse dataset of protein 3D-structures is available. 
Sequential protein descriptors, on the contrary, can be computed for almost all drug 
targets, since they only require the amino acid sequence. They consist in lists of 
descriptors encoding for the properties (mostly physicochemical properties) of each 
residue in the protein. Among them, the alignment-dependent sequence descriptors 
are the most commonly used in PCM models. This descriptors require the 
sequences of all the targets in the model to be aligned and, therefore, models using 
them are limited to proteins with a sufficient similarity in sequence or in structure
5
.  
The alignment-dependent sequence descriptors are computed using a large property 
matrix that describes all the individual amino acids, and performing a process of 
dimensionality reducing, usually by using the Principal Component Analysis 
(PCA). 
 
 
2.5.1   PCA and alignment-dependent sequence descriptors  
PCA is a technique used in the statistical field to simplify the description of the 
analysed objects, by reducing the number of their representative variables. The 
input is a matrix with rows corresponding to the objects and columns 
corresponding to the variables, called ‘original variables’, which describe the 
objects.  
For the protein descriptors, the objects are the amino acids and the variables are 
more often physicochemical properties, but also topological or electrostatic ones. 
The aim is to extrapolate the variables showing the largest variances, assuming 
that, in PCM, as in all predictive approaches such as the Machine Learning 
methods, variables with largest variance are the most significant ones, since they 
are able to highlight the differences between the objects. Each variable in the 
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matrix is a vector described by a number of dimensions equal to the number of 
objects in the matrix. In order to catch the reciprocal influences of the variables, a 
linear transformation is applied to the matrix, by rotating the vectors. The output is 
a new matrix, including a new set of variables, called ‘latent variables’, ordered by 
the degree of variance. The plot which describes the reducing of the variance (from 
the first to the last latent variables) is very steep at the beginning and then it reaches 
a plateau. Each latent variable is obtained by combining some original variable, and 
is conventionally referred to the most important variable in terms of percentage.  
Thus, if the original variables are different physicochemical properties (Pr1, Pr2, 
Pr3... etc.), the obtained latent variables (PC1, PC2, PC3... etc.) can still be 
considered as some specific physicochemical properties, based on how much each 
Pri contributes to the definition of PCi.  
To reduce the number of the latent variables, the best ranked variables are taken 
into account, discarding the other ones. This is done with different approaches, 
such as the choice a priori of the amount of total variance to be described 
(‘cumulative percentage of variance explained’ method) or the observation of the 
plot which describes the decreasing trend of the variance (‘screen plot’ method).  
Table 2.1 shows the list of the amino acid descriptor sets used in this study and 
their main features.  
For example, the Z-scales (5) are based on physicochemical descriptors and derived 
by PCA. After the dimensionality reducing, they take into account only 5 
properties, which are the lipophilicity, the size, the polarity/charge, the 
electronegativity and the electrophilicity, with an amount of explained variance 
equal to 87%.  This means that each amino acid is described by five values. For 
other protein descriptors, there are different amino acids, different original 
variables, different latent variables and a different amount of explained variance.  
As shown in Table 2.1, Z-scales(3), Z-scales(5), T-scales and ST-scales descriptors 
cover a number of amino acids larger than the number of natural ones, which are  
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Descriptor set Type Derived by 
n. of 
comp. 
Variance 
explained 
AAs 
covered 
BLOSUM 
Physicochemical and 
substitution matrix 
VARIMAX 10 n/a 20 
FASGAI Physicochemical Factor Analysis 6 84% 20 
MSWHIM 
3D electrostatic 
potential 
PCA 3 61% 20 
ProtFP (PCA3) Physicochemical PCA 3 75% 20 
ProtFP (PCA5) Physicochemical PCA 5 83% 20 
ProtFP (PCA8) Physicochemical PCA 8 92% 20 
ProtFP (Feature) Feature based Hashing n/a n/a 20 
ST-scales Topological PCA 5 91% 167 
T-scales Topological PCA 8 72% 135 
VHSE Physicochemical PCA 8 77% 20 
Z-scales (3) Physicochemical PCA 3 n/a 87 
Z-scales (5) Physicochemical PCA 5 87% 87 
 
Table 2.1: Amino acid descriptor sets. Not available is abbreviated as n/a.  
 
 
relevant in bioactivity models. Therefore, the PCA applied might select 
information that is not the most significant one to describe the space we are 
interested in, resulting in a lack of resolution.  
There is a large arsenal of different descriptors and it is possible to group them on 
the basis of the type of variables (physicochemical, topological, electrostatic...), 
and of the technique used for dimensionality reducing. When considering only the 
first two principal components, descriptor sets can be clustered according to the 
approach by which they are derived, while when increasing the numbers of 
considered components, the clustering pattern shifts significantly. This indicates 
that including more principal components changes the descriptor behaviour, 
although the added principal components typically describe less variance than the 
first two components
26
. 
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2.6   Machine Learning and Random Forest   
Machine Learning has been described by Arthur Samuel in 1959 as the "Field of 
study that gives computers the ability to learn without being explicitly 
programmed”. The focus of Machine Learning is the construction of algorithms 
capable of learning from data. In the context of medicinal chemistry, this refers to 
the capacity to build models able to predict properties of molecules learning from a 
set of input features.  
Machine Learning is commonly divided into unsupervised and supervised learning 
approaches
1
. The unsupervised methods do not give any output, and their goal is to 
describe association and patterns among a set of input variables. An example can 
be a PCA applied to PCM data to reduce their dimensions. The supervised 
methods, on the contrary, aim at predicting the value of an outcome variable based 
on a collection of input variables. This is the case of QSAR or PCM models, in 
which the outcome variable is a measure of bioactivity, and the input variables are 
protein and ligand descriptors. 
PCM relies on many different Machine Learning algorithms, including both linear 
and non-linear methods, and Random Forrest (RF) is one of the most efficient 
approaches.  
RF is a highly versatile and all-purpose Machine Learning method, developed in 
the nineteens. It belongs to the large class of Machine Learning algorithms called 
“ensemble methods”, which use multiple learning algorithms to obtain predictive 
performances higher than those reachable by exploiting separately the constituent 
learning algorithms. In other words, it builds many models, each model providing 
an independent prediction, and combines these predictions resulting in the final 
model. In the case of RF, the models are classification or regression decision trees.     
The input data are collected into a matrix including a set of samples and of features 
or attributes. Each sample has different values for each feature, leading to a given 
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prediction, or label. The “decision tree” method essentially uses “if-then” 
statements to cluster the data and to obtain a final prediction.  To evaluate the 
models, the “decision tree” methods generally use the so called mean decrease 
impurity (MDI, normally using the Gini impurity function), which roughly 
corresponds to the abundance of randomly incorrect selections within a predictive 
model. This means that in a suitably performed decision tree procedure, the random 
incorrect predictions should progressively decrease during the simulation and the 
so obtained final models can be ranked according to their resulting mean decrease 
impurity.  
Hence, the “decision tree” method begins with the so-called “root”, which 
corresponds to the best predictor, namely the feature that allows the greatest 
partition of the data in terms of “impurity” of the prediction. After the first 
partition, the tree is built along the subsets of “impure” data by adding nodes, 
which represent questions about the other features, and branches, which represent 
the outcome of the decisions. This process continues until all the groups are devoid 
of “impure” data and lead to a unique final prediction, which can be obtained by 
following the so generated decision tree.  As said above, the level of “impurity” at 
each node gives a measure of the confidence of the final prediction. Figure 2.5 
depicts a scheme of how Random Forest works. 
The Random Forest algorithm automatically generates bunch of random decision 
trees, based on many subsets of the datasets. The final prediction comes from a 
process of averaging of all the collected predictions. It is interesting to note that 
most single predictions, around 99.9%, are not helpful for the final result, because 
they cancel each other out and only a minority of the single predictions (about 
0.1%) contributes to the final result. 
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Figure 2.5: Random Forrest flow chart 
 
 
 
2.7   Selection of data and building of the dataset        
All the predictive models, including QSAR and PCM ones, are built on datasets 
and the first step involves the generation of a good database. Indeed, it has been 
proved that the quality of the descriptors in a dataset has much greater influence on 
the prediction then the nature of the model optimization techniques. The accuracy 
of the experimental data is a key prerequisite to calculate good descriptors
27
. The 
collection of data is done by searching from the available resources, which can 
include extremely large online databases, or small databases manually collected 
directly from the literature. Regardless of the utilized approach, the collected data 
should always undergo a manual curation, which can remove inadvertent mistakes 
or undesired features leading to substantial increase in the model predictivity.  
Node 
Terminal node 
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This procedure consists in many “cleaning steps”. First, inorganic compounds, 
counter-ions, organometallics, and molecules with rare elements should be 
removed, depending on the capability of the modelling tools to handle them. 
Secondly, some specific chemotypes as tautomers should be standardized, since 
they could be represented with different structural patterns, leading to different 
descriptors. Finally, the ionization state of all ionisable molecules should be 
defined by considering specific pH conditions. 
Starting from a curated collection of data, it is possible to build the dataset by 
calculating properties and arranging them in a matrix. To be used in the model 
generation, the input dataset is modified to be compatible with the chosen Machine 
Learning technique. This process includes a dataset cleaning phase followed by 
some steps of data pre-processing, described in the following sections
28
. At the end 
of this process, the size of the input dataset is highly reduced.   
 
 
2.7.1 Dataset cleaning 
The cleaning and the plausibility checking of the dataset is a crucial step to avoid 
failures of the model in the following steps.  First of all, the missing values in the 
features have to be checked and replaced by the mean of all values for that feature 
or, more likely, if the dataset is large, simply removed. Then, the dataset has to be 
checked for outliers, the features values of which are far away from the others. The 
outliers could be due to a mistake in data or can be seen as suggestive of an unusual 
behaviour, which might have a predictive power, even though the most common 
procedure when dealing with outliers is to remove the corresponding features. 
Indeed, a broad normal distribution for most features, as well as a wide range of the 
target values, are generally considered as the best situations for training a 
predictive model
29
. Moreover, at this stage, it is not possible to guess which 
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features offer the richest information about the target values, and make a decision 
on that basis. This information is though later derived by the predictive model 
itself.  
 
 
2.7.2   Removing “Near Zero Variance” features 
“Near Zero Variance” features are features whose values along the column show a 
very low amount of variance. Since “Variance” is a measure of how a set of values 
is spread out, columns which are found to have a near zero variance, contain nearly 
identical values. In other words, this situation corresponds to a column reporting 
values which differ very slightly from their average value. Including these columns 
in the model does not add any information and can, in the worst case, causes the 
model to fail. Therefore, these features, as well as those with zero variance, which 
include always a constant value, need to be removed. This procedure has some 
customizable parameters, which can be set to adapt the model to specific situations. 
One of those is the “frequency-cut-off”, which corresponds to the ratio between the 
frequency of the most common value and the frequency of the second most 
common value. The most used frequency-cut-off is equal to 30/1. A second 
parameter is the “unique cut-off”, which represents the percentage of unique values 
out of the number of total samples. Generally, a cut-off of 90% is chosen
30
. 
Another rather obvious parameter to control the deleting of features with “near zero 
variance” is the threshold of variance below which the columns will be discarded.  
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2.7.3   Feature normalization 
Features with highly different scales can compromise the performances of the 
model, resulting in unrealistic predictions. By standardizing the input features, all 
features are weighted equally in their representation and similarly their role in the 
model is normalized. As a down-side, the variables are no longer in their original 
units and lose interpretability. The procedure to standardize the data consists in 
“centring” and “scaling” the input features. First of all, the mean and the standard 
deviation for each compound feature column are calculated. Then, the mean of a 
given feature is subtracted to every individual feature value to obtain the centring, 
and the resulting values are divided by the standard deviation of that feature to 
perform the scaling step.  
 
 
2.7.4   Removing correlated features 
Correlated feature are features which, while describing different characteristics, are 
influenced by some common properties and tend to be interrelated. While 
correlated features can impair the predictive power of correlative equations, the do 
not affect accuracy of classifications per se. Increasing the number of features 
typically increases classification accuracy, but this holds true until we are not 
under-sampled relative to the large number of features. Taking correlated features 
into account does not add any additional information to the model and causes a 
longer training time for the model. For this reason, the dataset analysis to search 
and delete the correlated features is usually recommended, as the last step of the 
pre-processing phase. 
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2.8   Model building        
The key idea in the model building is that the prediction is trained by using the 
input database, which is a list of sample features with the corresponding labels, in a 
process that allows the predictive algorithm to learn from data. In other words, the 
model offers a plausible explanation of the relationships between data points. After 
that, the Machine Learning is able to exploit the learnt information to make a 
prediction about the labels of new samples. These labels are usually measures of 
bioactivity, for regression models, and binary labels, for classification models. A 
regression model is a function which maps objects to a real-valued outcome 
variable, whereas a classification model is designed to classify objects into two or 
more discrete classes
1
.   
The building of the model has to be performed fulfilling different aspects. Indeed, 
many parameters can compromise the predictive power of the model, and the 
accuracy of the original design is of crucial importance to obtain the best predictive 
performances. Very often, the ligand target interaction matrix is not complete, and 
the large variability both on the chemical and on the target sides can lead to wrong 
predictions. Therefore, the model building has to be based on a procedure of 
validation, chosen with respect to the size and the variability of the input dataset 
and to the kind of required prediction
31
. This ability can be tested on a subset of 
data appositively discarded from the dataset and assessed by comparing the 
predicted labels with the known values. The difference between the known values 
and the predicted labels in the test set determines the accuracy and the precision of 
the model.  
That said, the ideal validation for any computational model, and also the only one 
that can be really true, is the prospective validation. The prospective validation uses 
new samples as the test set and the experimental determination of their activity to 
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assess model performance. Obviously, this is a not often feasible condition, and 
other kinds of validation are applied.  
 
 
2.8.1   External and internal validation 
The external validation consists in subdividing the input dataset in two subsets with 
different sizes, usually about 70% and 30%, respectively. The model is trained on 
the larger subset, called “training set”, and then tested on the smaller one, the “test 
set”, predicting the labels of the samples. In this case, because the subdivision is 
done randomly, it is likely that all targets and compounds are present in both the 
training and the test sets. This hypothesis depends on the number of different 
compounds and targets. This method is usually used to assess whether a reliable 
model can be generated for the dataset
32
. 
Very often, this method is completed by exploiting the so-called “Nested Cross 
Validation” (NCV), in which two validation loops are nested. The outer loop, 
which corresponds to the external validation, is run just after the inner loop is 
completed and has provided the best parameters. The inner loop is used to optimize 
the values of the Machine Learning parameters through the “internal validation”. 
Among different types of internal validation, the “k-fold cross-validation” 
represents the current state of the art. This procedure consists in subdividing the 
training set into k equal subsets. Then, a model is trained on k-1 subsets and tested 
on the remaining subset. This process is repeated k times, each time changing the 
composition of the test set, until all k subsets are selected as the test set. In each 
round, the best values of the parameters are selected, obtaining a set of best values, 
which change according to the variance of the different training set. Therefore, the 
k-fold cross-validation does not provide an absolute set of best parameters
33
, but 
more likely a q
2
 value and cross-validated RMSE
34
.          
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2.8.2   Leave One Target Out  
The “Leave One Target Out” method (LOTO) consists in excluding all the 
bioactivity data or the classification labels about one target out from the training 
set, and testing on it the predictive performances of the model. This corresponds to 
an external validation in which the test set is formed by all the data points 
belonging to one target. This procedure is repeated until all the targets are left out 
from the training set, whose composition is thus changing at all iterations. 
Differently from the external validation, in this case, the model is trained on a 
training set which does not include at all the target of the test set.   
 
 
2.8.3   Leave One Compound Out  
The “Leave One Compound Out method” (LOCO), similarly to the LOTO 
validation, excludes all the bioactivity data or the classification labels about one 
compound from the training set, using it to test the predictive performances of the 
model. This corresponds to an external validation in which the test set is formed by 
all the data-points belonging to one compound. This procedure is repeated until all 
the compounds are left out from the training set, the composition of which is thus 
changing at all iterations. Differently from the external validation, in this case, the 
model is trained on a training set which does not include any compounds of the test 
set. This situation perfectly corresponds to the scenario where a PCM model is 
applied to the selection of novel interesting chemicals. This is also the more likely 
situation in drug discovery, and the objective of this study.  
If the number of compounds in the training dataset is large, the compounds can be 
grouped in cluster, performing the “Leave One Compound Cluster Out” method 
(LOCCO).   
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2.9   Model Evaluation      
The efficiency of the predictive model is assessed by comparing the predicted 
values for the test set with the experimental ones. The evaluation of these 
performances depends on whether the modelling task is a classification or a 
regression. In a classification model, a common method for describing its 
performance is the Confusion Matrix (Figure 2.6).  
 
 
 
Figure 2.6: Confusion Matrix scheme for a binary classification 
 
 
The Confusion Matrix for a classic binary model is a simple cross-tabulation of the 
observed labels: the actual and the predicted ones. The two classes are typically 
transformed in binary values, where 0 corresponds to the “negative” class and 1 to 
the “positive” class. In this way, “true positive” (TP) and “true negative” (TN) are 
the well predicted labels of both classes, and “false positive” (FP) and “false 
negative” (FN) are similarly the incorrect predictions in both classes. Looking at 
the matrix, the green diagonal cells denote cases where the classes are correctly 
predicted, while the other off-diagonal cells indicate the number of errors for both 
classes.  
From the Confusion Matrix values, it is possible to calculate other metrics for the 
model performance.    
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The “error rate” is the percentage of a test set that is misclassified, while the 
“accuracy” is the percentage of a test set that is correctly classified. 
 
error FNFPrate   
TNTPaccuracy   
 
These metrics reflect the agreement between the observed and predicted classes 
and offer the most straightforward interpretation, but are not free of disadvantages. 
First, accuracy cannot distinguish between the types of errors which are made. 
Therefore, in applications where certain errors are to be considered more serious 
than others, weighting those errors is advisable.  
Second, error rate and accuracy do not consider the frequencies or the percentages 
of each class. “Recall”, also called “sensitivity”, is the ratio of true positives on the 
total amount of actual positives. This measure is particularly interesting when one 
class is considered as the event of interest. In this case, recall corresponds to the 
rate that the event of interest is correctly predicted, for all samples having that 
event. In other words, it is the ability of the model to successfully identify the 
samples having the event of interest. The sensitivity is sometimes also called the 
“true positive rate” since it measures the accuracy in the event population. 
 
FNTP
TP
recall

  
 
In contrast, the “specificity” is the ratio of true negative on the total amount of real 
negative. In other words, it is defined as the ability of the model to correctly 
identify the samples not having the event of interest. The “false-positive rate” is 
defined as described below.  
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FPTN
TN
yspecificit

  
 
yspecificitrate positive false 1  
 
Intuitively, sensitivity and specificity are inversely proportional, meaning that 
when a model increases its sensitivity, likely it will show a loss of specificity, since 
more samples are being predicted as events. For each situation, it is possible to 
establish a typical trade-off between sensitivity and specificity. This is particularly 
appropriate when dealing with types of errors with different penalties. 
The “precision” is the ratio of the true positive on the total amount of the predicted 
positive.  
 
FPTP
TP
precision

  
 
Usually, precision and recall scores are not analysed individually. Indeed, either 
values for one measure are compared for a fixed level at the other measure (e.g. 
precision at a recall level of 0.75) or both are combined into a single parameter. As 
examples for metrics that are combinations of precision and recall, we can mention 
the F1-score and the Matthews Correlation Coefficient (MCC). 
The former corresponds to the harmonic mean of precision and recall, in which 
both parameters are evenly weighted. 
 
recallprecision
recallprecision
scoreF


 21  
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The latter, introduced by biochemist Brian W. Matthews in 1975, can be seen as a 
correlation coefficient between the experimental and predicted binary 
classifications. It takes into account all the values in the Confusion Matrix and it is 
generally regarded as a balanced measure which can be used even when the classes 
show very different sizes. It returns a value between −1 and +1. A coefficient of +1 
represents a perfect prediction, 0 corresponds to a random prediction and −1 
indicates a complete disagreement between predicted and experiential 
classification.  
 
       FNTNFPTNFNTPFPTP
FNFPTNTP
MCC


  
 
Recall and Inverse Recall, namely true positive rate and false positive rate, are 
frequently plotted in the ROC curves which provide a well-established way to 
graphically represent the predictive performances of a given model.  
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3.1   Metabolism  
The term “metabolism” comes from the Greek word “μεταβολή”, which means 
“change”. This change refers to the complex of chemical and physical 
transformations taking place within the cells of leaving organisms, to keep them 
alive. The changes result in assimilation of new materials, growth of cells, 
maintenance of homeostasis, production of life-sustaining energy and elimination 
of waste material.  
Considering these changes in more detail, they can be seen a series of chemical 
reactions occurring on small molecules, defined as “substrates”, to make energy 
available and transform them into products, easily eliminated from the organism.  
Going even more in-depth, we will recognize as mainly responsible for these 
changes the activity of the enzymes, which take a crucial role in metabolism. In 
effect, metabolic enzymes allow organisms to drive desirable reactions that require 
energy and will not occur spontaneously, by coupling them to spontaneous 
transformations, which release energy. Enzymes basically act as catalysts that help 
the reactions to proceed more rapidly, and the metabolic processes depend upon 
their activity. At the same time, enzymes cannot work unless the body is kept at a 
consistent temperature, therefore homeostasis must be maintained within the cells 
to allow the reactions required by metabolism to take place. This assumption closes 
the circle of interdependence between metabolism and homeostasis, on whose 
foundations is based the whole of life (Figure 3.1). 
To try to look over the principles of metabolism and to figure out the rules on 
which they are founded is an ambitious porpoise, which always represents an 
extremely interesting topic for scientists. To put effort into the field of metabolism 
prediction, in particular, means to be involved in drug discovery from a 
comprehensive point of view, since all new drugs need to be screened based on 
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their pharmacokinetic profile, in order to maximize their bioavailability and, as a 
consequence, their efficacy. 
    
            
Figure 3.1: Role of enzymes in organisms. Enzymatic metabolism, thanks to the production of 
energy, contributes to the maintenance of homeostasis.  Homeostasis, thanks to the maintenance of 
the internal equilibrium in the organism, allows the enzymatic metabolism. 
 
 
 
3.1.1   Xenobiotic metabolism 
The metabolic system has evolved as the main line of defence against what is 
considered “foreign to life”: exogenous substances which do not possess nutritional 
or biochemical roles and are broadly defined as “xenobiotics”. They include natural 
and synthetic pollutants, cosmetics, food additives, toxins coming from the 
secondary metabolism of bacteria and fungi, drugs and more generally, all 
synthetic chemicals. They are transformed into more hydrophilic metabolites which 
are usually (but not necessarily) less active or totally inactive and are always more 
readily excreted.  
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Focusing on drugs, the metabolic biotransformation alters the physicochemical 
profile of the starting molecules, resulting in an alteration of their physiological, 
pharmacological and toxicological profiles. This can mediate either a deactivation 
and detoxification of the original drug, or its activation ˗ in the case of prodrugs ˗ 
up to a conversion into a toxic effect. However, for about 75% of all drugs, 
metabolism represents the major clearance pathway
35
.  
The metabolic system is characterized by a complex organization, based on many 
different classes of enzymes, whose activities are meticulously coordinated and 
classifiable in two main phases: the functionalization and the conjugation. The 
enzyme expression patterns are highly adaptable and their substrates specificities 
are extremely variable among different species, as well as different tissues and 
organs in the same organism. Moreover, many other individual factors concur to 
define distinctions in the metabolic process, such as gender differences, genetic 
polymorphism, age, diseases, lifestyle, diet, intestinal flora, medications
36
. 
As a consequence, even though the new technologies and the available knowledge 
are rapidly advancing, an accurate prediction of drug metabolism remains 
extremely challenging. 
 
 
 3.1.2   Metabolism prediction                                          
An exhaustive comprehension of the metabolic process at a molecular level is at 
the basis of a successful research in drug discovery. An unsuitable metabolic 
profile of lead compounds represents an important cause of failures and attrition in 
drug development
37
. An accurate knowledge of the metabolic properties of the hit 
compounds can lead to the optimization of the stability of new drugs. 
Therefore, these last years have seen a continuous development of experimental 
methods for investigating the metabolic fate of the hit compounds. Among them, 
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High-Throughput methods (HTS) for metabolic screening are conveniently applied 
for large chemical libraries and in the early phases of drug development
38
.  
Unfortunately, these experimental approaches are often too demanding with respect 
to scientific equipment, human expertise, cost and time. Therefore, the interest 
around computational tools for metabolism prediction is increasing, since the 
virtual strategies offer a higher throughput at a lower cost, and can be applied to 
large chemical libraries at the early beginning of the discovery process
39
. 
Nevertheless, it is crucial to realize that there is an important potential synergy 
between experimental and theoretical approaches and, probably, the right way to 
best investigate drug metabolism can be found in the integration of the both areas
40
. 
The various in silico predictive approaches reported in literature can be subdivided 
into two main classes
41
. Local methods utilize classic ligand-based or structure-
based approaches (e.g., QSAR models, pharmacophore mapping or molecular 
docking), to predict the outcome of a single metabolic reaction
42
, whereas global 
methods use meta-analyses and expert systems to interrogate metabolic databases 
and extrapolate general rules or metabolic networks, in order to predict the entire 
metabolic pathway of a new molecule
36,43
.  
In spite of the mentioned advantages, computational approaches are affected by 
some drawbacks, which restrict their broad and truly successful application. In 
more details, local methods require to know a priori which metabolic reactions a 
given substrate can undergo, and which specific isozymes are involved in these 
reactions. Furthermore, structure-based approaches also necessitate the 3D-
structure of the enzymes involved in the reaction. When all necessary data are 
available, local methods can provide accurate predictions, but it is evident that such 
requirements markedly reduce their general applicability.  On the other hand, the 
global methods can suffer from inaccuracies hidden in their metabolic datasets, 
which are usually collected interrogating large online databases, such as PubChem, 
ZINC, ChEMBL, Drug Bank, WOMBAT. 
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Mistaken data in the metabolic databases markedly affect the reliability of the 
derived global predictions. In particular, the level of curation of the dataset has 
much greater influence on the prediction then the nature of the model optimization 
techniques
27
. What is now lacking in the available global methods is a good level 
of critical review of the retrieved data; a condition that can be filled only by a 
meticulous manual curation, which cannot be automatized. 
 
 
3.1.3   MetaSar        
The here presented project concerning the in silico metabolism prediction involved 
the development of a novel global method which aim at overcoming the inaccuracy 
drawback affecting other global methods. On these grounds, our approach is based 
on a meta-analysis and the resulting database, called MetaSar. MetaSar is an 
extension of a database previously published by Testa et al
44
., in which all the 
metabolic reactions are manually collected by critically reviewing the recent 
specialized literature. This accurate procedure is actually a continuous work in 
progress in our research group.  
The selected specialized journals are “Chemical Research in Toxicology”, “Drug 
Metabolism Disposition” and “Xenobiotica”, and more than 1200 papers have been 
analysed in the period from 2004 to 2012.  Currently, MetaSar comprises 1730 
metabolic substrates, on which the metabolic reactions are annotated to obtain 
around 10 000 different metabolites. 
Some specific rules are always followed during the collection of data. The focus is 
on drugs and other xenobiotics, excluding endogenous compounds; both studies in 
humans or in mammalians are taken in consideration, with distinctions weather 
they are carried out in vivo, in cellular system, or at a subcellular or enzymatic 
level; both metabolic trees and single enzyme studies are analysed. Each substrate 
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is considered separately, avoiding duplicates. Regio-isomers and stereoisomers are 
treated as distinct substrates or metabolites, to underline eventual substrate or 
product selectivity. Most importantly, all selected papers have to report convincing 
analytical conditions, and all the collected data are critically reviewed. In MetaSar, 
all the substrates are reported with annotated the sites of metabolism and the 
specification of the class of reaction for each of them. Moreover, in the database, 
other levels of classification are included: the enzyme super-family involved in the 
reactions; the metabolic generation to which each metabolite belongs (1
st
, 2
nd
, 3
rd
 or 
plus); the annotations of which metabolites are pharmacologically active, reactive 
and/or toxic. 
Besides the MetaSar curation, the metabolism prediction involved the preparation 
of the three-dimensional structures for some important metabolic enzymes, both 
derived from resolved crystals and homology modelling. This research field started 
with some predictive studies on the enzymes involved in the hydrolytic metabolism 
(CES1, CES2, hBChE, PON1 and PON2) to arrive to the homology model of the 
human UGT2B7, whose optimization is presented in the following sections of this 
chapter. 
My personal contribution regarding MetaSar project involved the update of a 
previously existing classification of reactions to a new one, including now 21 
classes and 101 subclasses of reactions. Moreover, I contributed to the enrichment 
of the database, by adding 3D structures of new substrates and metabolites. Finally, 
I personally curated the preparation of the majority of the enzymes structure 
included. 
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3.1.4   Possible applications of MetaSar  
The MetaSar project was initially undertaken to collect a database suitable to 
develop global approaches, the main objective of which is the generation of 
predictive algorithms able to model the entire metabolic pathway of new 
molecules. Beside such a key project, MetaSar can find other interesting 
applications.  
MetaSar can be an exhaustive source of data for metabolism-driven virtual 
screening studies, aimed at validating predictive models of single metabolic 
reactions.  Indeed, the MetaSar substrates can be seen as an appropriate dataset for 
enrichment studies, since they include a minority of “active” substrates on a 
specific target (enzyme family), while the other part can be seen as a good 
collection of “inactive” decoys. This approach can be partly questionable, since 
some molecules can be considered as putative non-substrates simply because the 
corresponding metabolite was not searched in the reviewed study. Nevertheless,  
for the most studied metabolic reactions/enzymes (such as CYP450 or UGTs), or 
for those reactions/enzymes requiring substrates with well-defined reactive groups 
(e.g., hydrolysable functions for hydrolases), MetaSar can be seen as an effective 
database for virtual screening campaigns, and indeed it was successfully utilized to 
validate predictive models of the metabolism by Human Carboxylesterases.  
Furthermore, MetaSar is also a well curated source of data for PCM studies aimed 
at modelling the regioselectivity of the metabolic reactions occurring to a specific 
class of enzymes. We present in the following chapters a first example of this 
application, regarding the prediction of glucuronidation reactions. 
 
   
48 
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3.2   UDP-Glucuronosyltransferase 
UDP-glucuronosyltransferases (UGT) are recognized as the most important non-
P450 enzymes due to their relevant contribution to metabolism of endogenous and 
exogenous chemicals.  
They are responsible for the majority of the phase II metabolic reactions, and they 
are the most important conjugation enzymes in terms of number and diversity of 
substrates.  
UGTs are implicated in the last and crucial step of metabolism: the conversion of 
sufficiently polar molecules, drugs and other xenobiotics, or their first metabolites, 
into more readily excreted hydrophilic products, inducing the definitive 
interruption of their biological activity. Considering that the current trend in drug 
development strategy is to focus on new chemical entities with a lower 
lipophilicity, therefore ready for phase II metabolism, the non-P450 enzymes 
become the most prominent players to the clearance of drug candidates. 
Accordingly, there is an ever increasing quest for a better understanding of UGT, 
both at a functional and molecular level, since they can represent a key issue in 
drug development
45
.  
 
 
3.2.1   Historical notes 
The first compound ever characterized as a sugar conjugate has been the Euxanthic 
acid,  isolated in 1855 in the urine of cows fed mango leaves, and responsible for 
the colour of the famous dye Indian yellow. After that, almost 100 years have 
elapsed before the enzymatic nature of glucuronidation has been established and in 
1953 the process of formation of Euxanthic acid was elucidated since the Uridine 
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Diphosphoglucuronic acid (UDPGA) was identified as the co-factor in the UGT 
activity.  
In the period 1950–80, our knowledge about glucuronidation has been largely 
derived from in vitro studies. Cell fractionation experiments demonstrated that 
UGTs were integral membrane proteins residing in the Endoplasmic Reticulum and 
nuclear envelope. UGT enzymes were found in many tissues and organs, but 
predominantly in the liver and intestinal tract. Tissue homogenates and purified 
enzyme preparations have been used to elucidate many of their key features, such 
as the influence of the membrane environment for an optimal activity, their 
catalytic properties and capacity to react with a large number of lipophilic 
chemicals, their differential inducibility by compounds, such as barbiturates and 
polycyclic aromatic hydrocarbons, and their property of latency (i.e., the 
requirement for disruption of the membrane bilayer to achieve a maximal activity). 
The same studies also provided some progresses toward understanding the 
multiplicity of the UGT family and the substrate preferences of individual UGT 
isozyme. 
In the 1980s, thanks to the advent of the UGT cloning and expression, a substantial 
progress was made in elucidating UGT multiplicity, substrate preference, and 
structure–function relationships and in determining the mechanisms underlying the 
regulation of the expression of the UGT gene. In particular, the first cloning studies 
were carried out in rodents and provided the first amino acid sequence of a UGT, 
establishing that there were several UGT isoforms encoded by a superfamily of 
genes. After that, many cDNA expression systems have been developed with the 
aim of  defining  the substrate specificities of each UGT isozyme, and very soon we 
assisted to the cDNA cloning of human UGTs, quickly followed by the 
identification of all human UGTs by the human genome project
46
.  
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The nascent UGT polypeptide measures about 530 amino acids and contains a 
signal peptide, which is involved in integrating the protein into the endoplasmic 
reticulum, and a highly hydrophobic stretch of 17 amino acids near the C-terminus 
which most likely traverses the lipid bilayer. 
The mature protein is orientated on the luminal side of the Endoplasmic Reticulum, 
where catalysis occurs. It forms two domains: the N-terminal domain, which is 
involved in substrate recognition, and the more conserved C-terminal domain, 
which binds the co-factor, the UDP glucuronic acid. Due to this particular 
localization and in order to induce a maximal glucuronidation activity, the rupture 
of the membrane has to be performed by using detergents with controlled low 
concentrations or other mechanical procedures such as sonication.  
Nowadays, UGTs and their metabolites have been identified in a wide range of 
vertebrate species, including humans, other primates, other mammalian species, 
birds, and fishes, as well as in non-vertebrates, plants, and bacteria. The research 
has focused on vertebrate species, leading to the isolation of multiple UGT 
isoforms and to the identification of an extensive range of lipophilic chemicals that 
are metabolized by these enzymes. On one hand, each enzyme has its own distinct 
set of substrates; on the other hand, many compounds are recognized by more than 
one UGT enzymes, revealing a considerable degree of overlapping between the 
UGT substrate specificity. This redundancy in the glucuronidation system reduces 
the impact of genetic and regulatory aberrations
47
. 
 
 
3.2.2   UGT nomenclature and gene organization 
The UGTs are members of a broader superfamily of UDP-glycosyltransferases, 
enzymes that transfer glycosylic groups to lipophilic substances from a variety of 
UDP sugars. All UDP-glycosyltransferases, including UGTs, share a 44 amino acid 
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characteristic sequence signature in their C-terminal domain that appears to be 
involved in the binding of the UDP moiety of the nucleotide sugar.  
The gene superfamily contains four UGT families: UGT1, UGT2, UGT3 and 
UGT8
48
. Among these, the first two families are the most important and share the 
same UDP sugar specificity, using preferentially UDP glucuronic acid, and less 
frequently other sugars, including UDP glucose and UDP xylose. The UDP sugar 
specificity of the UGT3 family is still unknown, whereas UGT8A1 utilizes UDP 
galactose as the sugar donor. While the enzymes of the families UGT1 and UGT2 
play a notable role in detoxifying both endogenous and exogenous chemicals, other 
UGTs have a specific biosynthetic role, as exemplified by UGT8A1 which is 
involved in the synthesis of cell-membrane components
49
. 
Our interest is focused on the two major families of mammalian UGTs, UGT1 and 
UGT2. In general, members within each family share more than 45% of sequence 
identity but are less than 45% when compared to UGTs of the other family. The 
UGT2 family has been further divided into subfamilies, UGT2A and UGT2B, the 
members of each sharing more than 70% of amino acid identity.  
To date, humans are known to possess 19 functional UGT isozymes, including 9 
members of the UGT1 family (known as UGT1A genes), 3 members of UGT2A 
subfamily and 7 members of the UGT2B subfamily. The dendogram depicting the 
sequence similarity of human UGTs is shown in                                         Figure 
3.2. 
All the human UGT1A genes are found on a single locus on chromosome 2q37, 
spanning approximately 200 kb. This locus contains 13 unique exons, which 
encode for the N-terminal domains of 13 potential UGT1A forms, and 5 exons that 
are shared by all the full-length UGT1A transcripts. As a result, the UGT1A 
enzymes possess an unique N-terminal region, which provides functional diversity 
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and substrate selectivity, while the C-terminal domain is identical for each enzyme, 
and is involved in the binding of the sugar donor, namely the UDP glucuronic acid. 
On the opposite, the UGT2 genes are encoded by almost all discreet genes, with the 
only known exceptions of UGT2A1 and UGT2A2, which share exons in a manner 
similar to the UGT1A locus. All the UGT2 genes are located on chromosome 4 at 
position 4q13. The UGT2B genes consist of six exons and share similar intron/exon 
boundaries, although intron lengths vary between genes. Despite being separate 
genes, the C-terminal domains of the UGT2B forms, which bind the UDP 
glucuronic acid, are still highly conserved, both within the UGT2B family and, to a 
lesser extent, with the UGT1A subfamily
50
. 
 
 
 
 
                                        Figure 3.2: Dendrogam of UGTs subfamilies. 
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3.2.3   UGT structure  
UDP-glucuronosyltransferases belong to one of the main families of the large 
glycosyltransferase superfamily, the GT-B fold
51
. These enzymes catalyse the 
formation of glyosidic bonds using generic sugar donors and comprise proteins 
conserved across several species. Enzymes belonging to plants and bacteria have 
been crystallized, and, despite a low percentage of identity within the superfamily, 
the structural similarity is good enough to delineate the main features of the 
mammalian UGTs. These last enzymes have not been completely resolved yet, due 
to an additional transmembrane segment that complicates the crystallization 
process making its experimental conditions more delicate
52,53
.  
The UGT’s structure consists of two domains: the N-terminal domain, responsible 
for the binding of the substrate, which accepts the glycoside moiety, and the C-
terminal domain, which binds the cofactor, the donor of the glycoside group. The 
active site is, indeed, formed by a deep cleft at the interface of these two domains. 
Each domain is characterized by a Rossmann fold motif, including six parallel β-
sheets separated by seven α-helices. Two important modifications distinguish the 
mammalian UGTs structures from the corresponding plants and bacterial 
crystallized enzymes: (1) the above mentioned hydrophobic C-terminal region, that 
links the enzyme to the membrane of the Endoplasmatic Reticulum, and (2) a part 
of the C-terminal region that is crossing back to approach the N-terminal domain.     
In 2007, Miley et al. published the crystal structure of the C-terminal domain of 
UGT2B7 that, up to now, remains the only one ever resolved. The cofactor is not 
included in the crystal, but some insights can be deduced from a superimposition of 
the 2B7CT structure and the plant glucosyltransferase VvGT1. The key interactions 
stabilizing the binding with the cofactor can be schematized as follows: (a) Asp398 
and Gln399, which elicit H-bonds with the glucuronic acid moiety, (b) Asn378 and 
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His374, which interact with the phosphate groups, (c) Glu382, whose backbone 
atoms form a H-bond with the ribose moiety and (d) Trp356 and Gln359, which 
interact with the uracil base
54
.  
The N-terminal domain of UGT2B7 can be obtained through homology modelling 
using some plants crystals as the templates, even though it is less conserved than 
the C-terminal region, and so its modelling cannot be an easy task. Interesting 
insights about the residues which form the substrate binding site arise by the 
comparison with the templates. Two important residues in the mechanism of action 
have been identified, namely His35 and Asp151. They are highly conserved in 
vertebrates, probably mediate the nucleophilic attack of the substrate on the 
cofactor, promoting the deprotonation of the substrate. This event is not always 
necessary and UGT1A4, for example, has a Proline (Pro40) instead of the histidine 
and it still able to catalyse glucuronidation reactions on primary, secondary, and 
tertiary amines
54
.  Furthermore, replacement of Pro40 in UGT1A4 with a histidine 
residue greatly reduced the enzyme activity on secondary and tertiary amines but 
enhanced its capacity to react with phenols and carboxylic acids
55
. Similarly, 
UGT2B10 has a leucine instead of the histidine, consonant with its ability to N-
glucuronidate cotinine and nicotine, despite showing very low rates
56
. These 
studies emphasize that His35 plays a key role in determining substrate selectivity in 
UGT2B7, and the same holds true for the corresponding residues in the other 
human UGTs. 
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3.2.4   UGT catalytic mechanism 
UGTs catalyse the covalent linkage of the glucuronic acid from the high energy 
UDPGA cofactor on lipophilic substrates, to form D-glucuronides. The cofactor is 
produced endogenously by oxidation of UDP-α-D-glucose. This process is very 
abundant in the adult human body (about 5 grams daily synthesized), confirming 
the high capacity of this metabolic route
57
. The list of electron-rich functional 
groups which are potential substrates of the reaction is rather wide as summarized 
in Figure 3.3.   
 
 
 
 
        Figure 3.3: Summary of the functional groups being potential substrates for UGTs.  
(Reproduced from 58) 
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The reaction is a second order nucleophilic substitution (SN2), and the scheme of 
the reaction is reported in Figure 3.3.  
The nucleophilic group on the substrate is often activated by proton abstraction 
with a general base in the UGT catalytic site.  Then, the electron-rich group on the 
substrate attacks the anomeric carbon atom of UDPGA and induces the release of 
UDP. The degree of activation by proton abstraction varies depending on the 
stability of the charged product of the reaction
53
. For example, deprotonation of the 
hydroxyl groups is required because the formation of the positively charged 
oxonium ion has a large energy barrier. In contrast, deprotonation of amino groups 
is often not necessary as charged amines are relatively stable. The glucuronidation 
reaction relies on a single displacement mechanism, and requires that the attacking 
nucleophilic group and the leaving UDP molecule should be arranged on either 
side of the anomeric carbon atom and approximately in line. The nucleophilic 
substitution made by UGTs induces the inversion of the configurations of the 
anomeric carbon atom from α-UDPGA to β-glucuronides53. Their acidity is an 
important feature of glucuronides: the pKa of glucuronic acid is 3.0 and that of O-
glucuronides in the range of 2.9-3.1, implying nearly complete ionization at 
physiological pH range. The N-glucuronides show a special feature since, as a 
consequence of the loss of deprotonation, they have a permanent positive charge in 
addition to the negative charge of the carboxylate, namely they are zwitterions
57
. 
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Figure 3.4: UGTs catalytic mechanism of action.   (Reproduced from 58) 
 
 
 
3.2.5   UGT substrate selectivity 
A large number of structurally heterogeneous metabolites are metabolized by 
glucuronidation, including endogenous compounds, such as a variety of androgens 
(testosterone, andrsterone, epiandrosterone), estrogens (bestradiol, estriol) and 
gestagens (17a-hydroxyprogesterone), biliary acids (lithocholic acid, deoxycolic 
acid, chenodeoxycholic acid)
58
, bilirubin, thyroid hormone, the heme breakdown 
product, neurotransmitters, fatty acids, and eicosanoids, as well as drugs and 
dietary chemicals. Considering that there are only 18 functional isoforms of human 
UGT, each isoform can likely glucuronidate different classes of chemicals. 
Furthermore, a single chemical undergoes glucuronidation by more than one 
isoform.  
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The determination of the substrate selectivity of each UGT proceeds along with the 
discovery of new classes of metabolites and takes advantage from recombination 
studies involving mammalian or insect cells. However, the establishment of the 
accurate substrate profile for each UGT isozyme remains difficult, mainly because 
of differences in the utilized recombinant systems for expressing UGTs and in the 
assay sensitivities and methodologies
59
. In addition, many computational studies 
indicate that UGTs exhibit distinct, but overlapping, substrate selectivity
59,60
.  
Most UGT enzymes (with the exception of UGT1A4) are able to metabolize small 
alcohols and phenols but, when increasing the structural complexity of substrates, 
the selectivity appears to increase, due to steric, hydrophobic, and electronic 
factors. For example, bilirubin is glucuronidated only by UGT1A1, trifluoperazine 
by UGT1A4, and zidovudine by UGT2B7
59
, and many hydroxysteroids exhibit 
distinct enzyme selectivity
61
.  
Indeed, selective substrates have now been identified for most UGT enzymes, and 
this information can be useful for reaction phenotyping. One of the best techniques 
to investigate the selectivity is the use of “probe” substrates, when they have been 
identified (see Figure 3.5). The inhibition of metabolite formation obtained by an 
enzyme selective inhibitor on enzymes of human liver microsomes or hepatocytes 
provides strong evidence for the involvement of that enzyme in the metabolic 
pathway. However, few UGT enzyme selective inhibitors have been hitherto 
identified. For example, hecogenin is a highly selective inhibitor of UGT1A4
62
, 
and fluconazole shows moderate selectivity as an inhibitor of UGT2B7
63
.  
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Figure 3.5: Catalytic capacity and preferred substrates for human UGTs 
(Reproduced from Mackenzie et al.64) 
 
 
 
3.2.6   UGT role in toxicity and clinical significance 
The glucuronidation metabolic reactions are primarily a detoxification pathway and 
a protective mechanism to prevent the accumulation of highly hydrophobic 
chemicals. Indeed, UGT enzymes modulate toxicity of drugs and other chemicals 
because the addition of a glucuronic acid moiety to a given compound enhances its 
polarity and thus its rate of elimination from the body and as a trend decreases its 
toxicity.  
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Nevertheless, the possibility to have metabolites more toxic or biologically active 
than their parent compounds is also true for glucuronides. A first example is 
represented by steroid alpha-D-ring glucuronides, which are more cholestatic than 
beta-D-ring glucuronides
65
. A second example is given by the acyl glucuronides of 
drugs that can react with cell constituents forming adducts which induce 
apoptosis
66
. These drugs include clofibric acid, benoxaprofen, bezafibrate, and 
probenecid, which cause DNA nicking through their acyl-glucuronide 
metabolites
67
. Even though glucuronidation as a rule abolishes the biological 
activity of metabolized drugs, there are relevant examples of drugs the 
glucuronides of which maintain or enhance their bioactivity. For example, the 
morphine-6-glucuronide
68
 is an analgesic markedly more potent than morphine, 
and the retinoic glucuronide, acts as a chemopreventive agent in breast cancer and 
is more potent than the parent retinoic acid
69
.  
Also other negative events, such as adverse drug reactions, altered drug efficacy, 
and outcomes of organ transplantation, are associated with alterations in UGT 
function or variability in their expression. There are several examples of 
relationships between the outcome of pharmacological treatments and the patient’s 
genotypes for UGT enzymes.  
One of the best-known examples regards the association between Irinotecan, a 
widely exploited anticancer prodrug, primarily used to treat colorectal cancer, and 
UGT1A1. The metabolism of Irinotecan is firstly regulated by carboxylesterases 
enzymes, which transform the prodrug in its therapeutically active metabolite 7-
ethyl-10-hydroxycamptothecin (SN-38). SN-38 has a narrow therapeutic window, 
since over-dosing can cause life-threatening toxicities including diarrhoea and 
neutropenia, and its deactivation and elimination is mostly controlled by 
glucuronidation
70
. In particular, UGT1A1, UGT1A9, and UGT1A7 have been 
proposed to be the major catalysts of SN- 38 glucuronide formation
71
. Indeed, 
genetic variations of the underling isoforms that lead to a decrease of SN-38 
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glucuronidation have been associated with altered treatment outcomes. The 
association of Irinotecan-mediated toxicity with the UGT1A1 allele  
UGT1A1*28
72,73
, in particular, is so clearly established that the American Food and 
Drug Administration added recommendations for testing of the UGT1A1 genotype 
of patients prior to irinotecan treatment.   
Another example involving UGT1A1 isoform is given by the association between 
Indinavir and the development of severe hyperbilirubinemia in Thai HIV patients 
carrying the UGT1A1*6 or UGT1A1*6 plus UGT1A1*28 genotypes, but not 
UGT1A1*28 alone
74
. In addition, inhibition of UGT1A1 by Indinavir results in an 
additive effect in patients with already impaired bilirubin glucuronidation activity. 
A similar gene–environment interaction might be predicted for other inhibitors of 
the UGT1A1 activity.  
Other examples where UGT genotype may affect the outcome of pharmacological 
treatments involve other isoforms. One of them regards UGT1A6 enzymes, which 
play a role in the metabolism of Aspirin. In particular, some evidences associated 
the low-activity of UGT1A6 with a greater protective effect induced by aspirin on 
the risk of developing colorectal adenoma, while individuals carrying the wild-type 
of UGT1A6 do not benefit from the protective effect
75
. However, a conflicting 
study showed that low-activity UGT1A6 genotypes are protective against colorectal 
adenoma recurrence irrespective of aspirin intake
76
. Thus, the relationship between 
UGT1A6 genotype, aspirin, and colorectal adenoma remains controversial, 
particularly given the apparently minor role of the UGT1A6 isoform in the salicylic 
acid glucuronidation.  
Another example involves UGT1A9, and possibly UGT2B7, which are responsible 
for the glucuronidation of mycophenolic acid, an immunosuppressant characterised 
by considerable inter-individual variations in its pharmacokinetics
77
. In healthy 
volunteers, the UGT1A9*3 and the UGT2B7*2 alleles have been associated with 
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alterations in mycophenolic acid exposure, enterohepatic recycling, and production 
of the toxic acylglucuronide metabolite
46
.  
Similarly, UGT2B15 is an important enzyme for the metabolism of the 
benzodiazepines Oxazepam and Lorazepam, used as anxiolytic and hypnosedative. 
The UGT2B15*2 variant appears to be associated with lower glucuronidation of 
Oxazepam in human liver and lower clearance of Lorazepam in healthy 
volunteers
78,79
, thus influencing their dosage and their pharmacological effects 
78
.  
Finally, the UGT2B17 gene has been found connected to the transplant-related 
mortality in recipients of hematopoietic stem cells. In detail, the UGT2B17 protein 
seems to be immunogenic in individuals that are genetically devoid of the 
UGT2B17 gene, and may be responsible for a heightened risk of complications in 
recipients given transplants from donors mismatched for UGT2B17
80
.  
 
 
3.2.7   UGT: the current situation and future perspectives 
Considering the large importance of glucuronidation reactions in the metabolic 
process, the key aspects of the activity of the UGT enzymes, some of them still 
unclear, require an in-depth research. The lack of crystal structures for mammalian 
UGTs represents a crucial drawback, and its resolution remains a high priority in 
the field. In the meanwhile, the exploitation of reliable homology models for the 
mammalian UGTs, as generated using the available plant and bacterial templates, 
remains the best option.  
Many aspects need to be further investigated; first, how UGT enzymes’ activity is 
organized and the precise mechanism of their catalysis. In detail, the role of UGTs 
oligomerization and their complexes with other drug-metabolizing enzymes and 
possibly transporters should be clarify, in order to determine whether it is necessary 
to deliver substrates and sugar nucleotides to the active site, and then to remove the 
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glucuronidated metabolites. It is important to define which other proteins are parts 
of these complexes and how their formation is modulated. Moreover, the impact of 
phosphorylation and other post-translational modifications on glucuronidation 
capacity should be elucidated, as well as how the UGT proteins are integrated in 
the endoplasmic reticulum environment.  
The identification of selective inhibitors for each UGT remains a crucial requisite 
for reaction phenotyping. The use of probe substrates can assist the in vitro/in vivo 
correlations, but the selectivity of the underling probes is sometimes not enough to 
assure a high binding rate to the UGT of interest, compromising their use in assays 
(e.g., serotonin as a probe for UGT1A6). Another strategy to characterize the 
distribution and profile of UGTs in human tissues is based on antibodies which 
show specificity for each UGT, as  recently demonstrated in the kidney
81
.  
A complex system of co-activators and repressors determines the levels of UGTs in 
tissues and organs during development and in response to hormones and other 
external stimuli. A more extensive study of this system and the UGT regulation can 
clarify the relationships between changes in UGT expression and risk of chemical 
toxicity and diseases, and can suggest how to manipulate these metabolizing 
enzymes for therapeutic applications.  
Finally, considering that the role of UGTs in the pathway of uptake, metabolism, 
and egress of drugs from cells is intrinsically interconnected with the role of the 
other metabolic enzymes, only a better understanding of the entire metabolic 
process and the coordination between the various metabolic pathways can lead to 
significant progresses in drug discovery.   
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3.3   Modelling studies on UGT2B7 catalytic site 
UGB2B7 is the most important UGT isoform as it is responsible for the 
glucuronidation of 35% of clinically used drugs
45,82
. Among the main examples of 
metabolized drugs, we can mention opioids, including morphine, codeine, 
buprenorphine and naloxone
83,84
, anti-cancer agents
85,86
, gemfibrozil
87
, valproic 
acid and other carboxylic acid containing drugs
88
, and anti-viral drugs including 
zidovudine
83
and efavirenz. Moreover, UGT2B7 is also found to be implicated in 
metabolism and detoxification of anti-inflammatory agents, as S-Naproxen and 
other non-steroidal drugs
88,89
, as well as the mineralocorticoid aldosterone and 
other C19 and C21 hydroxy-steroids
90,61
. In addition, UGT2B7 metabolizes 
endogenous compounds, including bile acids, fatty acids, and steroids
45
. 
For these reasons, the research around glucuronidation enzymes, up to now, has 
been mainly focused on human UGT2B7, unanimously considered the most 
interesting enzyme within UGT family
45
. A better understanding of its structural 
features and catalytic mechanism can represent the right starting point for a correct 
interpretation of the drug glucuronidation processes.  
 
 
3.3.1   UGT2B7 structure: state of the art 
UGT2B7, as all human UGTs, belongs to the GT1 family and is predicted to adopt 
a GT-B fold. The GT-B structural organization consists in two Rossman-like 
domains, associated to form a catalytic cleft at their interface. The C-terminal 
domain contributes to the majority of the contacts with the donor cofactor, whereas 
the N-terminal domain is responsible for the main interactions with the acceptor 
substrate. Nevertheless, a strong cross-talk between both domains is recognized to 
be important to determine the final shape of the binding site
91
.  
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In 2007, Miley et al. published the first and the only ever resolved structure of a 
mammalian UGT: the 1.8-Å resolution apo crystal structure of the UDPGA binding 
domain of human UGT2B7 (see Figure 3.6)
54
. The crystal structure includes an 
asymmetric dimer of the UGT2B7 C-terminal domain, consisting in two nearly 
identical molecules. Each molecule comprises the residues 285-472 but lacks in the 
final C-terminal region, which has a transmembrane segment between the residues 
493-509, anchoring the enzyme to the luminal side of the Endoplasmic Reticulum. 
The globular domain consists in a β-sheet core formed by six individual strands, 
surrounded by seven α-helices. 
 
 
 
(a) 
 
(b) 
 
Figure 3.6: Overall structure of UGT2B7 C-terminal domain. (a) Asymmetric dimer of 2B7CT. 
(b) Ribbon cartoon of 2B7CT with labelled secondary structure elements.                                 
(Reproduced from Miley et al.54)      
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The cofactor is not included in the crystal, but some insights about his binding site 
can be derived from a superimposition of the 2B7CT structure and the plant 
flavonoid glucosyltransferases VvGT1 and UGT71G1
52,92
.  These sequences reveal 
a high level of structural homology, despite a lower sequence identity (~.19%). In 
particular, the putative UDPGA binding site sequence of UGT2B7 is remarkably 
similar to the UDP-glucose binding site of VvGT1. A more complete structure-
based sequences alignment of representative GT1 family enzymes is shown in 
Figure 33.7.  
These observations suggested that the cofactor can be modelled in the UGT2B7 
predicted binding site using the VvGT1 crystal as the template.  Moreover, the 
sequence alignment shows that UDPGA binding site is highly conserved also 
among human UGTs, suggesting a common binding mode for all the isoforms.  
The mechanism of action, already hypothesized by studies with selective 
inhibitors
93
 and site-directed mutagenesis
54
, finds a confirmation also in the 
structure-based sequence alignment. It consists in a serine hydrolase-like catalytic 
triad, in which Asp151 stabilized the protonation of His35, which, in turn, activates 
the electron rich substrate by proton abstraction, here holding the role of serine in 
the hydrolase enzymes. The substrate then attacks the anomeric carbon of the 
cofactor by a second order nucleophilic substitution, leading to the conjugation 
reaction.      
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Figure 33.7: Structure-based sequence alignment of GT1 family enzymes. All unique C-
terminal domain sequences from human UGTs were aligned to the crystallized 2B7CT sequence: 
six 2B subfamily UGTs and all 1A subfamily UGTs, which share an identical C-terminal domain. In 
the alignment are also comprised a representative GT from bacteria, GtfA, and two plant flavonoid 
GTs, VvGT1 and UGT71G1. The secondary structure of 2B7CT is depicted above its sequence. The 
conservation mapping is highlighted, and the regions important for donor ligand binding are 
comprised in a shaded box. The inferred important residues for interaction with UDPGA are 
specifically marked.   (Reproduced from Miley et al.54)      
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In 2011, Lewis et al. generated a homology model of the whole human UGT2B7 
structure, using the FUGUE and ORCHESTRAR pieces of software
94
. The crystal 
templates used in the study are the UDPGA binding domain of human UGT2B7 
obtained by Miley et al. (PDB Id: 2O6L), for the C-terminal domain, and some 
crystals of grape UDP-glucose flavonoid 3-O glucosyltransferase (PDB Id: 2C1X, 
2C1Z, 2C9Z)
52
, plus barrel medic UDP-glucose flavonoid glucosyltransferase 
UGT71G1 (PDB Id: 2ACV and 2ACW)
92
, for the N-terminal domain.  
The protein consists in eleven α-helices, designated as A-K, and nine β-sheets, 
numerated from 1 to 9, with four additional helices which called A’, B’, C’ and F’. 
Two main domains can be recognized: the N-terminal and the C-terminal domains, 
responsible for the catalytic activity, which are hinged together by I, J and K 
helices, and are joined by the A-A’ loop. A third, smaller domain, separated to the 
catalytic domains, encompasses the hydrophobic B’-C loop region (Figure 3.8)94.   
This homology model represented the starting point of our computational study 
concerning the UGT2B7 three-dimensional structure, which was undertaken with a 
view to optimizing the catalytic binding site, including the cofactor, as well as to 
investigating the correct position of the substrate, and its path to enter into an exit 
from the binding pocket.    
 Chapter 3 – Prediction of xenobiotic metabolism  
70 
 
 
 
Figure 3.8: The tertiary organization of the UGT2B7 homology model. (Panel A and B) The 
catalytic N-terminal and C-terminal domains are coupled via helices I, J and K, and the A-A’ loop. 
(Panel C and D) A third smaller domain, in the circle, separated to the catalytic domains, 
encompasses hydrophobic residues of the B’-C loop.  (Reproduced from Lewis et al.94)      
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3.3.2   Computational detail 
Our computational studies involved the UGT2B7 homology model, which was 
kindly provided to us by Lewis. The obtained model was lacking in bound ligands 
(both cofactor and substrate), therefore the first step of our study was aimed at 
optimizing the catalytic site by docking UDPGA and Naproxen, chosen as 
exemplificative substrate. The completed structure underwent to SMD simulations 
to better assess the stability of the computed poses as well as to investigate the 
different pathways of the substrates. 
In detail, the optimization of the catalytic site in the homology model by Lewis et 
al.
94
 was based on the resolved crystal structure of the plant flavonoid 
glucosyltransferases VvGT1 (PDB Id: 2C1Z)
52
. This crystal contains the cofactor 
uridine-5’-diphosphate-2-deoxy-2-fluoro-alpha-D-glucose, the conformation of 
which was considered as a good template for the pose of the UDPGA cofactor 
within the UGT2B7 binding pocket. The VvGT1 binding site also includes the 
substrate 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-a-one (Kaempherol), 
which was similarly used as the template to accommodate the UGT substrate 
Naproxen. (Figure 3.9-A) 
The overall studies consisted in three main steps: the modelling of the UGT2B7-
UDPGA complex, the docking of the substrate, and, finally, the analysis of the 
ligand’s pathways, by Steered Molecular Dynamics simulations (SMD). 
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Figure 3.9: Modelling studies of the UGT2B7. (A) Crystal structure of VvGT1 with its cofactor 
and Kaempherol in the binding pocket. (B) UDPGA structure extracted from crystal 2Y0C and 
optimized. (C) UGT2B7 model structure with UDPGA. (D) UGT2B7 model structure with UDPGA 
and Naproxen. 
A B 
C D 
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3.3.2.1   Modelling of UGT2B7-UDPGA complex 
The molecule of UDPGA was extracted from the crystal of Burkholderia Cepacia 
Udp-Glucose Dehydrogenase (2Y0C)
95
, standardized according to physiological 
pH to a double negatively charged ligand, and optimized by the semi-empirical 
quantum chemistry program MOPAC
96
. (Figure 3.9-B) The obtained structure was 
docked in the catalytic pocket with the docking software PLANTS
97
 and the best 
conformation out the 100 generated was selected as the best superimposing to the 
cofactor of VvGT1 enzyme, in the crystal 2C1Z
52
.  
The complex was optimized by a first energetic minimization, in order to find a 
lower intermolecular energy, coupled to a Molecular Dynamic simulation. In detail, 
the minimization was performed with NAMD software
98
, setting the protein in a 
water cluster, considering free of moving all the residues included in a 12 Å radius 
sphere centred on the cofactor, fixing with constraints the backbone of the others, 
and running 50 000 steps. The Dynamic simulation was performed with NAMD, 
for 1 nanosecond and at a temperature equal to 300 K. The frame with the UDPGA 
conformation best overlapping the shape of the cofactor in 2C1Z crystal was 
selected and minimized (Figure 3.9-C). 
 
 
3.3.2.2   Modelling of UGT2B7-UDPGA-Naproxen complexes 
Two complexes were prepared starting from the UGT2B7-UDPGA complex.     
The complex with the Naproxene substrate was prepared superimposing the 
UGT2B7-UDPGA minimized complex to 2C1Z crystal and adding a molecule of 
Naproxen by aligning it to Kaempherol molecule present in 2C1Z binding site. The 
obtained complex was optimized with a minimization performed by NAMD with a 
sphere of free residues measuring 12 Å radius centred on the cofactor. The 
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substrate was then extracted and re-docked with Plants software to verify the 
reliability of the complex (Figure 3.9-D). 
The UGT2B7-UDP-GANaproxen, namely the ternary complex involving the 
enzymatic product, was prepared by manually transforming the optimized 
UGT2B7-UDPGA-Naproxen and was minimized by keeping fixed all atoms 
outside a 12 Å radius sphere around the bound ligands.  
 
 
3.3.2.3   Steered Molecular Dynamics 
Due to their net negative charge equal to -5, the two optimized complexes were 
neutralized by adding 5 sodium ions using the SODIUM tool
99
. The neutralized 
complexes were then inserted into a 50 Å radius spherical box of water molecules 
so as to generate hydrated complexes containing about 10000 solvent molecules. 
The so obtained systems were finally minimized to optimize the relative position of 
solvents and ions, and underwent the following SMD simulations. 
The two prepared complexes underwent 1.5 ns all-atoms SMD simulations with the 
following characteristics: (a) 60 Å radius spherical boundary conditions  were 
applied to stabilize the simulation space; (b) Newton's equation was integrated 
using the r-RESPA method (every 4 fs for long-range electrostatic forces, 2 fs for 
short-range non bonded forces, and 1 fs for bonded forces); (c) the temperature was 
maintained at 300 ± 10 K by the Langevin’s algorithm; (d) to the selected atoms 
the spring constant equal to 5 kcal/mol/Å
2
 was applied with a pulling velocity of 
0.003 nm/ps (e) Lennard-Jones (L-J) interactions were calculated with a cut-off of 
10 Å and the pair list was updated every 20 iterations; (e) a frame was memorized 
every 10 ps, thus generating 150 frames; and (f) no constraints were imposed to the 
systems.  
The simulations were carried out in two phases: an initial period of heating from 0 
K to 300 K over 10000 iterations and the monitored phase of 1.5 ns.  
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3.3.3   Computational results 
 
 
3.3.3.1   Analysis of the UGT2B7-UDPGA-Naproxen ternary complex 
Figure 3.10-A shows the key interactions stabilizing the computed pose for the 
UDPGA cofactor, which can be summarized, as follows. The phosphate groups are 
involved in ionic interactions with Arg338 reinforced by H-bonds with His374, 
while the hydroxyl groups of the ribose ring are engaged in clear H-bonds with 
Gln359 and Glu382. The uridyl moiety is tightly inserted between the side-chains 
of Gln359 and Arg338 with which it can stabilize  stacking reinforced by 
charge transfer interactions. Finally the glucuronic acid substructure approaches the 
substrates and stabilizes H-bonds with Gln399. Interestingly, its carboxyl group is 
not involved in significant contacts apart from some weak H-bonds with the 
backbone atoms of Met312 and Val313 and, more generally, the glucuronic acid 
appears to be not engaged in strong interactions. This finding can be explained 
considering that this substructure has to maintain a certain degree of flexibility to 
better approach the substrate, thus promoting the enzymatic reaction. 
Similarly, Figure 3.10-B shows the key interactions stabilizing the putative pose of 
the Naproxen substrate, which appears to be engaged in a rich network of p-p 
stacking and hydrophobic interactions with the surrounding residues such as Tyr33, 
Phe105, Trp106 and Phe174. The carboxyl group approaches the catalytic residue 
His35 and stabilizes H-bonds with Ser34 and Asn374. 
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Figure 3.10: Modelling studies of the UGT2B7. (A) Principal and lateral door in UGT2B7 model. 
(B) Rotation of the complex of 90° to better show the lateral door.  
 
A 
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Figure 3.11: Modelling studies of the UGT2B7. (A) Main residues stabilizing the UDPGA 
cofactor in the complex. (B) Main residues stabilizing Naproxen in the complex. 
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3.3.3.1   Analysis of the substrate’s pathways by SMD 
As a preamble, Figure 3.10 shows the overall structure of the above described 
ternary complex and highlights the two main doors through which substrate and 
cofactor can reach the catalytic cavity. As outlined in Figure 3.10, these two 
entrances can be defined as principal and lateral doors. One may reasonably 
suppose that the cofactor can enter through the former, also considering its final 
pose within the catalytic pocket as shown by Figure 3.10-C, while the exact role of 
the lateral door is still unclear. When considering that the substrate reaches the 
catalytic site after the cofactor is already bound to it (see below), the first objective 
of the performed SMD runs was to assess whether the substrate can however enter 
through the principal door, even though its pathway would be obstructed by the 
bound cofactor, or the lateral door is actually the entrance by which substrates can 
reach the catalytic pocket.  
Hence, the SMD simulations compared the energy profiles as computed when 
moving the substrate through the two possible doors. For completeness also two 
intermediate pathways were simulated, thus exploring all possible channels 
characterizing the modelled UGT2B7 structure.  
Figure 3.12 compares the pull force profiles for the substrate undocking as 
computed for the principal and lateral doors, and shows that the latter is clearly 
favored. This is also confirmed by Table 3.1, which reports the pull force 
maximum and average values for all simulated pathways, and reveals that the 
pathway through the lateral door shows a pull force average which is nearly half 
that through the principal door. The intermediate pathways reveal even worse pull 
force profiles, especially to be concern the average values, thus indicating that they 
are in fact unrealistic solutions.  
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Notably, when focusing the attention on the last part of the SMD runs (namely the 
last 0.5 ns) a contrasting trend is observed in the average values, since the principal 
door shows an average value which is largely lower than that of the lateral door 
(52.48 pN vs 130.48 pN). This finding can have two different explanations.  
The first consideration is that the key difference between the two compared 
pathways is represented by the presence of the cofactor, which impedes the 
substrate ingress along the pathway of the principal door. Without this, the channel 
corresponding to the principal door is clearly wider and thus can be easily passed 
through as emphasized by the last part of the MD runs. This means that, without 
the cofactor, the substrate ingress through the principal door would be surely 
favored, but this case is unrealistic. Indeed, several recent studies confirmed that 
the enzyme involves the formation of a compulsory order ternary-complex in 
which the cofactor binds first even in presence of factors (such as BSA), which can 
impair (or modulate) the catalytic efficiency of the UGT enzymes. As a matter of 
facts, the planned SMD runs involved neither the substrate movements without 
cofactor, as they are unrealistic, nor the analysis of the cofactor pathway, since it 
should reasonably pass through the principal door, which represents the favored 
path for the free enzyme.  
The second explanation for the observed discrepancies in the last part of the SMD 
simulations can involve the geometrical arrangement of the rim of the lateral door, 
which is not finely optimized as that of the principal door. In this case, the 
performed simulations had also the indirect effect of optimizing the folding of this 
lateral channel allowing a proper ingress for every substrate.  
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Pathway average maximum 
Principal door 195.63 1042.61 
Intermediate2 497.72 1063.28 
Intermediate3 290.40 983.76 
Lateral door 116.21 687.47 
 
Table 3.1: Pull force for the substrate undocking. The table reports the pull force maximum and 
average values for the substrate undocking as computed for the principal, lateral and two 
intermediate doors (all values are expressed in pN). 
      
 
 
 
 
 
Figure 3.12: Pull force profiles for the substrate undocking. The principal and the lateral doors 
are colored in blue and orange respectively.  
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3.3.3.1   Analysis of the product’s pathways by SMD 
When considering the results obtained for the substrate’s pathways, SMD 
simulations on the ternary complex containing the enzymatic product and the 
aglyconic UDP cofactor were similarly performed, with a view to revealing the 
product’s pathways.  
As depicted in Figure 3.13, three SMD simulations were performed by considering 
the pathway through the lateral door as well as that through the principal door as 
simulated with and without the bound UDP cofactor. Indeed and differently from 
what was previously discussed for the substrate pathways, here the sequential order 
with which UPD and substrate leave the catalytic pocket is unknown. Nonetheless, 
the computed pull force profiles allow for some relevant considerations.  
First, the product egress through the lateral door shows the worst profile with high 
force values during all the simulation (average = 528.74 pN, maximum = 1175.41 
pN). These results may indicate that this pathway is reasonably unrealistic and the 
channel is completely unsuitable for product undocking. As already seen but here 
markedly more pronounced, the last part of the SMD run shows a remarkable 
increase of the pull force which suggests that the product is substantially unable to 
pass through the cavity rim.    
Second, the pathway through the principal door without UDP (average = 217.51 
pN, maximum = 821.77 pN) shows a notably more favored pull force profile 
compared to the same path with UDP (average = 337.33 pN, maximum = 1202.94 
pN). Even though, this difference cannot offer a clear indication concerning the 
order with which UDP and product leave the enzyme, it leads to the hypothesis that 
(as already seen for the binding), the UDP leaves first, followed by the product 
both of them passing through the principal door.       
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Figure 3.13: Pull force profiles for the product undocking. The principal and the lateral doors are 
colored in blue and orange respectively.  
 
In summary, the performed SMD simulations allow a complete binding/unbinding 
mechanism for the UGT reaction to be reasonably supposed. In detail such a 
mechanism can be schematized as follows: 
- first, the UDPGA cofactor binds entering through the principal door; 
- second, the substrate binds with the bound cofactor entering through the lateral 
door; 
- third, the transformed UDP cofactor leaves reasonably first egressing through the 
principal door (even though as detailed above the cofactor movements were not 
investigated), thus the UDP egressing through the lateral door cannot be excluded a 
priori; 
- fourth, the enzymatic product leaves for last egressing through the principal door. 
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3.4   PCM 
In this study, a Proteochemometric technique was applied to MetaSar substrates 
and UGTs enzymes resulting in the first PCM model concerning the 
regioselectivity of glucuronidation reactions. A simple classification algorithm was 
built to predict if a given molecule can be a UGTs substrate or not.  
The input dataset was assembled starting from three sources: the structures of 
compounds collected within MetaSar database, including substrates as well as 
“non-substrates” of UGTs enzymes, the annotation of the reactions, namely the 
occurrence or not occurrence of glucuronidation reaction for a given molecule, and 
the sequences of the human UGT enzymes belonging to families A and B. The first 
two sources were taken from MetaSar. In details, we referred to the version of the 
database updated at January 2015. With regard to the targets, 18 UGTs sequences 
were taken in consideration and retrieved from the website Uniprot
100
.  
Many different models were tested, changing the Machine Learning technique, its 
parameters, the combination of descriptors, the number of compounds and targets.  
For simplicity’s sake, the attention will be focused only on the best so obtained 
results.   
 
 
 3.4.1   Chemical descriptors    
The study involved all the 1730 molecules included in MetaSar. The cleaning 
phase of data was rather simple, because the original database is manually 
compiled, and thus already well curated. First, the molecules were checked for 
duplicates and cases of homonymy. Then, some substrates were discarded because 
they include counter ions and others because they were identified as outliers in 
terms of molecular size. In particular, molecules having less than 8 atoms were 
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considered too small and compounds with molecular mass higher than 1000 u.m.a. 
were considered too big. Finally, the remaining 1700 molecules were standardized 
by considering their most probable ionization state at physiological pH using a 
specific script implemented in the VEGA ZZ
101
 software.  
The compound’s three-dimensional structure was optimized by a specific feature of 
the Molecular Operating Environment software (MOE) version 2012.10
17
, which 
builds reasonable and minimized conformations starting from a database of 3D-
structures. During this procedure, the stereochemical configuration of the 
molecules was preserved. Indeed, more than one stereoisomer for a single 
compound is often reported in the database and glucuronidation reactions seem to 
be influenced by configuration.  
Then, some descriptors were calculated directly by MOE, while other descriptors 
required different pieces of software. For this second case, the 3D-structures of the 
compounds were exported from MOE as smiles containing the stereochemical 
configuration, and then converted into an “sdf” file containing atomic coordinates 
and connectivity by using MarvinViewer version 15.2.9.0
102
, a software supplied 
by ChemAxon Software Company
103
. 
In detail, the ESshape3D descriptors were calculated by MOE
17
, obtaining a matrix 
with fingerprints measuring 122 integer values. Together with this kind of shape 
fingerprints, all the other fingerprint descriptors implemented in MOE were also 
calculated. The presence of duplicates was checked with a code written in R 
version 3.1.3 specifically for this aim, running it by using RStudio Version 
0.98.1103
104
. Actually, ESshape3D were found to be the only MOE fingerprints 
able to distinguish between all the stereoisomers included in our dataset. 
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Some physicochemical descriptors were calculated by MOE
17
 and a complete list 
of those  included in the models is reported in Appendix 1, with a brief explanation 
of their characteristics.   
The ECFP were calculated from the “sdf” file by using the software Molecular 
Descriptor Generator (GenerateMD) version 15.3.2.0 supplied by ChemAxon
103
. 
Specifically, the folded form of these fingerprints was calculated, so generating a 
matrix including the ECFP descriptors for all compounds and measuring 1024 
binary values. As expected and accordingly to the well-known ECFP incapability 
to handle stereoisomers, the checking for duplicates revealed the presence of 299 
molecules with the same string of binary values. 
The 3DAPfp and 3DXfp were calculated exploiting the “sdf” file and the Java 
commands supplied by Awale et al.
20
 by using Java Runtime Environment (JRE) 
version 1.8.0_51
105
 and dependencies from the ChemAxon package. The output 
files were matrices of fingerprints for all the compounds measuring respectively 16 
and 80 integer values. The use of these fingerprints was especially oriented to 
obtain descriptors able to distinguish stereoisomers. Disappointingly, the checking 
for duplicates revealed the presence of an extremely high number of molecules 
having the same string of fingerprints. For this reason, these descriptors were not 
included in the models. 
 
 
3.4.2   Protein descriptors  
The protein descriptors chosen for this study belong to the class of alignment 
dependent sequence descriptors. The sequences were downloaded from UniProt
100
 
and the total number of the considered enzymes was reduced from 19 to 18 because 
the UGT2A2 protein does not have a distinct sequence but is considered as a 
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“synonyms” of UGT1A1. According to the information reported in the PubMed-
UniGene
106
, UGT2A2 seems to be an isoform of UGT1A1, whose sequence is still 
unknown.  
The list of the considered proteins with their UniProt ID is summarized in the 
following Table 3.2. 
 
 
 
Gene 
names 
Uniprot id 
N. amino 
acids 
Identity % 
   UGT2B7 P16662 529 100 
UGT2B10 P36537 528 88 
UGT2B4 P06133 528 86 
UGT2B11 O75310 529 86 
UGT2B28 Q9BY64 529 85 
UGT2B15 P54855 530 78 
UGT2B17 O75795 530 77 
UGT2A1 Q9Y4X1 527 60 
UGT2A3 Q6UWM9 527 59 
UGT1A1 P22309 533 42 
UGT1A7 Q9HAW7 530 42 
UGT1A8 Q9HAW9 530 42 
UGT1A9 O60656 530 42 
UGT1A10 Q9HAW8 530 42 
UGT1A3 P35503 534 41 
UGT1A5 P35504 534 41 
UGT1A4 P22310 534 40 
 
Table 3.2: UGT proteins analysed in the study. For each enzyme name, the Uniprot id is 
reported, together with the number of residues in the whole sequence and the percentage of identity 
referring to UGT2B7. The colour ramp encodes for the degree of similarity. 
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The sequence alignments were performed by using the webserver Clustal 
Omega
107
. As evidenced by Table 2, the identity percentages of UGTs to UGB2B7 
protein, which is the core of our study, can be subdivided into two classes of 
importance. The proteins belonging to the subfamily 2B exhibit the highest 
similarity, and the key models were built on them. The protein belonging to the 
subfamilies 2A and 1A show a lower similarity, and were introduced to the model 
afterwards to verify if they can improve the reliability of the predictions.  For this 
reason, two alignments were performed, one with only the 7 proteins with higher 
identity percentage, and another with the all the 18 sequences. 
To improve the resolution of the model, the sequences corresponding to domains 
not involved in the ligand binding can be discrded
5
. The selection of the residues 
belonging to the binding site was based on the previously obtained UGT2B7 
homology model. The corresponding residues on other UGT sequences were then 
derived from the alignment. The selected residues were those comprised in the 
following list of sub-sequences, referred to the UGT2B7 sequence having UniProt 
ID P16662:  
 
24-41     97-127     147-159     271-289     304-340     352-420 
 
All the alignment-dependent physicochemical descriptors were calculated by using 
a code written in R version 3.1.3 specifically for that aim
104
. 
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 3.4.3   Dataset building  
The files of the input dataset were suitably assembled by using a code written in 
Python
108
 and ran by PyCharm Community Edition version 4.0.4
109
 starting from 
three sources: two files containing the descriptors for the compounds and the 
proteins and a third file containing compound names annotated with labels 
indicating whether they are UGT substrates or not. The total number of the 
simulated compounds was equal to 1700, among which 338 were UGT substrates 
and 1362 were non-substrates. In contrast, the number of proteins in the different 
models ranged from 7, to 18, to 2.  All the possible “chemical-protein” 
combinations were included and, for each combination, the data in the input matrix 
included its name, its label and the related descriptors of both chemical and protein.  
 
 
3.4.4   The code  
The code to perform the model was written in Python and ran by PyCharm 
Community Edition version 4.0.4
109
. The code is organized in functions, one for 
each phase of the model generation, which can be schematized as follows: (a) the 
dataset reading, (b) the data pre-processing, (c) the splitting of data, (d) the 
generation and validation of the model through the NCV method, with the 
corresponding evaluation of the so obtained results, and (e) the validation of the 
model through the LOCO method, with the corresponding evaluation of the results. 
Thanks to this organization, the code can be used to perform different models, just 
by calling the specific required functions. Each part of the code was written by 
assembling online available functions imported by two open source BSD-licensed 
libraries, namely Pandas
110
 and Scikit-learn
111
for the Python programming 
language. The former provides high-performance tools for data manipulation and 
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analysis. The latter features various classifications, regression and clustering 
algorithms, including RF. 
 
 
3.4.5   Dataset pre-processing 
The pre-processing of the dataset involved three consequent steps, leading to a 
gradual decreasing of the features number.   
The first step is the removing of “near zero variance” descriptors, and exploits the 
“VarianceThreshold” function from the Scikit-learn sub library called 
“feature_selection”. To better define the threshold of the minimum variance value 
required for keeping a given feature, the descriptors were subdivided according to 
the type of values and three different sections were written to perform this pre-
processing step. In detail, the ECFP descriptors, which involve Boolean variables, 
were treated as a Bernoulli distribution, the ESshape3d fingerprints, which include 
discrete variables, were treated as a multinomial distribution, and physicochemical 
properties as well as protein descriptors, which correspond to continuous variables, 
were treated as a normal distribution. The variance threshold was set as a 
customizable parameter, and different values were tested to find the best 
performing one.  
For the ECFP descriptors, the best results were obtained using a threshold of 
minimum variance equal to 0.0475, which corresponds to a binary feature that is 
composed for 95% by the same value. With this threshold, the ECFP columns were 
reduced from 1024 to just 152 features.  
For all the other features, a threshold of minimum variance equal to 0.8 was found 
to be the most efficient one. Looking at the distribution of variances reported in 
Table 3.3, this threshold permitted about 70% of the non-binary features to be 
deleted, while maintaining about 30% of them.    
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Count 1.24E+03
Min 0.00E+00
Max 1.40E+09
Mean 1.25E+07
25% 4.53E-13
50% 6.17E-12
75% 9.24E-01  
 
Table 3.3: Distribution of variances in all the non-binary features. The analysis involved the 
ESshape3D fingerprints, the pyhsicochemical properties and the protein Zscales3 descriptor 
 
 
The second step is the normalization of the data, which was applied to all the “not-
binary” features exploiting the “preprocessing.scale” function of Scikit-learn. Each 
feature value was subjected to two mathematical operations:  the subtraction of the 
mean of that feature, obtaining the so called “centring”, and the division by the 
standard deviation of that feature, called “scaling”. Finally, the remaining features 
were checked for the presence of correlated features.       
Finally, in the third step, the remaining features were checked for the presence of 
correlated features.       
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3.4.6   Model building 
Random Forest was performed by using the specific function 
“RandomForestClassifier” imported from the Scikit-learn sublibrary called 
“ensemble”. The customized parameters were: 
- “max_features”, which refers to the maximum number of features that are taken 
in consideration to build the model. Depending on the input dataset, the internal 
validation set this parameter equal to 80, 100 or 200. 
- “n_estimators”, which is the number of decision trees built by the model.  
Depending on the input dataset, the internal validation set this parameter equal 
to 100 or 200. 
- “class_weight”, which assigns to the two classes in the dataset a different 
weight value to solve issues of unbalanced results, as those deriving from 
unbalanced datasets. The balanced weight corresponds to a value of 0.5 for both 
classes. All the possible combinations of different weights were tested in an 
iterative way, but the model predictive power did not increase significantly 
with any of them.  
Two methods for model validation were tested with Random Forest algorithms, 
namely the Nested Cross Validation (NCV) and the Leave one compound out 
(LOCO). 
The NCV method consisted in an external validation (outer loop), in which the 
dataset is subdivided into training and test sets, which is nested with an internal 
validation (inner loop), in which the customizable parameters are tested within the 
training set. For what concern the external validation, the splitting of the dataset 
corresponded to the 70% of the database for the training set and the 30% for the 
test set. Since all UGT enzymes are considered equally able to metabolize their 
substrates in the model, the data splitting was preceded by a preliminary data 
clustering according to the compound name, so to avoid biasing conditions 
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deriving by the presence of the same compound with the same label both in 
training and test sets. For the internal validation, the “k-fold cross-validation” 
method was chosen, by setting k equal to 5 and performing the selections of 
parameters based on the F1 score. The so selected best parameters were then 
employed to predict the labels of the test set in the external validation.  
The evaluation of the NCV analyses was performed on the basis of Precision, 
Recall, F1 score and Matthews Correlation Coefficient.  
The LOCO method consisted in the training of the model on the whole dataset 
except for one compound, with all its combinations with the enzymes properties. 
The model was trained using the same best parameters selected by the previously 
performed NCV on the same dataset. The evaluation of the model was done on the 
basis of the Precision, Recall and F1 score.  
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3.4.7   NCV results  
The Random Forest classifier was tested on many different input datasets, changing 
the descriptors for the compounds and the proteins, the number of the targets, and 
the model parameters, in order to find the best classification algorithm. The 
following sections illustrate the composition of the input dataset, the best values for 
the customizable parameters, as selected by the “k-fold cross-validation”, and the 
resulting performances obtained by the external validation. These results are 
reported in terms of “precision”, “recall” and “F1 score”, with distinct values for 
the class “0”, corresponding to “non-substrates”, and the class “1”, corresponding 
to “substrates”, and an average value for the two classes together. The Matthews 
Correlation Coefficient (MCC) is also reported, as an overall measure of the 
predictive power of the model. 
 
 
 
3.4.7.1   Selection of the right combination of compound features  
The first objective involved the definition of the best combination of descriptors to 
include into the input dataset.  
A set of models was developed maintaining fixed all the conditions   with the only 
exception of the type of the compounds’ descriptors.  
 
 
 
 
 
 
 
 Chapter 3 – Prediction of xenobiotic metabolism  
94 
 
Model n. 1    - Descriptors: ECFP, ESshape3D, Zscales_3. 
 
 
 
Model n.2   - Descriptors: ECFP, ESshape3D, Physicochemical, Zscales_3. 
 
 
Figure 3.14: Tables and results of the model n. 1 and 2.  
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The reported results for the first two models set out what can be considered the best 
predictions that can be obtained when training the model on the whole dataset. The 
performances of all following models were, thus, compared with these first results. 
Both models were built using 7 targets (i.e., the 2B subfamily of the UGT 
enzymes), and the only difference between them consists in the introduction of the 
compounds’ physicochemical properties in the second model. 
As can be seen in the Figure 3.14, the resulting performances are broadly similar, 
underling that in this case the physicochemical properties are not crucial for the 
prediction. The most striking result to emerge from the data is that the predictive 
performances of both models are outstanding for the “non-substrates” class, in 
which about 97% of compounds are correctly predicted, but not satisfactory enough 
for the “substrates” class, successfully predicted only in the 39% of cases. Clearly, 
the attention is here focused on the recall results rather than on the precision ones, 
since the former is effectively a measure of the correctly predicted compounds 
among the entire set of compounds belonging to a certain class. Even though the 
average recall value is satisfying, the unbalanced dataset is the main weakness of 
the model, and the overcoming of this drawback was the primary objective of the 
following studies.  
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Model n.3   - Descriptors: ECFP, Zscales_3. 
 
 
 
 
Model n.4   - Descriptors: ESshape3D, Zscales_3. 
 
Figure 3.15: Tables and results of the model n. 3 and 4. 
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After verifying the marginal importance of the physicochemical properties, two 
models (n. 3 and n. 4) were developed to establish the relative relevance of the 
computed fingerprints (Figure 3.15).  
In the model number 3, only the ECFP fingerprints were used. The performance of 
the model is very near to that of the model n. 2, thus confirming the considerable 
ability of these descriptors in catching the molecule structure. However, we can’t 
exclude that these correct predictions are, in part, the result of a bias introduced in 
the model by the use of compounds descriptors unable to distinguish among all the 
molecules in the dataset. Indeed, considering the high number of duplicates 
reported in the similarity matrix build with Tanimoto distance based on ECFP, the 
probability of having the same compound-target combination both in the training 
and in the test set is high.   
In the model n. 4, only the ESshape3D fingerprints were used. On the opposite, the 
results showed an important decrease of accuracy, in particular in predicting the 
substrate class. This trend is reflected also in the MCC value. This means that 
ESshape3D, even though crucial to achieve a complete distinction among all 
compounds, prove to be insufficient to provide a complete molecular description, 
and, as a consequence, a correct prediction. This weakness is even more evident for 
the unbalanced class, already affected by worse performances due to its insufficient 
presence in the training set.   
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3.4.7.2   The issue of unbalanced data 
A dataset is called unbalanced if it contains many more samples within one class 
than within the other one, or within the remaining classes
112
. The issue of 
unbalanced data intrinsically characterizes MetaSar, since the number of substrates 
for a specific enzyme family is clearly a minority compared to the total number of 
compounds in the database. Therefore, the capacity to suitably address this problem 
is of particular importance, especially considering that MetaSar can be a fertile 
source of data for other PCM studies on other enzyme classes.  
As already described, the number of substrates in our dataset is one fifth of the 
number of non-substrates, namely 338 against 1362. Two techniques were then 
performed in order to solve the problem of the unbalanced dataset.  
The first attempted strategy exploited the “class weight” parameter of the function 
“RandomForestClassifier”. This parameter allows assigning a different weight to 
the two classes in the model, and by default is set to 0.5 for both classes, so as to 
assign the same weight to them. By assigning a heavier weight to the less 
represented class in the training set, it should be possible to compensate the 
unbalanced data.  
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Model n.5   - Descriptors: ECFP, ESshape3D, Physicochemical, Zscales_3. 
 
 
 
Figure 3.16: Tables and results of the model n. 5. 
 
 
According to the instructions
113
, in the model n. 5, different couples of relative 
weights were  associated to the classes of compounds
113
. The reported results in 
Figure 3.16 showed that, among the possibilities, the “k-fold cross-validation” 
selected the combination of the class weights equal to 0.2 / 0.8, which corresponds 
to a weight of 0.2 for “non-substrates” and 0.8 for substrates, as expected. 
Nevertheless, the performances of the model were substantially superimposable 
with those of the model n. 2, taken as the benchmark for our comparisons, and, in 
particular, the recall for the substrate’s class did not increase. 
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Model n.6   - Descriptors: ECFP, ESshape3D, Physicochemical, Zscales_3. 
 
 
 
Figure 3.17: Tables and results of the model n. 6. 
 
 
In the model n. 6, the class weights were set as 0.8 for non-substrates and 0.2 for 
substrates, which correspond to the opposite of the right correction to solve the 
problem of unbalanced data. The aim of this model was to confirm that the “class 
weight” strategy is ineffective for our purpose As seen in Figure 3.17, the results 
were not significantly worse than those of the model n. 2, confirming the 
hypothesis. 
In conclusion, we can emphasize the complete inefficiency of this approach for our 
intent. This result is in line with other on-line reported examples of inadequate 
returns of this method
114
.   
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Model n.7   - Descriptors: ECFP, ESshape3D, Physicochemical, Zscales_3. 
 
 
 
Figure 3.18: Tables and results of the model n. 7. 
 
 
The second strategy attempted in order to overcome the issue of the unbalanced 
dataset involved the so called “random under-sampling” srtategy112.  
According to this procedure and in the dataset used for the model n. 7, an amount 
of data points concerning the more abundant non-substrate’s class was randomly 
selected and deleted so to render the number of non-substrates equal to that of 
substrates. The resulting balanced dataset consisted of 338 compounds for both 
classes. As depicted in Figure 3.18, the performances of the resulting model were 
strongly influenced by the applied strategy. Indeed, the recall values underline that 
the substrate’s class is reasonably well predicted, even better than the non-
substrate’s one. This trend is also confirmed by the increasing of the MCC value, 
even though, as a consequence of the decreasing performances for the non-
substrate’s class, the averages for the precision and recall values are lower than 
those of the model n. 2. 
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Model n.8   - Descriptors: ECFP, ESshape3D, Zscales_3. 
 
 
Figure 3.19: Tables and results of the model n. 8. 
 
 
In the model n. 8, the same under-sampling strategy was applied, with the only 
difference consisting in the absence of physicochemical properties within the 
dataset features. This analysis was useful to confirm that even using balanced 
classes the model did not take significant advantages from including these 
descriptors. As shown in Figure 3.19, the performances were slightly worse than 
those of the model n. 7.  
The “random under-sampling” reveled to be an efficient method to correctly 
address unbalanced dataset, when using this kind of learning algorithms. However, 
the approach is not free of weakness and the main drawback is that it discards 
potentially useful information contained in the deleted datapoints
115
. Moreover, it 
basically reduces the size of the dataset, leading, in many cases, to a general 
decreasing in predictive accuracy.      
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The “oversampling” strategy, reported in some reviews116,115, was here not applied 
because it very often induces disadvantageous overfitting situations, due to the 
replication of already existing compounds in the minority class.    
 
 
 
3.4.7.3   Relevance of the included targets  
The first models were performed using 7 targets, namely all the human UGTs 
belonging to the 2B subfamily. Introducing more targets or reducing their number 
has two major consequences: the modification of the number of the data points, 
which influences the shape of the input matrix, and the variation of the overall 
similarity within the protein space. Two analyses were set up to investigate the 
relationships between the number of the considered targets and the predictive 
power of the model.   
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Model n.9   - Descriptors: ECFP, ESshape3D, Physicochemical, Zscales_3. 
 
 
Figure 3.20: Tables and results of the model n. 9. 
 
 
The model n. 9 replicated the conditions of the second model, with the only 
difference consisting in a higher number of targets included in the dataset. Indeed, 
the protein descriptors were calculated by considering the alignment of all 18 
enzymes, thus adding both the 1A and 2A subfamilies of the UGT enzymes. This 
led to a decrease of similarity within the whole set of sequences, as reported in 
Figure 3.20. As a result, the total number of data points is widely larger and this 
has impacted the larger number of features kept after pre-processing. This also 
reflects an increasing of the learning time.  
When introducing additional proteins and despite the increasing of diversity 
between the included UGT sequences, the model performances got worse only 
moderately, the class 1 Recall being dropped from 0.39 to 0.33. This suggested 
that, in these conditions, an identity percentage among sequences around to 40% is 
still suitable to build reasonable models. 
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Model n.10   - Descriptors: ECFP, ESshape3D, Physicochemical, Zscales_3. 
 
 
Figure 3.21: Tables and results of the model n. 10 
 
 
In the model n.10, only two targets were taken in consideration. In detail, to 
maximize the similarity and according to Table 3.2, UGT2B7 and UGT2B10 were 
selected, having 88% of identity. 
The first obtained result was a sensible decrease of the learning time, while 
maintaining relatively good performances, as shown in Figure 3.21. 
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3.4.7.4   Selection of the best protein descriptor 
A set of models was generated to verify the different performances of the 
calculated alignment-dependent physicochemical descriptors for the protein targets. 
In detail, ten models were built using the same conditions of the model n. 2 and 
changing the protein descriptors. The results are reported in Table 3.4, where the 
compiled values correspond to the averages of the results as obtained by running 
the model three times.  
As shown in the table and better clarified by the corresponding plots (see Figure 
3.22-Figure 3.25), all the computed scores follow a clear trend. The performance is 
always outstanding for the prevailing class of compounds, and indeed the non-
substrates exhibit F1 scores not lower than 0.90. Regarding the substrate’s class, 
while the precision scores are quite satisfactory, falling in the range between 0.69 
and 0.78,  the Recall scores are always under the random threshold. However, 
among the tested features, the four following descriptors were able to provide 
better results, both for recall of the substrates’ class and for Matthews Correlation 
Coefficient.  
- Zscales_3 and Zscales_5 are generated by a Principal Component Analysis 
based on physicochemical properties. More in detail, PCA mainly captures 
lipophilicity, size and polarity/charge for Zscales_3, while the fourth and the 
fifth component of Zscales_5 are more difficult to interpret relating to 
properties such as electronegativity, heat of formation, electrophilicity and 
hardness
26
. The database source for these descriptors includes many non-natural 
amino acids as shown in Table 2.1, but this does not seem to affect their 
capability to gather most of the key information for our study.  
- ProtFP_3 and ProtFP_8, termed “Protein Fingerprints”, are generated by a PCA 
based on a selection of different amino acidic physicochemical and biochemical 
properties extracted from the AAindex database
117
. The main difference in 
comparison with the previous descriptors is that they are focused only on the 20 
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natural amino acids. Moreover, they select the descriptors with the largest 
variance using a recursive elimination process which starts with the full set of 
descriptors.   
In conclusion, the analysis of different protein descriptors did not highlight features 
which were able to significantly improve the predictive power of the model but 
confirmed that the descriptors used for all previous models, namely Zscales_3, are 
the best performing ones. This allowed us to use the same protein descriptors also 
in the LOCO validation step. 
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Target 
descriptor 
Class 0 
Precision 
Class 1 
Precision 
Average 
Precision 
Class 0 
Recall 
Class 1 
Recall 
Average 
Recall 
Class 0    
F1 Score 
Class 1    
F1 Score 
Average 
F1 Score 
Matthews 
Correlation 
Coefficient 
ProtFP_feature 0.85 0.72 0.82 0.97 0.34 0.84 0.90 0.46 0.81 0.44 
MSWHIM 0.85 0.75 0.83 0.97 0.36 0.84 0.91 0.49 0.82 0.44 
ProtFP_3 0.85 0.73 0.83 0.97 0.36 0.84 0.91 0.48 0.82 0.44 
Zscales_3 0.86 0.72 0.83 0.96 0.39 0.84 0.91 0.51 0.82 0.45 
ProtFP_5 0.86 0.71 0.83 0.96 0.40 0.84 0.91 0.51 0.83 0.45 
Tscales 0.86 0.78 0.84 0.97 0.38 0.85 0.91 0.51 0.83 0.41 
Zscales_5 0.86 0.75 0.84 0.97 0.39 0.85 0.91 0.51 0.83 0.46 
FASGAI 0.85 0.69 0.82 0.96 0.35 0.83 0.90 0.47 0.81 0.41 
ProtFP_8 0.86 0.74 0.84 0.96 0.40 0.85 0.91 0.52 0.83 0.47 
VHSE 0.85 0.68 0.82 0.96 0.36 0.83 0.90 0.47 0.81 0.41 
STscales 0.85 0.73 0.83 0.97 0.36 0.84 0.91 0.48 0.82 0.44 
 
Table 3.4:  Protein descriptors performances. All models are built on ECFP fingerprints, ESshape3D fingerprints and physicochemical 
properties, and include 7 targets.  
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                     Figure 3.22:  Bar plot of precision for each protein descriptor. 
 
 
 
 
                    Figure 3.23:  Bar plot of recall for each protein descriptor. 
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                     Figure 3.24:  Bar plot of F1 score for each protein descriptor. 
 
 
 
 
                   Figure 3.25:  Bar plot of MCC score for each protein descriptor. 
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3.4.7.5   NCV results overall observations 
Interesting overall observations about NCV results arise from a comparison of the 
performances obtained with the ten generated models. To this purpose, we will 
consider the recall and the precision scores separately. 
Figure 3.26 summarizes the main differences between the performances of the 
NCV models as given by the recall results. We first focused our attention on this 
measure, as it represents the sensitivity of the model, namely the number of 
correctly predicted instances out of the total number of the instances belonging to a 
given class. 
 
 
 
                     Figure 3.26:  Class 0 Recall, Class 1 Recall and Matthews  
                                     Correlation Coefficient obtained with 10 NCV models. 
 
 
The recall scores of the non-substrates’ class (class 0) and the substrates’ class 
(class 1) as obtained by the 10 considered NCV models are reported as bar plots, in 
order to reveal the differences in the predictive performances between the 
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prevailing class and the minority one. As shown in Figure 3.26, the worse results 
are provided by the model n. 4, in which the ECFP descriptors were excluded from 
the input dataset. Nevertheless, all the other considered models present 
unsatisfactory recall values for the substrates, between 0.33 and 0.39, substantially 
under the random.  
The Matthews Correlation Coefficient (MCC) is reported as dot plot and describes 
the overall performances of the ten models, as it comprises the weighted average 
between the two Recall scores. Furthermore, for an easy comparison between the 
MCC results and the recall scores, it is important to consider that the former values 
are in the range of -1/+1, while the latter are in the range of 0/+1.  Therefore, a 
MCC score around 0.40 can be seen as a truly satisfactory performance. 
The obtained results also emphasize that the only strategy which proved successful 
in balancing the results involved the “random under-sampling” procedure, as 
applied in models n. 7 and n. 8. While this technique appears to lack in elegance, 
since it entails data discarding, it represents an efficient method to increase the 
absolute number of well predicted substrates. This is noticeable when considering 
the above below confusion matrices which are provided as the output of the models 
(see Figure 3.27).  
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Model n. 2 
 
     PREDICTED 
T
R
U
E
 
 
0 1 tot 
0 2699 111 2860 
1 433 277 710 
tot 3132 388 3570 
 
 
 Model n. 7 
 
     PREDICTED 
T
R
U
E
 
 
0 1 tot 
0 549 161 710 
1 129 581 710 
tot 749 665 1420 
 
 
Model n. 11 
 
     PREDICTED 
T
R
U
E
 
 
0 1 tot 
0 67 109 176 
1 43 667 710 
tot 110 776 886 
 
 
Figure 3.27:  Confusion matrices and results reports of model n. 2, 7 and 11. 
 
 
Results 
  Prec.  Recall F1 S. 
0 0.86 0.96 0.91 
1 0.72 0.39 0.51 
Ave. 0.83 0.84 0.82 
MCC      0.45 
Results 
  Prec.  Recall F1 S. 
0 0.86 0.77 0.81 
1 0.72 0.82 0.76 
Ave. 0.80 0.79 0.79 
MCC      0.58 
Results 
  Prec.  Recall F1 S. 
0 0.65 0.38 0.48 
1 0.84 0.94 0.88 
Ave. 0.79 0.81 0.79 
MCC      0.40 
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The under-sampling procedure does not affect the l number of substrates in the test 
set, which is 30% of total number of the substrates, thus allowing a comparison 
among the original models and the balanced ones. In details, the number of 
corresponding datapoints for a model with 7 targets is 710. This number does not 
change even when deleting other “non-substrate” datapoints, so generating a “re-
unbalanced” dataset, which exactly reproduces the opposite proportion between the 
two classes in the original dataset. Such a “re-unbalanced” dataset was then utilized 
to generate the last model n. 11, which was developed maintaining all the other 
parameters identical to those of the other considered models.  
The reported confusion matrices reveal that the true positive rate (namely the 
correctly predicted substrates) is related to their abundance in the dataset. The 
number of well predicted substrates rises from 277 in the model n. 2, to 581 in the 
model n. 7, up to 667 in the model n. 11. At the same time, the true negative rate 
(namely the correctly predicted non-substrates) drastically decreases due to their 
deletion when balancing and “re-unbalancing” the dataset.  
Moreover Figure 3.26 shows that model n. 2 and model n. 11 display opposite 
performances, with the recall score for the minority class around 0.40 and that for 
the majority class around 0.7. Nevertheless, the performance of the latter is slightly 
worse, as a result of the decrease of the total number of instances in the dataset. 
Indeed the Matthews Correlation Coefficients decrease from 0.45 to 0.40. In case 
of prediction on an external test, the balanced and the “re-unbalanced” datasets can 
be useful as a double check of the results after using the full dataset.  
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Figure 3.28 summarizes the main differences between the performances of the 
NCV models, as revealed by precision results. Indeed, a model which simply 
predicts all instances as active, achieving 100% recall, does not provide trustworthy 
predictions. To completely evaluate the predictive power of a model, the false 
positive rate has to be taken into account, and this is possible by considering the 
precision score. Precision indeed evaluates the number of correctly predicted 
instances, for a given class, out of the total number of instances predicted to belong 
to that class, namely the sum of true and false positive. 
 
 
 
 
           Figure 3.28:  Class 0 precision, Class 1 precision and average precision obtained              
with 10 NCV models. 
 
 
 
The precision scores of the non-substrates’ class and the substrates’ class are  
reported as bar plots, in order to reveal potential differences in the related 
predictive accuracy, and the average of precision for both classes is reported as dot 
plot, as a measure of the overall precision performances.  
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As shown in Figure 3.28, the worse results are provided, also in this case, by the 
model n. 4, in which the ECFP descriptors were excluded from the input dataset. 
Differently from the recall performances, the results of the other models are 
sufficiently balanced, underlying that the effect of the unbalanced dataset is weaker 
when weighting the results on the false positive rate. 
The first two models, already considered as the referring results, are the best 
balanced ones, along with the model n.8, built on the whole set of targets, which 
reaches scores equal to 0.85 and 0.76 for the non-substrates’ and the substrates’ 
classes, respectively. 
Therefore, for what concerns the precision performances, the random under-
sampling procedure is not necessary, and even not useful, because when applied, it 
does not improve the results (see Figure 3.28).  
 
 
3.4.8   LOCO results  
The NCV identified the model n. 2 as the best one in terms of combination of 
features in the input file. The same dataset was then used to validate the model by 
the procedure of “Leave One Compound Out”.  
According to this procedure, a group of data points referring to the same compound 
is left out, then the model is trained on the remaining data points and finally is 
tested on the previously discarded instances. The model can correctly predict all the 
labels of the discarded group, none of them or just some of them. As seen for the 
NCV results, the predictions are reported in a confusion matrix and the LOCO 
results can be expressed in terms of precision, recall and F1 scores. The analysis is 
repeated for all the groups included in the dataset and, in the end, the list of the 
corresponding predictive performances is generated.  
Some observations are possible about precision and recall values. First of all, 
differently from what happened when performing NCV, they are referred just to 
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one class, which is the class of the compound left out. Moreover, for this reason, 
the precision value is always either 0 or 1, while the recall value can be also a 
continuous number comprised between 0 and 1, when only some data points are 
correctly predicted.  
 
 
3.4.8.1   Recall LOCO results 
The first LOCO analysis was conducted to verify the number of correctly predicted 
compounds, as returned by the Recall values. The obtained results are reported in 
Figure 3.29. 
 
Model n. 12 
 
     PREDICTED 
T
R
U
E
 
 
0 1 tot 
0 1312 50 1362 
1 119 139 338 
tot 1431 189 1700 
 
 
Figure 3.29: Confusion matrix and results of the LOCO analysis performed on the same dataset 
used in model n. 2 for NCV analysis. 
 
 
In many cases, LOCO results are better than NCV results just as a consequence of 
the larger size of the training set. In other cases, LOCO results can be worse and 
reveal biases hidden in NCV models, due to the presence of the same compound 
both in the training and the test sets. Moreover, in LOCO models all data points are 
Results 
  Recall 
0 0.96 
1 0.41 
Total 0.85 
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predicted in the same analyses, revealing the overall predictive performances and, 
sometimes, resulting in worst results. 
In our model, as it is shown in the reported results, the overall LOCO recall values 
are comparable to the ones obtained by NCV. This finding confirms that the 
strategy consisting in the previous grouping of data according to the compound 
name, before the splitting, proved successful. Moreover, the results reveal that the 
different number of instances in the training set is not particularly relevant, and that 
the model is robust enough to maintain similar predictive powers, even when 
trained on the whole dataset. 
 
 
3.4.8.2   Probability LOCO results 
Using the specific function of Scikit-Learn called “predict_proba”, it is possible to 
print the probability associated with the prediction of each instance. More in detail, 
Random Forest assigns to each test instance two different probabilities, which are 
associated to the predicted label “0” (namely non-substrates) and to the predicted 
label “1” (namely substrates), respectively. Then, the algorithm chooses as the final 
predicted label the one with the higher probability. Therefore, each final predicted 
label has a probability within the range 0.51 to 1. This probability can be 
considered as a measure of the reliability of the final prediction: for correctly 
predicted labels, the higher is the probability, the stronger is the predictive power 
of the model; conversely, for incorrectly predicted labels, the higher is the 
probability, the weaker is the model performance.  
This probability measure can be also utilized to specifically evaluate the probability 
associated only with the correct prediction of each test instance. In this case, the 
probability takes continuous values in the whole range between 0 and 1. The results 
of this analysis are illustrated in the box-plot in Figure 3.30.  
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In the plot, the compounds are subdivided according to their true label, which 
corresponds to their classification into substrates or non-substrates based on 
experimental results. Then, the probabilities associated to a correct prediction are 
reported for the compounds of both classes. The most striking observation to 
emerge from the data comparison is the different distribution of the probabilities 
for the compounds predicted to be substrate (class 1, blue bar) and non-substrates 
(class 0, green bar).  
 
 
            
          Figure 3.30: Box plot of probabilities of correct prediction for both classes compounds.  
 
 
As depicted in Figure 3.30, the probabilities associated with the predicted 
substrates are spread out within the whole range between 0 and 1, and the median 
of data is below 0.50. This reflects the low recall value for the prediction of the 
substrate’s class. On the opposite, the majority of the probabilities associated with 
the predicted non-substrates is in the top half of the range, with a median higher 
than 0.90, as expected from the outstanding performances for this class.   
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3.4.9   Applicability Domain 
The LOCO validation method offers also the opportunity for an Applicability 
Domain (AD) analysis. The definition of the AD of the model is always a crucial 
step to increase the quality of the model itself
118
. A model will yield reliable 
predictions when its assumptions are valid and unreliable predictions when they are 
violated
119
. Therefore, it is important to define the space where model predictions 
are reliable.  
One of the possible approaches to applicability domain estimation is based on a 
similarity analysis among the training set: a compound will have a reliable 
prediction if it is enough similar to the ones used by the algorithm in the learning 
phase
120
. The similarity can be calculated according to many criteria and the 
performance of the model is plotted against the whole range of similarity in the 
training set. 
Here, we present a first attempt to define the applicability domain of the model n. 
2. It contains an important approximation, since the performance of the model takes 
advantage from three compound descriptors (ECFP, ESshape3D and 
physicochemical properties), while the similarity is here measured just according to 
one of them, the ESshape3D descriptor. This choice can be justified considering 
that the ESshape3D fingerprints account for the 3D structure of molecules and thus 
they are able to distinguish between different stereoisomers. 
Since these descriptors take discrete values, the similarity matrix, comprising the 
whole set of molecules, is computed as the Euclidian distance between each pair of 
compounds. The distance between a given test compound and its first neighbour is 
calculated from the matrix and then associated to the recall score for that 
compound. The distances are clustered according to their values and the 
percentages of correct predictions for each distance cluster are reported in the plot. 
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The analysis considers the predictions as a whole, without distinguishing between 
the two classes.    
The results of the analysis are shown in the Figure 3.31. A clear trend is shown in 
the dot plot: the performances of prediction tend to decrease when the first 
neighbour distance increases, which can be considered as a measure of the 
similarity between a test compound and the whole set of training compounds. This 
is consistent with what expected: the predictive power of the model is directly 
correlated with the similarity of the test molecule to the ones in the training set. 
The applicability domain evaluation can be utilised to foresee the reliability of the 
prediction for a new compound by measuring its first neighbour distance with the 
molecules in the training set. 
 
  
          
Figure 3.31: Applicability Domain analysis. The performances of the model get                         
worse with the increasing of first nearest neighbour distance.  
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3.4.10   Conclusions 
This study involved the generation of a classification model able to predict the 
regioselectivity of the glucuronidation reactions. The objective was reached by 
exploiting data included in the metabolic reaction database MetaSar, which has 
been manually curated and critically reviewed by our research group. The 
predictive technique used was PCM, here applied for the first time in the field of 
metabolism prediction.  
The global predictive accuracy of the model is encouraging, even though the recall 
results are unbalanced, as a direct consequence of an input dataset including two 
unbalanced classes of compounds. To increase the recall performances regarding 
the minority class, the under-sampling procedure has been successfully applied. 
Therefore, in case of prediction on an external test, the balanced and the “re-
unbalanced” dataset can be used as a double check of results, after the use of the 
full dataset.  
In detail, we can identify two interesting models. The first is the model n. 2, which 
is built on the whole dataset, and gives satisfying results for three out of the four 
measures, namely the precisions for both classes and the recall for only the non-
substrates' class. The second is the model n. 7, which is instead built on a subset of 
the available data, but reaches outstanding results for both classes, measured by 
precision as well as recall scores.    
The model can be improved to predict 8 different subclasses of glucuronidation 
reactions reported in the MetaSar reactions classification, or to predict selectivity 
among different UGTs isoforms. Moreover, the same predictive technique can be 
applied to the other metabolic classes of reactions. This can lead to a collection of 
models able to singly predict the regioselectivity of the specific metabolic reaction, 
as well as, on the whole, the entire metabolic pathway occurring to new substrates.
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4.1   Introduction 
The adenosine 5'-triphosphate, well known as ATP, is the ubiquitous energy 
currency of all living organisms. Its role in the transport of energy within the cell 
has been recognized for many years. Thanks to its high phosphate-transfer 
potential, ATP is involved in a broad variety of biological processes, such as 
energy metabolism, active transport, biosynthetic reactions, motility and cell 
division.  
Moreover, ATP can influence many biological processes also in the extracellular 
environment. It can be released from the cytoplasm of several cell types as a 
consequence of damage, and it is physiologically released by exocytosis from 
platelets and neurons. The role as a signaling molecule is held by interacting with 
specific receptors on the surface of different cells, before being quickly 
metabolized by ectonucleotidases. 
The field of purinergic signaling has grown steadily over the last forty years, since 
Holton confirmed the liberation of ATP on antidromic simulation of sensory 
nerves
121
 (in 1959), and later Burnstock and co-workers discovered that ATP is the 
principal transmitter of some of the "non-adrenergic, non-cholinergic" nerves
122
. 
Now, the purinergic receptors are found to be expressed throughout the human 
body, including the nervous, the cardiovascular and the immune systems. ATP as a 
signaling molecule is thus implicated in a wide range of physiological functions, 
such as synaptic transmission, smooth muscles contraction, taste perception, 
inflammation and nociception. So that, purinergic receptors hold great interest as 
new therapeutic targets for inflammatory, cardiovascular and neuronal disease. 
In the present Chapter, the attention will be focused on the P2X3 receptor, with the 
primary objective of going through its mechanism of action and, in particular, its 
allosteric modulation. To better frame the performed computational studies, an 
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introductive description of the main features of the purinergic receptors will be 
given in the next sections. 
 
 
4.1.1   Purinergic receptor classification 
The purinergic receptors are membrane proteins activated by ATP and its 
metabolites. In detail, two main classes can be recognized: P1, which are generally 
known as adenosine receptors, and P2, which respond to extracellular ATP.  
Focusing on P2 receptors, two main families can be recognized, on the basis of the 
type of protein: P2Y receptors, which are G protein-coupled receptors, and P2X 
receptors, which are ligand-gated ion channels.  
P2X receptors are homo- or hetero-trimers resulting by the combinations of 
different monomers. Up to know, seven subunits have been cloned and 
characterized (1-7). Each monomer consists of 379-472 amino acids, with the 
exception represented by the P2X7, which includes 595 amino acids, due to the 
increased length of its C-terminus.  
 
 
4.1.2   Molecular architecture 
P2X receptors are trimeric ion channels that exist in two main conformations: the 
closed conformation (apo), which corresponds to the inactive form, and the open 
conformation (holo), in which the receptor is activated by the binding of ATP. 
The architecture of the trimer started to be clarified thanks to the resolution of two 
important x-ray structures: the zebrafish P2X4 channel in closed state (PDB Id 
3HV9)
123
 and the later resolution of the same protein in its open state (PDB Id 
4DW1)
124
, in which the receptor is co-crystallized with three ATP molecules. 
Together with this second structure, a third crystal structure of the apo state having 
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a better resolution was published (PDB Id 4DW0)
124
. These resolved structures 
confirmed many of the functional experiments carried out since the mid-1990s. In 
particular, they revealed the molecular architecture of the trimeric cation channel 
and its biological assembly, and they elucidated the ATP binding mode and the 
ionic flow through the channel.  
 
 
4.1.2.1   The monomer structure 
The resolved purinergic receptor structures represent a model for the whole P2X 
receptors family, and key information regarding the monomer of the human P2X3 
can be derived by the alignment of its sequence with that of the zebrafish P2X4 
monomer, reported in Figure 4.1. The alignment shows the most conserved regions 
and the sequence correspondences in the crucial parts of the receptors, such as the 
ATP binding site. 
In the zebrafish resolved crystals, each monomer brings to mind the shape of a 
dolphin, and shares a common topology, characterized by the following regions 
(Figure 4.2): 
-  two transmembrane helices, TM1 and TM2, which form the cation permeable 
channel, akin to the tail of the dolphin; 
-   two short intracellular termini; 
-  a large extracellular domain, rich of glycosilated residues and disulfide bonds, 
corresponding to the head, the upper body, the two flippers, the dorsal fin and the 
lower body of the dolphin. This region also includes the binding site for ATP, 
competitive antagonists and modulatory metal ions. 
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P2X4_zf        1 MSESVGCCDSVSQCFFDYYTSKILIIRSKKVGTLNRFTQALVIAYVIGYV     50 
                     :.|...    ||.|.|:|.::::|..:|.:||..|.|:|:|.:|:| 
P2X3_h         1 ----MNCISD----FFTYETTKSVVVKSWTIGIINRVVQLLIISYFVGWV     42 
 
P2X4_zf       51 CVYNKGYQDTDTVL-SSVTTKVKGIALTNTSELGERIWDVADYIIPPQED     99 
                 .::.|.||..||.: |||.|||||..|     ...|:.||:||:.|||.. 
P2X3          43 FLHEKAYQVRDTAIESSVVTKVKGSGL-----YANRVMDVSDYVTPPQGT     87 
 
P2X4_zf      100 GSFFVLTNMIITTNQTQSKCAENPTPASTCTSHRDCKRGFNDARGDGVRT    149 
                 ..|.::|.||:|.||.|..|.|: .....|.|...|  |.....|.|:.| 
P2X3_h        88 SVFVIITKMIVTENQMQGFCPES-EEKYRCVSDSQC--GPERLPGGGILT    134 
 
P2X4_zf      150 GRCVSYSASVKTCEVLSWCPLEKIVDPPNPPLLADAENFTVLIKNNIRYP    199 
                 ||||:||:.::|||:..|||.|  ||....|::.:|||||:.|||:||:| 
P2X3_h       135 GRCVNYSSVLRTCEIQGWCPTE--VDTVETPIMMEAENFTIFIKNSIRFP    182 
 
P2X4_zf      200 KFNFNKRNILPNINSSYLTHCVFSRKTDPDCPIFRLGDIVGEAEEDFQIM    249 
                 .|||.|.|:|||:.:..:..|.|....||.|||.|:||:|..|.:||..: 
P2X3_h       183 LFNFEKGNLLPNLTARDMKTCRFHPDKDPFCPILRVGDVVKFAGQDFAKL    232 
 
P2X4_zf      250 AVHGGVMGVQIRWDCDLDMPQSWCVPRYTFRRLDNKDPDNNVAPGYNFRF    299 
                 |..|||:|::|.|.||||.....|:|:|:|.|||:....::|:||||||| 
P2X3_h       233 ARTGGVLGIKIGWVCDLDKAWDQCIPKYSFTRLDSVSEKSSVSPGYNFRF    282 
 
P2X4_zf      300 AKYYKNSDGTETRTLIKGYGIRFDVMVFGQAGKFNIIPTLLNIGAGLALL    349 
                 |||||..:|:|.|||:|.:||||||:|:|.|||||||||:::..|....: 
P2X3_h       283 AKYYKMENGSEYRTLLKAFGIRFDVLVYGNAGKFNIIPTIISSVAAFTSV    332 
 
P2X4_zf      350 GLVNVICDWIVLTFMKRKQHYKEQKYTYVDDFGL--------LHNEDK--    389 
                 |:..|:||.|:|.|:|....||.:|:..|::..|        ::..|:   
P2X3_h       333 GVGTVLCDIILLNFLKGADQYKAKKFEEVNETTLKIAALTNPVYPSDQTT    382 
 
P2X4_zf      390 ---------------    389 
                                     
P2X3_h       383 AEKQSTDSGAFSIGH    397 
  
Figure 4.1: P2X4zf and P2X3h alignment. The TM domain are highlighted in yellow, the N-
terminal part in light blue, the C-terminal in green, the residues implicated in the ATP binding in 
red, the residues involved in disulfide bonds in violet . The pipes (|) indicate the conserved residues, 
while the colons (:) indicate the homologues one.  
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Figure 4.2: the dolphin-like shape of the P2X monomer.                                                      
(Reproduced from Hattori et al.124)  
 
 
 
In detail, the central architecture of the extracellular body domain is characterized 
by a transthyretin-like β-sandwich motif. This segment appears to be rigid, and 
perhaps even resistant to conformational changes, because the two β-sheets of the 
sandwich are knit together by extensive contacts
123
. The stability of the monomer is 
also kept by disulfide bonds present in the extracellular ectodomain, which involve 
the following residues: 
- 258-267: connecting the ends of two antiparallel β-strands in the lower part of 
the dolphin’s body; 
- 214-224: in the dorsal fin; 
- 113-164; 124-147 and 130-158 located in the head region125. 
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4.1.2.2   The trimer structure: apo and holo conformations 
The purinergic receptors are composed of three monomers that can build 
homomeric or heteromeric trimers, organized in a chalice-like shape. Inside the 
receptor, three vestibules can be identified whose amplitude differs between the 
apo and the holo state, due to the structural rearrangement which happens during 
the channel activation (Figure 4.3-C).  
 
 
 
Figure 4.3: The trimer structures of the P2X4 zebrafish receptor. On the left, the apo 
conformation (a), on the right, the holo conformation (b). In the bottom of the figure the three 
internal vestibules of both conformations are depicted. (Reproduced from Hattori et al.124) 
c 
a  b 
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The apo conformation is the inactive structure, with the channel in a closed state 
(Figure 4.3-a). The shape of the TM region is like an hourglass and is formed by 
three pairs of helices, two from each of the three subunits. Considering a single 
monomer, the transmembrane helices are oriented approximately in antiparallel 
way each other and form an angle of about 45° with the membrane normal. The 
inner TM2 segments cross each other about in the middle of the membrane length. 
Therefore, the mutual arrangement of the TM segments constitutes the closed 
resting ion channel, where the ionic permeation pathway is occluded. 
The extracellular domain of each dolphin wraps around one neighbor with a right-
handed twist, establishing extensive interactions. The major interfaces that 
characterize this conformation are body to body, head to body and left flipper to 
dorsal fin. The upper region of the body domain contacts the other subunits, 
whereas there are no contacts at the base of the extracellular domain, proximal to 
TM segments. The body to body contacts involve a set of highly conserved 
external residues and are responsible for the structural rigidity of this region of the 
receptor. On the opposite, the residues in the left flipper and the dorsal fin are less 
conserved and these regions are characterized by a greater flexibility. 
The holo conformation is the active structure, with the channel in an open state 
(Figure 4.3-b). The overall protein structure of the ATP-complexed subunit is 
similar to that of the apo one, as demonstrated by the low root mean squared 
deviation between the two overlapped resolved structures (as computed considering 
the Cα atoms, about 1.8 Å).  
The substantial conformational changes associated with the ATP binding are 
localized at the interfacial regions adjacent to the ATP pocket in the extracellular 
domain, and within the ion conducting TM domain. Therefore, the lower body 
domain of the holo monomer does not superimpose well to that of the apo 
monomer, because of an outward flexing of the body domain resulting by the ATP 
binding.  
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This movement directly expands the lower extracellular vestibule, increasing the 
central separation between the monomers. Consequently, it leads to the iris-like 
motion of the lower body domain that elicits the separation of the TM helices, so 
opening the pore.  
 
 
4.1.2.3   The ATP binding site 
The ATP binding site is located in the extracellular domain, at the interface 
between two monomers. Therefore, in the whole trimer, there are three equivalent 
ATP binding sites, one at each of the three pairs of monomeric interfaces. In detail, 
the ATP biding pocket is cradled by the head domain, the upper body and the left 
flipper of the chain “A”, contacting the lower body and the dorsal fin of the chain 
“B”, of two adjacent monomers (Figure 4.4-a,b,c).   
The ATP binding site is rich in positively charged residues, which establish ionic 
interactions with the negatively charged ATP structure (see Figure 4.4-d). The ATP 
molecule, when bound to the trimer, adopts a particular U-shape conformation in 
which the β- and the γ-phosphates are folded toward the adenine ring, and the base-
sugar complex is in an "anti" conformation. Thanks to the resolved structure and 
the mutagenesis studies, the ATP binding mode is now completely clarified and the 
intermolecular contacts stabilizing the ligand-protein complex are identified. 
The three negatively charged phosphates establish salt-bridges and H-bond 
interactions with Lys70 and Lys72, located in the center of the “U”. Asn296 and 
Lys316 from chain “A” elicit additional contacts with the β-phosphate group, while 
Lys72, Arg298 and Lys316 participate in interactions with the γ phosphate 
group.The adenine base, which is deeply buried in the pocket, is involved in three 
H-bonds stabilized by the side chain of Thr189 and the backbone carbonyl oxygen  
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Figure 4.4: ATP binding site in holo trimer structure (PDB Id 4DW0) (a,b) An electrostatic 
potential surface of ΔP2X4-C contoured from −10 kT (red) to +10 kT (blue) (dielectric constant: 
80), and its close-up view. (c) The regions forming the ATP-binding pocket. The ATP molecule is 
shown in sphere representation. (d) Close-up view of the ATP-binding site. The oxygen atom from 
the glycerol molecule is shown in sphere representation. Black dashed lines indicate hydrogen 
bonding (<3.3 Å).  (Reproduced from Hattori et al.124) 
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atoms of Lys70 and Thr189. Leu191 in the lower body and Ile132 in the dorsal fin 
establish also hydrophobic interactions with the adenine base. 
Finally, the ribose ring of ATP is contacted only by Leu217 in the dorsal fin 
through hydrophobic interactions, while the O2 and O3 oxygen atoms of the ribose 
are solvent accessible. 
 
4.1.2.4   The pore conformation 
In the closed state, looking from the extracellular surface, Leu340 and Asn341 
define the extracellular boundary of the ion channel gate, with the hydrophobic side 
chains of every Leu340 occluding the pore. On the opposite side of the membrane, 
Ala347 and Ala346 define the cytoplasmic gate. Moreover, the center of the gate is 
occupied by Ala344, which corresponds to the closest contact between the TM2 
helices
123
. 
In the open pore, the same residues are positioned far from the central threefold 
axes, allowing the cation to pass inside the cell. Interestingly, there are no 
hydrophilic residues in the middle of the pore. Therefore, water molecules 
coordinated to permeating cations likely interact with the backbone atoms
124
. 
The pore can become permeable also to large organic cations, such as N-metyl-D-
glucamine (NMDG), thanks to the well-known “pore-dilatation” phenomenon, 
which causes an enlargement of the pore up to about 7.3 Å of diameter. According 
to the two-voltage clamps studies by Hattori at al., the pore dilatation appears upon 
to 5-minute application of saturating ATP. They found that the evoked current 
remains constant, suggesting that the resolved structure represents a non-pore 
dilated open state.  
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Thanks to the 4DW0 holo resolved structure, also the pathway by which the 
hydrated ions enter and exit through the channel has been clarified. This pathway 
involves the lateral fenestrations nearly above the membrane pore. Once the ions 
pass through the fenestrations, the highly acidic central vestibule attracts cations 
and repels anions.  
 
 
4.1.3   The mechanism of channel activation mediated by ATP 
The comparison of the extracellular regions in the apo and the holo crystals 
elucidates how ATP binding leads to channel activation. A clear scheme of the 
movements occurring is depicted in Figure 4.5. 
First, when binding within the inter-subunit cleft, ATP promotes closure between 
the head and the dorsal fin domains, inducing the movement of the dorsal fin 
domain up toward the head domain. Simultaneously, ATP pushes out the left 
flipper from the pocket. Because the dorsal fin and the left flipper are structurally 
coupled to the lower body domain, this movement promotes a concomitant outward 
flexing of the lower body domain that substantially expands the extracellular 
vestibule, increasing the separation by about 10 Å. During the flexing, the domain 
behaves as a rigid body and each subunit rotates by about 8° around an axis located 
in the upper body. Finally, the movement reaches TM1 and TM2 domains, which 
flex and rotate, opening the ion channel pore in an iris-like way. In particular, TM1 
and TM2 undergo a rotation of 10° and 55° counterclockwise and increase their tilt 
angle by about 8° and 2°, respectively. The consequence of the iris-like movement 
is the expansion of about 3 Å of the central pore.  
In the ATP bound state, the interactions between the helices are broken, and the 
open pore conformation is stabilized by new contacts between subunits involving 
Leu346 and Ile353. 
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Figure 4.5: ATP mechanism of activation. (a) The holo structure (coloured) is superimposed to 
the apo (in grey). Only two subunits are shown. The rotation axis describes the superposition of the 
apo subunit onto the ATP-bound one. (b) Close-up view of the conformational changes resulting 
from ATP binding. (c, d) Cartoon model of the ATP-dependent activation mechanism. The black 
arrows denote the movement from the apo closed state (c) to the ATP-bound open state (d). 
(Reproduced from Hattori et al.124) 
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4.1.4   Multiple allosteric conformational states in P2X receptors 
The P2X receptors can be classified as “allosteric proteins” with reference to their 
capability to interconvert among several conformational states (Figure 4.6). In 
normal conditions, the ATP binding drives the receptor from the resting closed 
channel state (R), to an active open channel state (O1), selective for small cations.  
 
 
 
Figure 4.6: Multiple allosteric conformational model. 
(Reproduced from Iiang et al. 126)  
 
 
However, as before mentioned, a subset of P2X receptors, including P2X2, P2X4, 
P2X7 and P2X2/3, displays an eventual second open state (O2) induced by a 
prolonged application of ATP
127
. In this other conductive state, known as pore 
dilation, the pore becomes progressively permeable to larger cations, such as 
NMDG and propidium dyes. During the pore dilation, structural rearrangements 
occur in both the pore and the cytosolic regions of the protein, but the amino acids 
involved in this conformational change are yet unknown
126
.  
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Generally, sustained ATP applications lead the receptor to a desensitized closed 
channel state (D), which is refractory to further activation. The P2X receptor class 
presents very different desensitization kinetics: the P2X1 and P2X3 display fast and 
nearly complete desensitization within 2 seconds of application of ATP, while, 
P2X2, P2X4 and P2X7 show nearly no desensitization when expressed in HEK293 
cells
128
. 
Moreover, recent studies supports also the existence of an intermediate closed 
channel state (F) that would precede the open state and follow the resting one, as 
already proposed for the pentameric Nicotin receptors
128
.n 
 
4.1.5   Physiological function of the P2X receptors 
All P2X receptors are characterized by a simple mechanism involving the opening 
of the central pore in response to ATP activation. The consequent permeation of 
cations, especially Ca
2+
, leads to the depolarization of the cells and, at the same 
time, to the generation of the downstream calcium signaling
126
. Then, the variety of 
different effects elicited by these receptors is mainly due to their different 
localization, expression and modulation (Table 4.1).  
Among the most observed pathways, we can include the following examples:  
P2X1 receptors are involved in the vas deferens contraction and the male infertility, 
as demonstrated by studies using the first knock out mice
121
; P2X3 and P2X2/3 
receptors are implicated in the nociception, being expressed in particular in 
terminal sensory nerves, where they detect ATP released from peripheral tissue or 
visceral organs
121
; P2X4 receptors are expressed in the microglia and they are  
recognized to play a role in mediating neuropathic pain
121
; P2X5 receptors are 
found in sensory neurons, where they are involved in sensing muscle ischemia; 
P2X7 receptors play a substantial role in inflammation and immunity; finally P2X6 
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receptors are likely expressed as heteromeric receptors with P2X2 and P2X4 in 
motoneurons of the spinal cord, with a still almost unknown role. 
 
 
 
 
 
 
 
 
 
Table 4.1: P2X receptors main distribution 
 
 
P2X3 receptors, on which the present chapter is focused, are predominately and 
selectively localized on small to medium diameter C- and Aδ-fiber of primary 
afferent neurons (PAN), within the dorsal root ganglion and the cranial sensory 
ganglia. They are also present on the respective peripheral nerve terminals in 
tissues comprising skin, joints and hollow organs.  
PAN can be grouped in more types which are characterized by differential 
morphological properties, speed of conduction, molecular markers and receptor 
patterns on their surface. These diversities among sensorial neuron types reflect 
functional differences: they recover a wide range of physio-pathological roles from 
RECEPTOR MAIN DISTRIBUTION 
P2X1 
Smooth muscle, platelets, cerebellum, dorsal horn spinal 
neuron 
P2X2 
Smooth muscle, CNS, retina, chromaffin cells, autonomic 
and sensory ganglia 
P2X3 
Sensory neurones, nucleus tractus solitarii, some 
sympathetic neurones 
P2X4 CNS, testis, colon 
P2X5 
Proliferating cells in skin, gut, bladder, thymus, spinal 
cord 
P2X6 CNS, motor neurones in spinal cord 
P2X7 Apoptotic cells in immune system, pancreas, skin etc. 
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low threshold (non-nociceptive), proprioceptive, mechanosensitive, and 
thermosensitive detection, to high threshold fibers (nociceptive).  
Although the expression of P2X3 receptors appears to be sparse elsewhere, there are 
reports indicating its localization in epithelial cell population, for example within 
the urinary bladder, and on brainstem neuron’s dendrites. In any case, thanks to 
these fibers, the signal induced by the painful stimulation in periphery can reach the 
central ganglion through the PAN system. ATP can be released by various cells as 
a result of tissue inflammation, injury or stress, as well as visceral organ distension 
and stimulate these local nociceptors
129
. 
Because of its specific and limited location, this receptor offers unique opportunity 
to investigate sensory and nociceptive mechanisms; moreover, its inhibition could 
provoke a lower likelihood of adverse effects in brain, gastrointestinal or 
cardiovascular tissues, effects that remain limiting factors for many existing 
painkillers.  
 
 
4.1.6   P2X3 antagonist: the current situation and future perspectives 
P2X3 antagonism has a uniquely broad range of activities across visceral, 
inflammatory and neuropathic models. The identification of potent and selective 
inhibitors is an interesting goal in drug discovery, with many fertile potential 
applications.  
Prior to 2000, there were no reports of “drug-like” small molecules that selectively 
antagonized the activation of P2X3 receptors by ATP. The existing antagonists 
were large poly-anionic molecules with little specificity (Suramin, PPADS) or 
nucleotides (TNP-ATP), neither of which provided ideal starting points for 
medicinal optimization
130
.  
In 2002, more promising leads were reported and patented by Abbott Laboratories, 
in particular A-317491, which offered sub-micromolar potency, competitive and 
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selective antagonism at P2X3 and P2X2/3 receptors, and which  presented properties 
that could offer applicability for in vivo studies in sensory models
131
 (Figure 4.7). 
However, all these antagonists were poly-anionic molecules, and despite having a 
good in vivo plasma half-life, they were almost completely bound to proteins. For 
this reason, they had essentially no permeability from enteric into systemic 
compartments. After all, the removal of the acidic functions led to loss of activity, 
and, despite considerable efforts, this class of competitive ATP antagonists could 
not be chemically optimized in developable small molecule candidates. 
 
 
 
 
 
 
Figure 4.7: Non-drug-like purinergic antagonist 
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Later on, from 2004 onwards, Roche Pharmaceuticals patented several novel 
classes of compounds with potential drug-like features, and new scaffolds of 
optimized competitive antagonists for P2X3 receptors were identified
132
 (Figure 
4.8).  
 
 
 
                            AF-353 (RO-4)                                                     AF-906 (RO-51) 
 
Figure 4.8: Potent orally bioavailable P2X3 and P2X2/3 antagonists  
 
 
Likewise, other companies, including Evotec AG, Astra Zeneca, Merck and 
Shionogi, identified potentially developable molecular scaffold.  
So far, despite the efforts of the pharmaceutical companies, only one candidate 
P2X3 antagonist is progressing into human studies: the orally available aryloxy-
pirimidine-diamine molecule AF-219, developed by Roche
133
. Its inhibitory 
potency (IC50) has been reported about 30 nM versus the recombinant hP2X3 and 
100-250 nM at the hP2X2/3 receptor. To date, AF-219 has being tested for four 
different therapeutic indications, which are osteoarthritic joint pain, BPS/interstitial 
cystitis, chronic cough and asthmatic syndrome. For the first three indications, the 
Phase II of the clinical trials has already been completed, while the studies on 
asthma have completed the Phase I.  
The results of the clinical trials on the chronic cough were disclosed in the 
European Respiratory Society Annual Congress in September 2013, where it was 
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shown a small pilot study in patients with considerable cough burden. 24 patients 
were treated for 2 weeks, with a single high daily dose of AF-219 compared with 
placebo. The molecule markedly reduced cough frequency in daytime of 75%. This 
was the first promising result of clinical use for a purinergic antagonist
133
. These 
findings also augur well for other symptoms of airways diseases, that are implicate 
by afferent hyperaxcitability.   
Competition binding and intracellular calcium flux experiments showed that Both 
AF-353 and AF-219 inhibit activation by ATP in a non-competitive manner. These 
studies clearly suggested the presence of one or more allosteric binding sites in the 
trimeric structure of P2X3 receptors, which might be the principal targets of the 
existing and the future ATP competitors. Therefore, the identification of a potential 
allosteric binding site is an essential and compelling requisite to support the 
rational development of purinergic inhibitors.  
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4.2   Binding site identification techniques 
 
 
4.2.1   Introduction 
The identification and the full characterization of the protein binding sites is a 
demanding problem in the field of computer aided drug design. The complete 
definition of the potential  pockets within a given protein structure is a crucial 
challenge in drug discovery, and its achievement can lead to a better understanding 
of the molecular interactions, and to an important improvement in the quality of the 
rational drug design. 
In the last years, the classic key-lock model for the ligand-receptor interaction 
evolved along with the discovery of the dynamic aspects of proteins, which consist 
in conformational changes that range from small side-chains adjustments to large 
domain motions. Furthermore, protein-ligand interactions rely not only on the 
steric complementarity, but also on the physicochemical compatibility. The 
approaches to search binding sites should be able to deal with these aspects, and to 
overcome the difficulty to find procedures that can be used universally for all 
proteins.  
On this ground, we assisted to the development of different new computational 
methods aimed at obtaining maps of the possible interactions and identifying the 
features of the binding sites. The structure based methods are one of the current 
solutions: they include approaches based on the geometrical space, on the energy 
space and on the analysis of the interacting key residues
134
. The first approach 
detects the possible binding site by searching for void volumes, while the energy 
based methods calculates the interaction energies with some representative probes 
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to identify the binding pocket. In both cases, the analysis is supported by the 
genomic characterization of the protein.  
Here, we present three different pieces of software which implement diverse 
approaches to face the problem:  
- FPocket: a classic geometric approach;    
- SPILLO-PBSS: an innovative structure-based approach; 
- PELE: a Monte Carlo-based technique. 
 
 
4.2.2   FPocket 
Fpocket is an open source software which exploits a classic geometric approach, 
based on the individuation of the void volumes within the protein
135
. Through this 
method, a clear map of the protein cavities and their structural characterization can 
be obtained. The identified pockets are then ranked according to their reliability in 
terms of capacity to accommodate small compounds. 
The FPocket approach is based upon the use of alpha spheres (Figure 4.9). An 
alpha sphere is defined as a sphere which contacts four atoms on its surface and 
contains no internal atoms. In proteins, these spheres can be large, when 
considering the surface of the whole structure, small, for the core of the protein, 
and medium, in correspondence with cavities and clefts. Therefore, a given pocket 
can be located by calculating the position and the corresponding radius of the 
medium alpha spheres
135
.  
The algorithm’s workflow can be summarized in three steps: first the whole 
ensemble of alpha spheres is calculated on the protein structure, then the spheres 
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are clustered together, finally the clustered pockets are ranked according to their 
ability to accept small molecules, so selecting the most interesting pockets.  
The ranking criteria of pockets do not reflect druggability, since the small molecule 
might be a drug or a sugar, a cofactor or a coactivator
135
. Moreover, the search is 
not based on a specific class of compounds and the method reveals to be not 
suitable for describing ligand selectivity. For these reasons, the algorithm often 
returns a large number of potential pockets, as in our case, and the selection of the 
most reliable binding sites can be problematic and too demanding.  
 
 
 
Figure 4.9: Example of pocket output 
(Reproduced from Le Guilloux et al.135) 
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4.2.3   SPILLO-PBSS: protein binding site searcher 
According to the concept of protein druggability, all the protein binding sites, 
despite their structural differences, share key properties that allow them to form 
stable complexes with the respective ligands. On this basis, different approaches 
were developed to identify potential binding sites within the protein 3D-structures. 
An important limitation of the currently available structural approaches for the 
binding site prediction is that they are not able to find the right binding sites on 
protein 3D-structures unless they are already in a suitable conformation for the 
binding event: in fact, if the proteins are in a distorted conformational state, 
involving, for example, a closed conformation of the binding site, the software fail 
to identify the right binding sites.  
SPILLO-Potential Binding Site Searcher
136
 (SPILLO PBSS) is an innovative 
software which overcomes the limitations of the other tools for the binding site 
prediction, detecting potential binding sites within protein 3D-structures, even 
when these are highly distorted compared to a suitable binding conformation.  
SPILLO-PBSS is based on the assumption that ‘similar binding site can bind the 
same ligand in a similar way’, and it uses a well-known reference binding site 
(RBS) to search the target proteins for potential binding sites (PBSs) similar to the 
RBS (Figure 4.10). 
In detail, the RBS is obtained from the three-dimensional structure of a given 
protein bound to its ligand, by an analysis of the complex geometrical structure and 
physicochemical properties. In particular, the residues included in the RBS are 
those surrounding the ligand (i.e. having at least one atom within a predefined 
distance from the ligand), and for each of them a weight (a coefficient) representing 
the specific relevance in stabilizing the interaction (classical non-bonded 
electrostatic and Lennard-Jones potential energy) with the ligand is calculated. The 
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weights can be also assigned manually by the user when given residues are already 
known to have relevant roles in the complex stability. 
Once obtained the RBS, the software creates a reduced representation of the 
system, in which all the residues are described by spheres ad vectors. This 
simplified model, together with a specially designed geometric tolerance, allows 
SPILLO-PBSS to implicitly take into account protein flexibility without recurring 
to explicit simulations and to easily detect the binding sites even if they underwent 
to conformational distortions or similar phenomenon. 
The next step is the search of PBSs throughout the whole target proteins (not only 
on the surface), by a comparison of the RBS to the different regions in the proteins. 
To this aim, the target protein is put inside a virtual grid with cubic cells and the 
RBS is iteratively and systematically translated to all grid nodes, and for each of 
them it is rotated around the three Cartesian axes. For each position of the template, 
the residues of the examined protein are individuated and analysed to see if they 
can correspond to those present in the RBS. The scoring function takes also into 
account binding sites with different amino acid composition with respect to the 
RBS, but with similar physicochemical properties. In this way, a set of potentially 
relevant binding sites are collected on a list in decreasing order according to their 
similarity to the program input (to the RBS).  
As already mentioned, the geometric tolerance plays a fundamental role in the 
PBSs individuation, because the software allows that the residues on the target 
proteins can be disposed in a different way compared to the reference. Furthermore 
the tolerance is also expected to compensate the inaccuracies introduced during the 
simplification steps.         
Finally, the scoring function of the identified PBSs is expressed as a percentage, so 
that the maximum value of 100% correspond to the ideal case of complete 
agreement between RBS and PBS.  
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Figure 4.10: SPILLO-PBSS workflow 
(Reproduced from Di Domizio et al.136) 
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4.2.4   PELE: Protein Energy Landscape Exploration 
PELE (Protein Energy Landscape Exploration)
137
 is a Monte Carlo based technique 
that combines protein structure prediction algorithms to explore all-atom energy 
landscapes. It was first developed to map ligand entrance and exit from proteins 
binding site, but its application was then expanded to other similar issues, such as 
ligand diffusion in the binding site, induced fit docking, evaluation of ligand-
protein binding energy, and overall protein dynamics. It is always characterised by 
a reduced computational cost if compared to canonical MD simulations.  
Pele performs an unconstrained ligand exploration or a binding site search. In the 
present study, it was indeed exploited to identify binding site arrangements, by 
using a method that considers the conformational flexibility of the protein.  
The software workflow (Figure 4.11) is organized in consecutive steps which are 
iteratively executed to explore the protein landscape. First, after an initial 
estimation of the starting energy, the system is subjected to a local perturbation, a 
process that can involve the protein backbone, the side chains, and the ligand. The 
second step involves the conformation optimization of the side chains, by using a 
specific algorithm and a rotamer library.  Finally, the perturbed regions are 
minimized to generate a rearrangement of the backbone in response to the initial 
system alteration. The overall process was designed on the assumption that first the 
protein side chains act as sensors that trigger the protein and ligand perturbations, 
and then the backbone atoms follow the side chains perturbations.   
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Figure 4.11: PELE workflow 
(Reproduced from Madadakar-Sobhani et al138.) 
 
These three steps compose a move which can be accepted or rejected, based on a 
Monte Carlo algorithm, which provides an efficient method for sampling the 
conformational space.  
In detail, the software input consists in a file containing the protein and the ligand 
located to a certain distance from the macromolecule surface
138
.  Among the 
calculation parameters that can be set, there are the number of CPUs used, which 
corresponds to the number of different trajectories created, the number of Monte 
Carlo steps and the wall clock time limits (maximum time provided for the 
simulation).  
Once the simulation is completed, the software returns a trajectory file with 
different parameters, calculated at each step of the simulation: 
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- SASA: percentage that show the exposed surface area of the ligand; 
- Binding energy: computed between the ligand and protein;  
- Native RMSD: root mean square deviation calculated  between the protein 
and a given native protein; 
- Ligand RMSD: root mean square deviation  of the ligand in respect to the 
starting position; 
- Point/atoms distance: distance calculated between a ligand atom and a 
point/ atom of the protein 
Moreover, these data are visualized in a table and in a plot, which are continuously 
updated during the simulation (see for an example Figure 4.12).  
The trajectory file shows the movement of the ligand around and inside the protein 
structure, and the most stable complexes can be selected looking at the simulation 
frames reporting the lowest binding energy values. By using this approach, we 
were able to identify an interesting potential binding site on the purinergic 
receptors structure (see Chapter 4.3.10)  
 
 
 
Figure 4.12: Pele output file: Binding energy of ten trajectories around P2X3 receptor.
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4.3   Modelling of human P2X3 receptor allosteric 
inhibition.  
 
4.3.1   Setting the scene 
The field of purinergic signalling has grown constantly over the last forty years, so 
that the scientific community is now well aware of many characterizing features of 
this system. Both academic laboratories and pharmaceutical companies started 
projects and experimental trials to better explore the purinergic physiological path, 
in order to exploit the druggability potential of the purinergic receptors. P2X3 
receptors, in particular, are identified as pain-related membrane proteins, and are 
considered as new targets for the treatment of painful conditions in acute and 
chronical diseases. 
In the Chapter 4.1 we reported the main recent efforts carried out by Roche and 
Afferent Pharmaceuticals in order to identify and test P2X3 antagonists, which can 
represent a valid alternative to the painkillers already present in the pharmaceutical 
market. 
For the time being, many aspects of the purinergic signalling remain unclear. One 
of the most challenging is the complete definition of the actual molecular 
mechanism of action of P2X3 antagonists. Indeed, although the not-competitive 
behaviour of ATP inhibitors was demonstrated by functional in vitro studies, the 
allosteric binding site and the mode of action of the antagonists are not yet 
clarified.  
The aim of the present study was the modelling of the inhibition activity of 
purinergic antagonists through the identification and validation of a potential 
allosteric binding site on the trimeric structure of P2X3 receptors. The project 
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involved the homology modelling of the trimer structure, the identification of the 
potential allosteric binding sites by different approaches, and the validation of the 
defined pockets by a virtual screening approach coupled to the enrichment factor 
analysis and by a QSAR analysis.  
 
4.3.2   Modelling and optimization of hP2X3 receptor 3D-structures 
 
4.3.2.1   Set-up of the protein templates 
The first step of the project involved the homology modelling of the human P2X3 
receptor, both in the apo and in the holo forms, by using the resolved zebrafish 
P2X4 receptor structures as the templates. In particular, the crystal structure of the 
apo trimer, namely the PDB Id 4DW0
124
 structure, was used as the template for the 
closed model of the ion channel, while the resolved structure of the holo trimer, 
namely the PDB Id 4DW1
124
 structure, served as the template for the ATP bound, 
open model.    
To this end, the three-dimensional structures of the templates were assembled 
starting from the resolved monomers included in the crystals, by exploiting the 
reported transformation matrices. In detail, the three sets of transformation 
coordinates were applied to the single monomer and the three differently oriented 
subunits were assembled to build the trimeric structures. To optimize the inter-
subunit contacts in the so obtained structures and to avoid high-energy 
arrangements, an energy minimization was performed by using NAMD
98
. The 
atomic partial charges were computed by the Gasteiger-Marsili method, while the 
potential and the atom types were assigned using the CHARMM 22 force field. In 
order to preserve the resolved structure of the templates, the protein backbone 
atoms were kept fixed. For the holo trimer, the three ATP molecules included in 
the binding sites were free to move.  
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4.3.2.2   Modelling methods 
Both the models were obtained by using the modelling software Modeller 
9.10
139
and applying the same modelling protocol, as follow.  
The software firstly calculated the alignment of the template monomer’s sequences 
with the monomer’s sequence of the human P2X3 receptor. The alignment of the 
subunit 4DW0-A is reported for example in Figure 4.13.  
 
 
aln.pos         10        20        30        40        50        60 
4DW0A     -----------------------GTLNRFTQALVIAYVIGYVFVYNKGYQDTDTVL-SSVTTKVKGIA  
P2X3      MNCISDFFTYETTKSVVVKSWTIGIINRVVQLLIISYFVGWVFLHEKAYQVRDTAIESSVVTKVKGSG  
 _consrvd                        *  **  * * * *  * **   * **  **   *** ***** 
 
 _aln.p   70        80        90       100       110       120       130 
4DW0A     LTKTSELGERIWDVADYIIPPQEDGSFFVLTNMIITTNQTQSKCAENPTPASTCTSHRDCKRGFNDAR  
P2X3      LYA-----NRVMDVSDYVTPPQGTSVFVIITKMIVTENQMQGFCPESEE-KYRCVSDSQCG--PERLP  
 _consrvd *        *  ** **  ***    *   * ** * ** *  * *       * *   * 
 
 _aln.pos  140       150       160       170       180       190       200 
4DW0A     GDGVRTGRCVSYSASVKTCEVLSWCPLEKIVDPPNPPLLADAERFTVLIKNNIRYPKFNFNKRNILPN  
P2X3      GGGILTGRCVNYSSVLRTCEIQGWCPTE-V-DTVETPIMMEAENFTIFIKNSIRFPLFNFEKGNLLPN  
 _consrvd * *  ***** **    ***   *** *   *    *    ** **  *** ** * *** * * *** 
 
 _aln.pos    210       220       230       240       250       260       270 
4DW0A     INSSYLTHCVFSRKTDPDCPIFRLGDIVGEAEEDFQIMAVRGGVMGVQIRWDCDLDMPQSWCVPRYTF  
P2X3      LTARDMKTCRFHPDKDPFCPILRVGDVVKFAGQDFAKLARTGGVLGIKIGWVCDLDKAWDQCIPKYSF  
 _consrvd         * *    ** *** * ** *  *  **   *  *** *  * * ****     * * * * 
 
 _aln.pos      280       290       300       310       320       330       340 
4DW0A     RRLDNKDPDNNVAPGYNFRFAKYYKNSDGTETRTLIKGYGIRFDVMVFGQAGKFNIIPTLLNIGAGLA  
P2X3      TRLDSVSEKSSVSPGYNFRFAKYYKMENGSEYRTLLKAFGIRFDVLVYGNAGKFNIIPTIISSVAAFT  
 _consrvd  ***       * ************   * * *** *  ****** * * *********     * 
 
 _aln.pos        350       360       370       380       390       400 
4DW0A     LLGLVNVICDWIVL-----------------------------------------------------  
P2X3      SVGVGTVLCDIILLNFLKGADQYKAKKFEEVNETTLKIAALTNPVYPSDQTTAEKQSTDSGAFSIGH  
 _consrvd   *   * ** * *  
Figure 4.13:  Modeller alignment of hP2X3 and zfP2X4 (4DW0A) monomer’s sequences. The 
symbol (*) indicates the conserved residues. 
 
 
Then, two sets of five different models for the human monomers were generated, 
one for the apo structure and another for the holo one. The selection of the best 
models was made based upon the scores provided by Modeller 9.10 (namely DOPE 
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and GA341) and the Ramachandran Plots, as reported in Figure 4.14. In both cases, 
the best selected model was the model n. 1, which reports the highest values for all 
the considered scores. 
 
 
Apo 
Model 
DOPE 
score 
GA341 
score 
RP favoured 
residues (%) 
RP highly fav. 
residues (%) 
1 -33507.25 1.000 89.92 65.74 
2 -33021.60 1.000 89.92 65.24 
3 -32994.92 1.000 89.18 65.20 
4 -33296.24 1.000 89.69 65.68 
5 -32467.81 1.000 89.54 64.74 
 
 
 
Holo 
Model 
DOPE 
score 
GA341 
score 
RP favoured 
residues (%) 
RP highly fav. 
residues (%) 
1 -32230.53 1.000 91.18 64.74 
2 -32189.07 1.000 91.18 64.24 
3 -31941.93 1.000 89.67 64.01 
4 -31928.46 1.000 90.68 64.50 
5 -31812.09 1.000 88.66 64.74 
 
Figure 4.14: Scores values of the sets of five models for apo and holo monomers. 
 
 
Finally, the selected monomer structures were assembled to generate the trimers, 
using the previously prepared trimeric templates by superimposing each modelled 
monomer to the corresponding monomer template. During this procedure, the 
unsatisfactorily superimposed segments were manually modified to be coherent to 
the template folding, and consequently optimized through a minimization 
performed by NAMD (10000 iterations, dielectric constant = 1). Since a perfect 
superimposition was clearly impossible, the matching atoms guiding the 
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overlapping were differently weighted and the priority was given to the regions 
close to the ATP binding site. Then, the trimeric structures of the human apo and 
holo P2X3 receptors were generated by applying to the same transformation matrix 
of the corresponding templates.  
The obtained trimeric models were optimized by carrying out a minimization (fixed 
backbone atoms, 30 000 steps, free ATP molecules), followed by a 10 ns MD study 
performed by NAMD. In detail, firstly, the trimers were embedded in a box of 
water (85 Å x 85 Å x 85 Å) containing 16250 solvent molecules. The systems were 
then minimized to optimize the relative position of the solvent molecules and then 
were subjected to MD runs with the following characteristics: (a) periodic 
boundary conditions (95 Å x 95 Å x 95 Å) were applied to stabilize the simulation 
space; (b) Newton's equation was integrated using the r-RESPA method (every 4 fs 
for long-range electrostatic forces, 2 fs for short-range non bonded forces, and 1 fs 
for bonded forces); (c) the long-range electrostatic potential was computed by the 
Particle Mesh Ewald summation method (80 × 80 × 80 grid points) (d) the 
temperature was maintained at 300 ± 10 K by Langevin’s algorithm; (e) Lennard-
Jones (L-J) interactions were calculated with a cut-off of 10 Å and the pair list was 
updated every 20 iterations; (e) a frame was memorized every 10 ps, thus 
generating 1000 frames; and (f) no constraints were imposed to the systems. The 
simulations were carried out in two phases: an initial period of heating from 0 K to 
300 K over 100000 iterations (100 ps, i.e. 0.3 K/ps) and the monitored phase of 10 
ns.  
The lowest energy structures was then extracted by the MD runs and finally 
optimized after removing water molecules and neutralizing ions.   
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4.3.2.3   Modelling results 
As a preamble, Figure 4.15 shows the optimized monomeric and trimeric structures 
of the templates for the apo and holo state, obtained as before described.  
Figure 4.16 depicts a comparison between the superimposition of a single modelled 
monomer before and after its optimization. The pictures underline the importance 
of the refinement performed on the models generated by standard homology 
modelling technique, in order to obtain truly reliable final models.  
The trimeric structures underwent a structural validation  performed by  
PROCHECK
140
, which calculates all structural parameters of a protein model and 
gives indications of its reliability. In particular, the attention was focused on: 
Ramachandran plot, bond lengths, angles distortions and planar group distortions. 
The obtained trimeric models are depicted in Figure 4.17 . 
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Figure 4.15: Optimized trimer templates. (a) Apo structure. (b) Holo structure.  On the left the 
monomers, on the right the trimers. In the holo trimer, are depicted also the three ATP molecules 
included in the binding sites. 
 
a 
b 
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Figure 4.16: Optimization of the superimposition for the monomer structure. The crystals are 
coloured and the models are while. On the left is reported the superimposition before the 
optimization, on the right the result after the optimization. (a) apo trimer, (b) holo trimer 
 
b a 
b 
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Figure 4.17: P2X3 models and relative Ramachandran plots. (a) apo trimer, (b) holo trimer 
P2X3 apo trimer 
P2X3 holo trimer 
a 
b 
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4.3.3   Set-up of the selected purinergic inhibitors 
The second step of the project involved the collection of allosteric ligands for the 
P2X3 purinergic receptor by focusing the attention on allosteric inhibitors with a 
value of IC50 in the range of nanomolar activity. In detail, we collected molecules 
belonging to two structural families of purinergic ligands:  
- the diaminopyrimidines (DAPs)132,141,142,143, which are unselective for P2X3 
being also active on P2X2/3. These compounds came from a series of Roche 
molecules developed as structural analogues of Trimethoprim, a well-
known inhibitor of the bacterial dihydrofolate reductase (DHFR).   
- the arylamide derivatives (SAAs)144, which are selective for P2X3 receptor 
(pIC50 for P2X2/3 <5). Their parent compound has been identified thanks to 
a high throughput screening campaign using the rat P2X3 recombinant 
receptor at Roche.  
The dataset of purinergic ligands consisted in 24 compounds belonging to the 
DAPs family (deriving from 21 compounds by generating all possible 
stereoisomers), and 6 compounds belonging to the SAAs family. The complete list 
of these compounds is reported in Appendix 2, with the relative pIC50 values 
experimentally obtained using the FLIPR method on recombinant P2X3. 
To be compatible with physiological condition (pH = 7.4), SAA molecules were 
simulated in their ionization state by protonating the tertiary ammine group of the 
piperazinic ring. On the other hand, DAP molecules can present the piperazine ring 
either protonated or not, and both protonation states of these compounds were 
taken in consideration. 
Each ligand included in the study underwent the same protocol of preparation, 
based on a MonteCarlo procedure which generated 1000 minimized geometries by 
randomly rotating the flexible torsions. The so generated lowest energy structure 
underwent the following docking simulations.  
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4.3.4   Generation of decoy datasets  
The first strategy adopted to assess the reliability of a potential allosteric binding 
pocket was based on a virtual screening study coupled with an enrichment factor 
analysis. Therefore, to perform such analysis, two different decoy databases were 
built, both including 30 active molecules, namely the purinergic inhibitors 
previously collected, and 2970 presumably inactive compounds.  
Both decoy databases are characterized by a random percentage of active 
molecules equal to 1 (this means that choosing randomly 100 molecules, 1 active 
molecule is expected to be found). The inactive molecules were collected within 
the Directory of Useful Decoys (DUD)
145
, taking in consideration the size and the 
charge parameters. In detail, when considering that DAP derivatives can be 
protonated or not, the two decoy sets had the following characteristics: 
- DECOY_1: The DAP molecules were considered in the protonated state, 
according to the condition of Trimethoprim when it is bound to its target, 
namely the Diyhdropholate reductase (see Figure 4.18). Therefore, all the 
active molecules have one positive charge and, consequently, the whole set 
of inactive molecules was collected choosing compounds with one positive 
charge, searching from a database of inactive compounds on 
acetylcholinesterase.   
- DECOY_2: The DAP molecules were considered in the neutral state, 
therefore also a proportional part of the inactive molecules were chosen 
with a neutral charge, searching from a database of inactive compounds on 
Hivrt (HIV-retrotranscriptase) and on Inha (enoyl alyl carrier protein).  
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Figure 4.18: Trimetoprim protonation state 
 
 
 
 
4.3.4.1   Reliability of the collected datasets 
The potentially unbiased composition of the two decoy datasets was assessed by 
performing a preliminary virtual screening study using a different biological target, 
namely the recently resolved muscarinic AChM2 receptor structure (PDB Id 
3UON), also objected of modelling studies which are reported in Chapter 5.   
Docking simulations involved both datasets and, as mentioned above, were 
performed by using PLANTS and focusing the search in a 10 Å radius sphere 
around the key residue Asp103.  
In all performed simulations and for both datasets no significant enrichment factors 
were obtained, thus suggesting that the decoy sets do not have biases which can 
weaken the following analysis.  For example, Figure 4.19 shows the results 
depicted by the above mentioned bar plot for the PLP95 score on dataset 1 
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Figure 4.19: Bar plot of enrichment analysis performed on M2 receptor. 
The docking study uses the DECOY set number 1 and the scoring  
function Plp95, normalized on the number of heavy atoms. 
 
 
 
4.3.5   Docking simulations strategies 
Apart from the blind docking analysis, which was performed by applying specific 
conditions as detailed below, all docking simulations carried out for the here 
described virtual screening campaigns were performed by using the PLANTS
146
 
software, which calculates reliable poses by a colony optimization algorithm. Three 
score functions were taken in consideration, namely CHEMPLP, PLP and 
PLP95
147
, by focusing the search within a 10 Å radius sphere around key residues 
characterizing the explored binding pocket. For each ligand, one pose was 
generated with speed equal to 1. The ligand was considered as flexible during the 
simulations, while the protein atoms were kept fixed. Each post-docking 
optimization procedure was applied to the so computed poses.  
For the enrichment studies, the obtained results were analysed by subdividing the 
entire ranking in 30 clusters composed of 100 compounds, and graphically 
reporting how many active molecules are found in each cluster. Such a new 
approach to evaluate the reliability of a virtual screening campaign will be better 
detailed in the next chapter.   
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4.3.6   Strategies for the allosteric binding site search 
Since in literature there are no information about the position of the putative 
allosteric pocket on the human P2X3 receptor, the identification of some potential 
binding sites was a challenging and demanding issue. Different approaches were 
applied, based on different conceptual strategy; some of them proved successful, 
suggesting the presence of more than one binding site, others revealed to be 
failures.  
In the results’ subchapters, we will report the outcome of four strategies which are 
indeed representative of three major approaches for binding site search, based on 
docking calculations, on pocket detection, and on ligand pathway simulations by 
MonteCarlo procedure, respectively.  
 
- Blind docking 
- Fpocket135 
- SPILLO-PBSS136 
- PELE137 
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4.3.7   Blind docking   
The first strategy applied to identify e potential allosteric binding site on the human 
P2X3 receptor exploited the blind docking approach. This method consists in 
performing a molecular docking study by considering a single ligand on the entire 
receptor structure, so generating multiple poses (form 100 to 500). The resulting 
potential pockets are selected by considering the most populated ones among the 
docking poses. 
The blind docking was performed by PLANTS
146
 as integrated in the software 
VEGA ZZ on both the apo and the holo P2X3 models. Three score functions were 
taken in consideration, namely CHEMPLP, PLP and PLP95. To perform this 
docking analysis, the receptor structures was subdivided into three overlapped 
regions, because the software does not allow a docking sphere with a maximum 
radius greater than 60 Å to be considered, while the receptor would require a 
sphere of about 108 Å.  
500 poses were generated in five different studies, carried out by simulating three 
representative compounds: Trimethoprim, in both charged and neutral form, the 
most active DAP compound, namely the one with id: 13t_20 (see Appendix 2), in 
both charged and neutral form, the most active SAA compound, namely the one 
with id: 16_4 (see Appendix 2), only in the charged form. 
For each P2X3 model, the poses obtained with all the docking studies were merged 
on the same structure, to better identify the most populated pockets (Figure 4.20). 
13 binding sites, both on the apo and the holo models were tested by docking 
simulations and enrichments studies by using both decoy sets as previously 
collected.  
Disappointingly, none of the examined pockets were able to discriminate between 
the active molecules and the other ones included in the databases. 
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Figure 4.20: Example of cluster of poses derived from one of the blind docking studies. 
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4.3.8   Fpocket   
The first applied strategy involved the search of reliable binding pockets based on a 
simple geometrical analysis as performed by Fpocket. This open source package 
for pocket detection can individuate voids and cavities in a macromolecule and, for 
each of the identified pocket, the software provided also a detailed physicochemical 
characterization and a rank according to their reliability. 
The weakness of the method consists in the lacking of a criterion which considers 
the specific ligand features, resulting in the identification of a huge number of 
potential pockets. In detail, among them, the first ranked was the ATP binding 
pocket, followed by a long list of potentially allosteric pockets, all interestingly 
positioned at the interface between two or three monomers.  
The number of identified pockets was too high to allow their exhaustive 
examination by enrichment factor studies. However, the results can be exploited as 
an additional confirmation for the pockets found by other approaches. In particular, 
Fpocket ranked in second position the same pocket identified by the SPILLO-PBSS 
approach, both in the apo and in the holo model, increasing the reliability of the 
prediction (see below, Figure 4.23).   
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4.3.9   SPILLO-PBSS    
SPILLO-PBSS is software able to detect potential binding sites within protein 3D-
structure, even when they are highly distorted and the binding site does not assume 
a suitable conformation. Differently from Fpocket package, SPILLO-PBSS 
searches pockets based on a specific ligand and uses, as a reference, a complex of 
that ligand with another protein (the so-called “reference protein”).  
Since none of the P2X3 antagonists was co-crystallized with any protein, the 
pivotal intuition that allows us to use the software was the opportunity to exploit 
the structurally analogue Trimethoprim as a surrogate.  
In detail, the DHFR inhibitor was co-crystallized with two classes of proteins:  
- Dihydropholate Reductase: PDB entries 2W3A, 2W3V, 2W9S, 3FL9, 
3NO0H, 3TQ8,4G8Z and 4KM2; 
- Pteridine reductase 1: PDB entry 2BFM.  
 
 
4.3.9.1   Dihydropholate Reductase 
Concerning the Dihydropholate reductases, the resolved structures PDB id 4KM2 
and 3NOH were selected according to the best resolution and the absence of any 
other co-crystallized molecule in the trimethoprim (TOP) binding site.  
Both the Dihydropholate reductases resolved structures underwent the same 
preparing steps applied to the zebrafish templates (see chapter 4.3.2.1). The 
reference binding sites (RBS) were generated on both reference structures, 
considering the ligand in its charged state.  
SPILLO-PBSS provided as output a list of the potential binding sites (PBS) of 
Trimethoprim in the apo as well as in the holo model, ranked according to the 
similarity to the RBS. The analysis of the accessibility by the ligand of the best 
 Chapter 4 – Purinergic Receptors  
173 
 
ranked identified pockets leads to discard all of them. The potential binding sites 
proved unrealistic since they were symmetrically located in the central body of 
each monomer, within structurally rigid and inaccessible regions. 
 
 
4.3.9.2   Pteridine reductase  
The resolved structure of the Pteridine reductase is a multimeric model, and a 
single monomer was taken into consideration. The monomer included a molecule 
of Trimethoprim and a molecule of the NADP
+
, which is considered the natural 
cofactor of the enzyme. The 3D-structure was optimized by using the same 
protocol already utilized for the Dihydropholate reductases. 
 
4.3.9.2.1   Identification and optimization of the pocket 
As a preliminary study, an enrichment factor analysis was performed directly on 
the TOP binding site of the Pteridine reductase protein. To verify the importance of 
the cofactor in the pocket, two docking simulations were carried out, one including 
NADP+ and another without it. Both the decoy sets were used. Both docking 
simulations with and without cofactor gave encouraging results, the best results 
being obtained by using the score PLP95 normalized on the heavy atoms and the 
dataset 2. As detailed in Figure 4.21, these simulations afforded in the TOP 1% 
enrichment factors of 30.00 and 10.00 for the pockets with and without the NADP
+
, 
respectively. 
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Figure 4.21: Enrichment factor analysis of the TOP binding site on Pteridine reductase.  
 
 
 
Before the generation of the RBS, the Trimethoprim pocket on Pteridine reductase 
was optimized.  
First, since the better results were obtained with the pocket containing NADP+, but 
considering that SPILLO-PBSS can only handle amino acidic residues and cannot 
parametrize the cofactor, its stabilizing contribution was approximate by replacing 
it with an amino acid. More in detail, complex between Trimethoprim and NADP
+
 
was analysed, revealing two main kinds of interaction: 
   Top %   Mol     Att      EF 
  ======================  
     1.00       30       9     30.00      
     2.00       60     10     16.67      
     5.00     150     11       7.33        
   10.00     300     12       4.00        
   20.00     600     18       3.00        
   
   Top %   Mol     Att      EF 
  ======================  
     1.00       30       3     10.00      
     2.00       60       8     13.33      
     5.00     150     11       7.33        
   10.00     300     12       4.00        
   20.00     600     20       3.33        
   
DECOY_2    Plp95 _NORM_H_ATOMS 
Pocket with NADP+ 
DECOY_2    Plp95 _NORM_H_ATOMS 
Pocket without NADP+ 
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- a π–π interaction between the ethero-aromatic cycle of the NADP+ and the 
diamminopyrimidinic moiety of Trimethoprim; 
-  potential hydrogen bonds.    
On these bases, tyrosine appeared to be the most suitable amino acid to replace the 
NADP
+
, since it is able to stabilize both interactions. Therefore, a molecule of 
tyrosine was manually inserted within the Pteridine reductase binding site, 
superimposing it on the cofactor and the obtained ternary complex was finally 
minimized to optimize the arrangement of the “new” cofactor.  
Moreover, the charge of Trimethoprim was investigated by a re-docking study in 
which both ionization states were tested, and the best complexes, according to all 
score functions, were always found with the molecule in the protonated state (see 
Table 4.2).  
 
SCORE CHARGED NOT CHARGED 
Plp95 -123,58 -94,15 
Plp -86,28 -69,63 
ChemPlp -81,84 -63,5 
 
Table 4.2: re-docking scores of TOP in the binding site on Pteridine reductase.  
 
Finally, the so optimized pocket was submitted to SPILLO-PBSS for the 
generation of the RBS, as reported in Figure 4.22, which also compiles the key 
stabilizing residues ranked by relative relevance.  
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Figure 4.22: Pteridine reductase RBS 
 
The software found three symmetrical pockets in both the apo and the holo trimers 
and all pockets were located at the interface between two monomers, in the top of 
the extracellular part of the receptor (see Figure 4.23).  
 
Since the three pockets were symmetrical and almost identical and there were not 
significant differences between the two receptor states, the following steps of 
optimization and validation were carried out on a single binding site, selected 
within the receptor structure in its closed state. 
The optimization of the binding site involved two iterative induced fit procedures 
performed with a view to rendering the pocket able to accommodate the entire 
datasets. The first one took advantage of the re-docking of Trimethoprim in the 
binding site, while the second induced fit procedure exploited the DAP inhibitor 
13W_20 (see Appendix 2), chosen as the best performing one in the previous 
docking study on the pocket resulting from the first induced fit. This second 
procedure improved the stability of the ligand-target complexes, and after it all the 
docked inhibitors assumed a binding mode in satisfactory agreement with the RBS 
generated by SPILLO-PBSS. 
 
ASP A 181         52.931 
ASP A 232         10.660 
PHE A 113          8.333 
GLY A 225          5.818 
VAL A 230          4.740 
TYR B   1          4.137 
LEU A 188          3.833 
LEU A 229          3.568 
TYR A 191          2.215 
LEU A 226          1.775 
MET A 233          1.718 
TYR A 194          0.270 
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Figure 4.23: Potential allosteric binding site identified by SPILLO-PBSS  
on the apo model of the human P2X3 receptor.  
 
 
4.3.9.2.2   Validation of the pocket by virtual screening study 
Once the binding site was optimized, its reliability was tested by performing virtual 
screening studies using both datasets and the three scoring functions implemented 
by PLANTS (i.e., CHEMPLP, PLP and PLP95). The best obtained results for the 
enrichment factor analysis are reported in Figure 4.24. 
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Figure 4.24: Enrichment factor analysis of the optimized pocket identify by SPILLO-PBSS.  
 
 
The score function Plp95 normalized on the heavy atoms ranked in the top 1% and 
top 2% respectively 9 and 18 active molecules, so reaching an outstanding 
enrichment factor of 30.00. In particular, using both datasets, the enrichment of top 
clusters was obtained thanks to the high scores of the DAP molecules, which were 
well discriminated by the pocket.  On the opposite, the SAA molecules are not 
ranked in the best positions, thus suggesting that this model do not successfully 
describe their interactions with the receptor. 
An analysis was carried out on the complexes formed by the DAP molecules to 
identify the key residues for the interactions in the binding site. To this purpose, the 
RBS of each complex has been calculated by SPILLO-PBSS, obtaining the list of 
the residues in the pocket with the relative contribution to the overall interaction. 
   Top %   Mol     Att      EF 
  ======================  
     1.00       30       8     26.67      
     2.00       60     10     16.67      
     5.00     150     17     11.33        
   10.00     300     18       6.00        
   20.00     600     22       3.67        
   
   Top %   Mol     Att      EF 
  ======================  
     1.00       30       9     30.00      
     2.00       60     18     30.00      
     5.00     150     20     13.33        
   10.00     300     24       8.00        
   20.00     600     24       4.00        
   
DECOY_1    Plp95 _NORM_H_ATOMS 
DECOY_2    Plp95 _NORM_H_ATOMS 
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Four key residues were identified, namely Asp79, Thr82, Leu298 and Tyr70, all 
belonging to the same chain.  
Table 4.3 reports the scores assigned by SPILLO-PBSS to the key residues for each 
complex with DAP compounds.   
 
Figure 4.25 depicts an example of inhibitor in the allosteric pocket. The above 
mentioned key residues are involved in the following interactions: 
- the carboxylate group of Asp79 establishes an ionic interaction with the 
positively charged nitrogen of the Trimethoprim heterocycle; 
- the  hydroxyl group of Thr82 establishes a H-bond with the amino 
substituent of the heterocycle; 
- Leu289 and Tyr70 surround the ligand, stabilizing hydrophobic and π-π 
interactions.  
 
 
 
Figure 4.25: Allosteric pocket identified by SPILLO-PBSS. On the left the interaction map, on 
the right the same pocket as it was identified by Fpocket approach. The cavity is coloured in yellow, 
the atoms around in in blue.  
D79 
T82 
Y70 
L298 
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ID ASP79 LEU298 TYR70 THR82 
c_6 54.549 9.171 < 5 5.506 
13a_20 45.991 9.560 6.889 7.244 
25_19 54.906 9.111 5.993 < 5 
a_6 56.917 9.700 < 5 < 5 
c_13 50.787 9.793 < 5 6.639 
39_19 51.967 7.161 7.431 < 5 
30_19 54.859 9.587 6.768 5.732 
31_19 53.257 9.399 6.182 5.540 
13e_20 42.138 8.496 5.840 6.701 
13o_20 41.350 8.406 5.873 8.569 
13r_S_20 47.067 9.066 5.673 10.215 
13r_R_20 42.848 8.554 5.930 8.419 
13q_20 40.939 9.799 6.317 7.662 
13m_20 43.686 8.403 6.480 8.391 
13d_20 38.926 8.349 5.460 11.233 
13w_20 40.810 8.176 5.324 7.040 
32_19 51.967 7.161 7.431 < 5 
13s_S_20 44.990 7.588 5.082 9.273 
13s_R_20 43.322 7.309 5.616 6.672 
13p_S_20 15.825 11.052 6.953 5.674 
28_19 50.437 9.803 < 5 6.984 
13p_R_20 40.939 9.799 6.317 7.662 
13u_20 41.667 7.236 < 5 8.252 
13t_20 44.850 8.058 6.077 7.898 
 
Table 4.3: SPILLO-PBSS pocket interaction profile. The 
reported values are percentages. 
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4.3.9.2.3   Validation of the pocket by QSAR study 
The reliability of the binding site was also assessed by a QSAR analysis using a 
specific script implemented in VEGA ZZ software which performs combinatorial 
regression analyses by exhaustively combining all computed descriptors. For this 
analysis, only the 21 DAP derivatives were taken in consideration, and for the 
undefined chiral molecules both stereoisomers were simulated by averaging the 
corresponding descriptors. The ligand-based features included in the analysis were 
represented by constitutive and structural descriptors as well as physicochemical 
properties. Moreover, a docking study of the compounds in the binding pocket was 
performed by the docking algorithm PLANTS and a set of docking scores were 
calculated on the minimized obtained complexes and included among the 
compound features exploited by the QSAR analysis. The complete list of the 
ligand-based and docking-based descriptors taken in consideration is reported in 
Appendix 3.     
The best predictive equations are reported in Table 4.4. The compound activity, 
measured by the value of pIC50 is well correlated with the docking score 
CHEMPLP, found in almost all reported equations. H-bonding seems to play a 
fundamental role in the stabilization of the ligand-target interaction and the 
compound features HbTot and HbDon are positively correlated with the activity 
measure. The polarity of the molecules (Dipole and H-bond terms) is also an 
essential element to define the affinity for the receptor, as well as the flexibility 
(FlexTorsion and Torsion terms) which presumably account for entropic factors.  
Figure 4.26 reports the plot obtained by predicting the inhibitors’ activity using the 
best equation, highlighted in yellow.  
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Mols Vars Outliers R
2 
Q
2
 SE F Equation (pIC50=) 
21 3 None 0.63 0.41 0.254 9.49 1.9576 - 0.0486 CHEMPLP + 
0.0629 Dipole + 0.1404 HbDon 
21 2 None 0.59 0.44 0.259 12.93 2.6060 - 0.0503 CHEMPLP + 
0.0531 Dipole 
20 3 1 (32_19) 0.71 0.51 0.230 12.88 
1.5560 - 0.0528 CHEMPLP + 
0.0646 Dipole + 0.1339 HbDon 
20 2 1 (32_19) 0.67 0.53 0.236 17.54 
2.1660 - 0.0545 CHEMPLP + 
0.0554 Dipole 
19 3 2 (32_19)                  
(13w_20) 
0.76 0.62 0.212 16.20 1.6347 - 0.0533 CHEMPLP + 
0.0395 Dipole + 0.1607 HbDon 
19 3 2 (32_19) 
(13w_20) 
0.76 0.53 0.213 15.94 3.0003 - 0.0589 CHEMPLP - 
0.3185 Gyrrad + 0.0642 hbtot 
19 3 2 (32_19) 
(13w_20) 
0.75 0.59 0.217 15.19 
3.1735 - 0.0394 CHEMPLP + 
0.0310 Flex Torsions + 0.1573 
Hb Don 
19 3 2 (32_19) 
(13w_20) 
0.75 0.58 0.220 14.62 
2.7800 - 0.0456 CHEMPLP - 
0.0002 PLP95 + 0.1480 
HbDon 
19 2 2 (32_19) 
(13w_20) 
0.75 0.63 0.213 23.40 2.7785 - 0.0458 CHEMPLP + 
0.1485 HbDon 
19 2 2 (32_19) 
(13w_20) 
0.73 0.55 0.221 21.24 3.2308 - 0.0444 CHEMPLP + 
0.0488 HbTot 
18 2 
3 (32_19) 
(13w_20) 
(13o_20) 
0.77 0.59 0.211 24.78 2.8862 - 0.0460 CHEMPLP + 
0.0335 Torsions 
18 2 
3 (32_19) 
(13w_20) 
(13o_20) 
0.77 0.61 0.122 24.53 2.9827 - 0.0479 CHEMPLP + 
0.0416 HbTot 
 
Table 4.4: Best correlative predicted equations for validation of SPILLO-PBSS pocket.  
Mols = number of molecules; Vars = number of variables in the correlative equation;              
Outliers = number of molecules excluded to improve the relationship; R
2
 = correlation coefficient; 
Q
2
 = predictive power by leave-one-out cross-validation; SE = standard deviation of the errors;       
F = Fisher statistical coefficient; Equation (pIC50 =) = correlative equation. 
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Figure 4.26: Plot of the linear equation yellow highlighted. 
The experimental IC50 are reported on the X axe,                       
the predicted IC50 are reported on the Y axe. 
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4.3.10   PELE 
PELE
148
 is an on-line server able to perform an unconstrained search for binding 
sites within a protein structure. It simulates the movement of a given ligand on the 
receptor, considering both partners in a flexible way, thus enabling the ligand to 
explore regions which would be inaccessible when the interaction partners were 
considered fixed. The opportunity to take in consideration the conformational 
flexibility of the protein is the specific advantage which suggested the use of this 
approach to search the allosteric pockets within the purinergic receptors 
 
4.3.10.1   Identification and optimization of the pocket 
The selected compound to be used as a probe was Trimethoprim and not a specific 
inhibitor, because PELE needs a correct parametrization of the ligand atoms and so 
can recognize only the ligands already present in the Protein Data Bank.  
 
 
 
Figure 4.27: Starting positions of Trimethoprim simulations 
  around P2X3 receptor 
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Four different simulations were performed by using always the P2X3 model in its 
apo state and by placing the probe about 30 Å distant from the receptor in different 
starting positions (Figure 4.27). The simulation parameters were set to obtain four 
simulations 24 hours long, including 600 steps, and using 11 CPU to obtain 10 
trajectories for each simulation. 
The 40 obtained trajectories were analyzed based on the binding energy calculated 
by PELE (see Figure 4.28) and the lowest energy frame was selected (-58.00 
Kcal/mol).  
 
 
Figure 4.28: PELE output. On the left, an example of binding energy plot. Each trajectory has a 
different colour. On the right, the best selected frame. Trimethoprim is highlighted in white. 
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The complex corresponding to the best frame was optimized by an energy 
minimization, keeping free all the atoms in a sphere of 12 Å around the bound 
Trimethoprim. The selected pocket is located in the body domain below the ATP 
binding site, in a superficial and easily accessible region of the trimer, at the 
interface between two monomers.  
The optimization of the pocket was completed with an induced fit procedure. A 
preliminary docking study was performed with the whole set of inhibitors and then 
the complex with the higher docking score (13o_20, see Appendix 2) was selected 
for the induced fitting procedure.  
 
 
4.3.10.2   Validation of the pocket by virtual screening study 
The reliability of the so optimized binding site was verified by a virtual screening 
study, following the same procedure used for the pocket identified by 
SPILLO_PBSS. The best EF was reached by using the decoy set number 1 and the 
PLANT scoring function Plp95, both as total score and as score normalized on the 
number of heavy atoms (Figure 4.29). 
Interestingly and in contrast to what was observed for the allosteric pocket 
identified by SPILLO-PBSS, SAA derivatives are ranked in the best positions of 
the Plp95 total score. This evidence gives insights about the presence of more 
allosteric binding site, one of which can be specific for SAA compounds. However, 
their poses are not all perfectly located inside the pocket, therefore further 
investigation are required.  
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Figure 4.29: Enrichment factor analysis of the optimized pocket identify by PELE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Top %   Mol     Att      EF 
  ======================  
     1.00       30       6     20.68      
     2.00       60       7     11.86      
     5.00     150     10       6.71        
   10.00     300     12       4.01        
   20.00     600     19       3.17        
   
   Top %   Mol     Att      EF 
  ======================  
     1.00       30       8     27.58      
     2.00       60     10     16.94      
     5.00     150     15     10.06        
   10.00     300     16       5.35        
   20.00     600     20       3.34        
   
DECOY_1    Plp95 _NORM_H_ATOMS 
DECOY_1    Plp95 _TOTAL_SCORE 
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An analysis to identify the key residues for the interactions in the binding site was 
carried out similarly to what was done for the SPILLO_PBSS pocket. In this case, 
the RBS were computed with the DAP molecules in the neutral state, because they 
provided better docking scores. The key residues were Leu265, Ser267 and Asp266 
in the chain A; Lys176, Glu187, Leu191, Ser178, Asn177 and Lys188, in the chain 
B.   The results are shown in Table 4.5.  
 
Mol Id 
LYS 
176 
LEU  
265 
GLU 
187 
SER 
267 
LEU 
191 
SER 
178 
ASN  
177 
GLY  
189 
ASN 
190 
ASP  
266 
ILE  
179 
LYS  
188 
c_6 8.36 12,23 11,51 8,82 8,76 7,72 7,81 9,71  6,29  10,34 
c_13_6 20.77 9,33 11,25 10,26 7,88  5,96 7,55    7,74 
a_6  16,35 14,08 10,12  5,46 110,56 9,03  8,52 5,60 10,95 
39_19  16,57 12,22  12,00  12,43   7,01 5,38 11,81 
32_19 12.13 10,49 8,35 8,58 7,14 7,74 8,62 7,52 5,81 6,61  5,31 
31_19 11.00 10,38 8,99 9,05 7,64 7,25 8,04  6,16 5,82  5,69 
30_19 11.30 10,22 9,18 8,96 7,72 7,15 7,83 8,04 6,15 5,92  5,65 
28_19 11.98 10,33 10,12 8,94 7,78 7,31 5,65 8,44 5,64   5,34 
25_19 10.47 10,69 7,85 8,23 6,89 7,25 8,21 7,31 5,54 6,21  5,46 
13w_20    8,33   10,85  6,04 11,54  9,93 
13u_20 7.42 10,33 12,17 5,17  8,84 5,77      
13t_20 9.92 10,57  7,45 6,00  9,64 7,64  6,92 7,25 5,57 
13s_S_20 8.87 9,55 6,67 6,65 5,12 10,22 5,73 5,58     
13s_R_20 10.29 10,91 8,82 6,37 5,65 9,73 6,38 5,32  5,23   
13r_S_20 11.52 12,30 11,08 6,75 6,47 10,43 6,44 5,27  6,05   
13r_R_20 9,26 9,95 9,22 5,82 5,76 7,75 6,33      
13q_20 9,71 10,96  6,58 5,64 8,24 7,06 5,74   5,31  
13p_S_20 8,75 9,80 8,36 6,39 6,28 5,49 6,14 5,75  5,33  5,68 
13p_R_20 8,42 9,99 13,53 6,59 5,42 7,02 5,98 5,52     
13o_20 9,91 10,27 9,09 7,36 5,47 11,67 6,64 6,16     
13m_20 9,52 9,59 6,97 6,28 6,62 6,11 6,05 5,97   5,38  
13e_20  18,23 6,71 8,50   10,54   8,11 11,57 9,74 
13d_20 9,37 9,06 9,76 5,37 6,01 10,53   6,10 5,20 5,81  
13a_20 10,84 10,37 8,16 7,60 5,84 7,37 7,05 6,58 5,00 5,50  5,70 
 
Table 4.5: PELE pocket interaction profile. The reported values are percentages. 
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4.3.10.3   Validation of the pocket by QSAR study 
Similarly to the analysis performed on the SPILOO-PBSS pocket, the reliability of 
this binding site was also assessed by QSAR studies which included 21 DAP 
derivatives and the list of descriptors reported in Appendix 3.  
The analysis of the best obtained correlative equations (Table 4.6) pointed out that 
the activity of the inhibitors can be here predicted using combinations of these 
different descriptors: PLP95 normalized per heavy atoms, lipole, binding energy 
and HMScore computed by X-Score and PSA. In particular, we can observe that 
the activity is:  
- well correlated with the X-Score (both binding energy and HMScore) and 
the  PLP95 score (as is or normalized on heavy atoms);  
- proportional to the lipole value thus suggesting that the cavity prefers 
ligands in which apolar and polar moieties are structurally separated;  
- proportional to both PSA and the number of H-Bonds, both descriptors 
emphasizing the key role of this kind of contacts in stabilizing the 
computed complexes. 
 
Figures Figure 4.30 and Figure 4.31 report the plots obtained by predicting the 
inhibitors’ activity using the best equations which include two and three variables, 
(highlighted in yellow and in green, respectively).  
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Mols Vars Outliers R
2 
Q
2
 SE F Equation (pIC50=) 
21 3 None 0.60 0.41 0.306 8.56 3.3821 - 0.0452 PLP95 - 
0.0455 Atoms - 0.0070 Electr 
21 2 None 0.57 0.41 0.311 11.86 2.3795 + 0.7029 HMScore + 
0.1574 Lipole 
20 3 1 (28_19) 0.79 0.69 0.224 20.14 0.5461 + 1.1431 HMScore - 
0.3581 Gyrrad + 0.2215 Lipole 
20 3 1 (28_19) 0.78 0.67 0.225 19.27 1.1830 + 0.7713 HMScore + 
0.1771 Lipole + 0.1463 HbDon 
20 2 1 (28_19) 0.75 0.66 0.238 25.43 1.4146 + 0.8285 HMScore + 
0.1753 Lipole 
20 2 1 (28_19) 0.73 0.56 0.247 22.91 1.4025 + 1.0412 HMScore - 
0.1699 VirtualLogP 
20 2 1 (28_19) 0.72 0.59 0.251 22.09 1.4882 + 0.8458 HMScore + 
0.1435 HbDon 
19 3 
2 (28_19) 
(39_19) 
0.90 0.80 0.160 43.03 
-2.3833 - 1.4320 Binding 
energy + 0.0290 PSA - 0.1189 
Atoms 
19 3 
2 (28_19) 
(39_19) 
0.90 0.80 0.161 42.94 -2.3816 + 1.9529 Average + 
0.0291 PSA - 0.1193 Atoms 
19 2 
2 (28_19) 
(39_19) 
0.78 0.62 0.226 28.34 1.4233 + 1.1117 HMScore - 
0.2950 VirtualLogP 
19 3 
2 (28_19) 
(13t_20) 
0.84 
 
0.72 0.174 26.55 3.2159 + 1.1380 HMScore - 
0.4471 Vdiam + 0.1449 Lipole 
19 
3 
 
2 (28_19) 
(13t_20) 
0.83 0.73 0.184 23.73 
0.6799 + 0.7993 HMScore + 
0.1169 Lipole - 0.1969 
PLP95_NORM_H_ATM 
19 2 
2(28_19) 
(13t_20) 
0.79 0.72 0.194 30.99 
0.4366 + 0.8478 hms score - 
0.2714 
PLP95_NORM_H_ATM 
 
Table 4.6: Best correlative predicted equations for validation of PELE pocket.  
-  
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Figure 4.30: Plot of the linear equation yellow highlighted. 
The experimental IC50 are reported on the X axe,                       
the predicted IC50 are reported on the Y axe. 
 
 
 
 
Figure 4.31: Plot of the linear equation green highlighted. 
The experimental IC50 are reported on the X axe,                       
the predicted IC50 are reported on the Y axe. 
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4.3.11   Conclusions 
The aim of the present study was to identify the potential allosteric binding sites 
within the structure of the human P2X3 purinergic receptor. Several classes of 
compounds showing non-competitive antagonistic activities are reported in 
literature, but the binding pocket and the mechanism of action is yet unknown. 
The study required the homology modelling of both the apo and the holo 
conformations of the human P2X3 receptor, followed by the selection of highly 
active inhibitors, useful to validate the identified pockets. 
Among different approaches, two in particular were successful: SPILLO-PBSS and 
PELE.  The former identified three symmetrical pockets in the highest extracellular 
part of the receptor; the latter revealed a potential binding site in a lower region of 
the body domain, between two monomers. Both the potential pockets were 
validated by virtual screening approaches coupled to QSAR analyses.  
It was also possible to observe a different behaviour for the two classes of 
considered compounds: in particular the DAP derivatives show good performances 
on both the pockets, while the SAA compounds seem likely to prefer only the 
binding site identifies by PELE, suggesting the possibility that the allosteric 
modulation of purinergic receptors is defined by multiple regions and different 
binding modes on the trimer structure.    
We consider this study a first promising attempt to obtain reliable interaction 
models of the allosteric inhibition of P2X3 receptors’ activity, with the aim to gain 
insights for the rational drug design of novel purinergic ligands. 
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5.1   Introduction 
 
 
In the last few years, several experimental advances have resulted in an incredible 
increase of the number of resolved GPCR structures
149
. With regard to class A, 
they involve rather heterogeneous receptors, including aminergic, nucleoside 
binding, peptide binding, and lipid binding GPCRs.  
Although the inactive states are the most frequently resolved conformations, the 
GPCR structures include active, inactive and intermediate states, the comparison of 
which allows their activation mechanism to be investigated at molecular level
150
. 
Moreover, a systematic comparison of all resolved GPCR structures allows the 
common features of all binding sites as well as the key interactions stabilizing the 
GPCR folding to be revealed
151
.  
Such an abundance of resolved GPCR structures can clearly support homology 
modelling of the unresolved GPCRs
152
, and in this context muscarinic receptors 
represent an invaluable arena for some key reasons which can be summarized as 
follows.  
First, two muscarinic receptor subtypes have been recently resolved (i.e. mAChR2 
and mAChR3) and this could allow truly reliable homology models to be generated 
for the other unresolved subtypes, especially considering the high homology 
between them. Additionally and as seen in the first below reported study, the 
availability of such highly homologous resolved structures can be utilized as a 
benchmark to assess the reliability of innovative modeling strategies.  
Second, the mAChR2 subtype was resolved in its inactive more open state (namely 
co-crystallized with an antagonist, QNB) as well as in its active more closed state 
(namely in complex with a potent agonist, iperoxo) and this allows the differences 
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between the complexes generated by the two receptor states to be analyzed as seen 
in the second part of this Chapter.  
Third, muscarinic receptors possess both orthosteric and allosteric binding sites and 
both pockets are well studied and there is a plethora of known ligands with various 
biological activity including bitopic ligands. Notably, a mAChR2 in its active state 
and in complex with an allosteric ligand was resolved thus providing an invaluable 
tool to investigate also the allosteric recognition at an atomic level as explored in 
the third part of this Chapter.  
Fourth, since most known muscarinic agents are completely unselective there is a 
constant quest for improved ligands, the selectivity of which can be also gained by 
exploiting the allosteric site. Hence and although muscarinic receptors are probably 
the longest studied GPCRs, there is a continuous interest in these receptors and, 
due to the above mentioned reasons, the computational approaches can play a key 
role in the rational design of improved ligands.  
Thus and as mentioned above, this chapter presents three different structure-based 
computational studies focused on the muscarinic receptors.  
In detail, the first part described a standalone modeling study aimed at investigating 
the role of Pro-containing transmembrane helices to generate more reliable 
homology model.  
The second study was carried out in collaboration with Prof. Piergentili and Prof. 
Quaglia from the University of Camerino and involved a docking analysis on a set 
of dioxane-based muscarinic agonists considering for the mAChR2 both open and 
closed states. Its key objective was to investigate whether docking results obtained 
by using highly reliable resolved structures can conveniently account even for very 
specific ligand features as exemplified here by the conformational equilibria 
characterizing the dioxane ring.  
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The last study, performed in collaboration with Prof. Romanelli from the 
University of Florence, concerned docking simulations on a set of bitopic ligands 
which are structurally related to carbachol. This study represents a clear example 
about how docking studies on muscarinic receptors can simultaneously involve 
both orthosteric and allosteric binding sites. 
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5.2   The role of Pro-containing helices in GPCR 
homology modeling 
 
 
5.2.1   Setting the scene 
Even though the above mentioned richness of resolved GPCR structures can 
support homology modelling studies, two different situations can be however 
recognized. In the first case, homology studies involve a receptor which belongs to 
a subfamily, a member of which has already been resolved and therefore modelling 
can greatly benefit from such a highly homologous template allowing truly reliable 
models to be easily generated. In the second and, unfortunately, more common 
situation, homology studies involve a GPCR which does not possess a highly 
homologous resolved congener and thus the generated models, despite using the 
best available templates, unavoidably show less reliability compared to that of the 
models obtained in the first fortunate situation.  
Besides the availability of homologous templates, a deeper knowledge of their 
dynamic behaviour can further support the GPCR homology modeling. In this 
regard, great deal of attention has been paid to the conformational switches which 
modulate receptor activation
153
.  
Among them, several biophysical studies emphasized the key role of the Pro-
containing transmembrane helices which can vary their bending acting as hinges to 
modulate the width of the TM bundle and, thus, receptor activation
154
. In a recent 
study, we showed that the structural effects of the Pro-containing transmembrane 
helices can be simulated by generating the so-called conformational chimeras, 
namely GPCR models in which the possible conformations of the Pro-containing 
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helices are exhaustively combined. These chimeras were found to account for 
receptor flexibility and were applied to explore ligand recognition by the human 
Cys-LTR1 receptor
155
.  
By accounting for the flexibility of their binding sites, such an approach should 
also be able to enhance the reliability and the predictive power of the modelled 
GPCR structures and such an effect should be particularly beneficial in the above 
described unfortunate situation, namely when the lack of highly homologous 
templates prevents the generation of truly reliable homology models.   
On these grounds, the present study was undertaken with a view to investigating 
whether the reliability of GPCR models can be enhanced by simulating the bending 
of their Pro-containing TM helices. Specifically, the study involved the modeling 
of a muscarinic receptor subtype (mAChR1) which can be generated by using 
highly homologous templates, since the mAChR2 and mAChR3 subtypes have 
recently been resolved in complex with agonist and antagonist
156
. Such a 
reasonably reliable model was then compared with a homology model obtained 
starting from a less homologous non-muscarinic GPCR template, and optimized by 
varying the bending of its Pro-containing transmembrane helices.  
The human mAChR1 subtype was here selected due to its relevant medicinal role, 
since selective modulation of this muscarinic receptor was found to be effective in 
cognitive models of Alzheimer's disease
157
, and antipsychotic models of 
schizophrenia
158
. Hence, selective agonists (also including allosteric and bitopic 
ligands) are currently being pursued for the above mentioned therapeutic effects, 
avoiding the cholinergic adverse events induced by an unselective activation of all 
muscarinic receptor subtypes, which have hitherto limited the use of the available 
mAChR1 agonists in neurodegenerative disorders
159
.   
The evaluation of the so obtained models (and chimeras) was carried out by virtual 
screening campaigns where the reliability of the models was assessed by 
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computing the enrichment factors as well as a novel parameter based on the 
distribution of the active compounds within the entire screened database. The 
possibility of combining the scores of more chimeras was also evaluated by using a 
specially developed maximizing consensus algorithm.  
         
 
5.2.2   Computational Methods 
 
5.2.2.1   Generation of the starting models 
The primary sequence of the human mAChR1 was retrieved by the Uniprot 
database (Entry Id: P11229, Entry name: ACM1_HUMAN). As discussed above, 
two homology models were initially generated. The first model (hereinafter named 
M1M3) was built by using the highly homologous rat mAChR3 structure as the 
template (PDB Id: 4DAJ, Identity = 52.8%; similarity = 91.2%)
160
, while the 
second model (hereinafter named M12) was generated by using a less homologous 
non-muscarinic template. The human 2 adrenergic receptor was chosen as the 
second template due to the good homology with mAChR1 (PDB Id: 2RH1, Identity 
= 22.1%; similarity = 62.2%) and the fact that both GPCRs belong to the family of 
human aminergic receptors
161
.  
In detail, both models were generated by Modeller9.10 using the default parameters 
and generating 20 models for each run
162
. Among the generated models, the best 
structures were selected according to the scores computed by Modeller9.10 (i.e. 
DOPE and GA341) as well as to the percentage of residues falling in the allowed 
regions of the Ramachandran Plot. The satisfactory structural quality of the two 
selected models was then assessed by (a) the agreement with the predicted 
secondary structure from the sequence alignment, as obtained using ClustalX (see 
Figure S2, Supporting Information); (b) the lack of not predicted gaps; (c) the 
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remarkable percentage of residues falling in the allowed regions of the 
Ramachandran Plot (93.0 % and 91.8 %, for M1 and M12, respectively) and of 
the χ-space (96.0% and 95.4%, for M1 and M12, respectively).  
The selected models were then completed by adding hydrogen atoms and to remain 
compatible with physiological pH, Asp, Glu, Lys and Arg residues were considered 
in their ionized form while His and Cys were maintained neutral by default. Such a 
standard protonation state should not influence the following docking results since 
the mAChR1binding site (as defined by a 12Å radius sphere around Asp105) does 
not include ionizable residues apart from the mentioned Aps105 which has to be 
stably ionized to interact with ligands and Cys407 which is in its neutral state as 
suggested by its very high pK value as predicted by PropKa
163
.  
The completed models were carefully checked to avoid unphysical occurrences 
such as cis peptide bonds, wrong configurations, improper bond lengths, non-
planar aromatic rings or colliding side-chains. Finally, the mAChR1 models were 
optimized by a minimization made up by two phases: a first minimization without 
constraints until RMS = 0.1 kcal mol
-1
Å
-1
 and then a second minimization with 
backbone fixed until RMS = 0.01 kcal mol
-1
Å
-1
 to preserve the predicted structures. 
As said before, both modelled mAChR1 structures were utilized in the following 
docking simulations and the M12 model was also exploited to generate the 
corresponding chimeras by varying the conformation of its Pro-containing helices. 
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5.2.2.2   Generation of conformational chimeras 
By breaking an intra-helical H-bond, a proline residue, when inserted in a TM 
helix, increases its flexibility and assumes two major conformations. In the first, 
the proline causes the helix axis to bend by about 20° while in the second the helix 
maintains a straight axis annulling the proline bending effect. When viewing the 
receptor from the extracellular side, such helices are usually bent outwards, thus 
increasing the overall opening of the TM bundle
164
. Since the TM region generally 
includes more Pro-containing helices, the effect of these flexible segments can 
significantly vary the opening of the TM bundle which indeed can shift from a 
cylindrical to a calix shape.  
The mAChR1 receptor includes four Pro-containing TM helices, namely TM4 
(Pro159), TM5 (Pro200), TM6 (Pro380) and TM7 (Pro415). Since the study 
involved the generation of all possible chimeras as obtained by exhaustively 
combining the two conformations of the four Pro-containing helices, the number of 
the so modelled mAChR1 chimeras was equal to 16 (2
4
). By considering that the 
major difference between straight and bent helix conformations involves the 
angle, the four Pro-containing TM helices underwent a systematic search in 
which 360 conformers were generated for each helix by systematically rotating the 
proline’s  angle (1 conformer/1 degree). The obtained conformers were 
minimized to discard high-energy interactions. Similarly to what was obtained in 
the previous study, all Pro-containing helices show two major conformations. The 
first is a negative synclinal geometry (which is typical for left-handed 
helices and corresponds to the straight conformation, whereas in the second the 
angle assumes a synperiplanar conformation (, inducing the corresponding 
bending in the helix axis. 
Starting from the so generated conformations, the 16 chimeras were assembled by 
systematically combining the straight and bent conformations of each Pro-
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containing helix. In detail, the model assembly was performed by superimposing 
the backbone atoms of a helix conformation with those of the correspondent 
segment in the M1 model and manually connecting the adjacent segments using 
the VEGA suite of programs
165
. After a careful scrutiny of the obtained structures 
to avoid unphysical conditions, the sixteen models underwent a local minimization 
until RMS = 0.05 kcal mol
-1
Å
-1
, where all atoms were kept fixed except for those 
included within a 10.0 Å sphere around the manually connected bonds (at the helix 
ends). Finally, the models were minimized with backbone fixed until RMS = 0.01 
kcal mol
-1
Å
-1
 to preserve the folding of the assembled structures. All described 
minimizations were performed using the conjugate gradient algorithm by 
Namd2.9
166
 with the force field CHARMM and the Gasteiger’s atomic charges.  
The chimeras are termed according to the nomenclature proposed in the previous 
study
155
. Briefly, their name defines in sequence the conformation of the four Pro-
containing helices (namely, TM4, TM5, TM6 and TM7) using the code “S” for 
straight conformations and “B” for bent conformations. For example, SSSS 
indicates the fully close chimera (i.e. all straight helices) while BBBS denotes the 
chimera with all bent helices apart from TM7. 
 
 
 
 
 
 
 
 
 
 
 Chapter 5 – Muscarinic Receptors  
205 
 
5.2.2.3   Dataset collection 
As reported in Figure 5.1 and Table 5.1, a representative dataset of 35 mAChR1 
agonists were collected from the literature
167,168,169,170,171,172,173,174,80,175,176,177
.  
The dataset shows a good heterogeneity as assessed by a Tanimoto distance 
average equal to 0.18 and spans a rather wide range of activity of 5.55 logarithmic 
units.  The ligands were simulated in their ionized forms since they are involved in 
molecular recognition. The conformational behaviour of the compounds was 
investigated by a clustered MonteCarlo procedure (as implemented in VEGA) 
which generated 1000 conformers by randomly rotating the rotors. For each ligand, 
the so obtained lowest energy structure was then exploited in the following docking 
simulations.  
 
 
Figure 5.1: mAChR1 agonists.  Molecular structure of the lesser known mAChR1 agonists 
included in the dataset 
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Cpd 
Common name         
(when available) 
pKM1 
(nM) 
Ref. Cpd 
Common name 
(when available) 
pKM1 
(nM) 
Ref. 
1 Oxotremorine 8.95 19 19  5.08 19 
2 Xanomeline 8.10 19 20  5.04 19 
3 WAY-132983 7.75 20 21  4.96 19 
4  7.04 19 22 Carbachol 4.92 19 
5  6.92 19 23  4.90 19 
6 Talsaclidine 6.86 25 24 Muscarine 4.74 19 
7 Sabcomeline 6.64 19 25 Oxotremorine-M 4.69 19 
8 Tiopilocarpine 6.53 26 26  4.67 19 
9 
Arecaidinepropargyl 
ester 
6.53 24 27  4.67 19 
10 RS-86 6.31 27 28 Methylfurmethide 4.55 30 
11 LY593093 6.21 21 29 Areocolina 4.53 19 
12 CI-1017 6.17 22 30 Methacholine 4.52 28 
13 77-LH-28-1 6.00 23 31  4.28 19 
14 Alvameline (Lu25-109) 5.72 29 32 Furmethide 4.11 30 
15 AC-42 5.52 23 33  4.09 19 
16  5.23 19 34 Bethanechol 4.01 28 
17 Pilocarpine 5.18 19 35  3.55 19 
18 McN-A-343 5.10 28     
 
Table 5.1: mAChR1 agonists.   Set of 35 known mAChR1 agonists taken from literature 
 
By combining the selection features of the ChemBridge website
178
 with those of 
the database explorer of the VEGA suite of programs, a set of decoys to be used in 
virtual screening campaigns was collected. The selected compounds had to fulfil 
the following criteria: (1) the molecular charge equal to +1 due to the presence of 
only one positively charged group (quaternary ammonium or ionizable amino 
group) belonging to a linear or cyclic moiety; (2) the presence of at least one H-
bond acceptor group; (3) the molecular weights within the same range of the active 
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ligands (i.e. from 159 Da to 378 Da). In this way 2465 decoy molecules were 
identified and collected in a database together with the 35 active ligands, so as to 
have a complete dataset of 2500 compounds, where the active ones represent the 
1.4 %.  
The decoy molecules were prepared by using an automatic script of the VEGAZZ 
suite of programs which for each compound performs the following tasks: (i) 
generating the 3D structure; (ii) adding the hydrogen atoms; (iii) assigning atom 
types and atomic charges according to Gasteiger method; (iv) for ionizable 
molecules, selecting the predominant form at physiological pH; (v) for undefined 
chiral molecules, generating all possible stereoisomers; (vi) minimizing the so 
obtained molecules combining steepest descent and conjugate gradient algorithms.   
 
 
5.2.2.4   Docking simulations and virtual screening  
Docking simulations involved: (1) the more reliable M1M3 model; (2) the less 
reliable M12 model; (3) all sixteen chimeras. Docking simulations were carried out 
using PLANTS, which finds plausible ligand poses by ant colony optimization 
algorithms (ACO)
147
. For all docking simulations, PLANTS was used with default 
settings and without geometric constraints. The search was focused on a 10.0 Å 
radius sphere around Asp105 thus encompassing the entire binding cavity. To 
avoid excessively time-demanding calculations which would be unsuitable for 
screening of large databases, the ligands were considered as flexible, while protein 
atoms were kept fixed. For each campaign, speed 1 was used and 1 pose was 
generated for each ligand. 
 
Virtual screening campaigns can be subdivided into two parts. The first involved 
the two starting models (namely M12 and M1M3) and the simulations were 
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repeated by scoring the poses with all three implemented score functions 
(ChemPlp, Plp and Plp95) with a view to revealing the most predictive scoring 
function. The second part involved the 16 generated chimeras and the simulations 
utilized only the most predictive Plp95 score.  
In order to compare the predictive power of each chimera, the so generated scores 
were analysed by using a script which analyses the distribution of the active 
compounds throughout the entire ranking. In detail, the script subdivides the 
ranking into an user-defined number of bins (by default 100 bins) and counts how 
many active molecules are contained in each bin. Such an approach helps the 
analysis and comparison of virtual screening campaigns by providing both a 
graphical output (see Figure 5.3) and a metric based on the so obtained 
distributions. In detail, this novel parameter corresponds to the skewness of the 
distribution which is a measure of its asymmetry and is computed by Eq. 1 as the 
third standardized moment where xi is the number of active compounds within the 
bin i and n is the total number of bins. In a satisfactory distribution the parameter 
has to be the largest possible positive number.  
 
 
 
(Eq. 1) 
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5.2.2.5   Consensus algorithm  
There are several applications for consensus algorithms in computational 
chemistry. When applied to docking simulations, they are based on the concept that 
an optimal combination of more docking scores always performs better than even 
the best performing score
179
. In correlative studies, linear correlations are thus 
developed by regression techniques involving more docking scores and aimed at 
maximizing the predictive power of the so obtained equations. Several studies have 
reported that a proper combination of different scoring methods can perform better 
than individual scoring functions in virtual screening, as well
180
.  Several consensus 
approaches (rank-by-score, rank-by-rank, and rank-by-vote strategies) have been 
proposed even though maximizing algorithms have been scantly exploited to 
enhance virtual screening performances. For example, several general algorithms 
have been reported to maximize the Area under ROC Curve even though 
applications to virtual screening are not yet described (see for example ref 
181
).  
On these grounds and considering the possibility of combining the scores of more 
chimeras, we developed a fitting consensus algorithm which maximizes the 
enrichment factors by combining more scoring functions. As generalized by Eq. 2, 
the consensus algorithm allows a new ranking function to be obtained, resulting 
from the linear combination of two or more docking scores. Notice that the 
included S values can be both docking scoring functions and ligand-based 
descriptors.  
 
  (Eq. 2) 
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The script calculates the k coefficients (k0….kn) by using the gradient-free Hooke-
Jeeves algorithm
182
 and, to avoid local maxima, random sampling is also applied. 
In detail and for each trial, random coefficients are initially assigned to each term 
of the linear combination and then optimized iteratively by maximizing the sum of 
the ranking positions of the active compounds in the list (as sorted from worst to 
best scores). This procedure is repeated for the selected number of the random trials 
and at the end of the calculation the best performing equation is shown.   
The algorithm was implemented in two scripts. In the first, the user has to indicate 
two or more descriptors to be utilized to maximize the enrichment factors, while in 
the second script the user has to define only the number of descriptors to be 
included in the consensus equation and the script automatically searches for the 
best consensus equation by exhaustively combining the set of descriptors defined 
by the user. Due to the large number of combinations that can be generated, the 
second script was parallelized to exploit modern multi-core CPUs. The scripts are 
written in C language as implemented in the script engine of the VEGA ZZ 
software. They read the input data (biological activities plus ligand-based and/or 
docking-based descriptors) from CSV files and include a graphical interface which 
permits a user-friendly setting of all required parameters.  
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5.2.3   Results and Discussion 
 
 
5.2.3.1   Overview of the generated chimeras 
Figure 5.2 reports the superimposition of the 16 generated chimeras and shows in 
the right panel the regions with the greatest structural differences. Understandably, 
marked differences are seen in the two regions including the Pro-containing 
helices, namely the TM4-EL2-TM5 region (Ala142-Trp203) and the TM6-EL3-
TM7 region (Leu367-Cys421). In both regions, one segment (i.e., TM7 and TM4) 
has the proline in the middle and shows clear differences between the simulated 
chimeras, whereas the other TM segment (i.e. TM5 and TM6) includes the proline 
residue in a more lateral position and thus induces more restricted conformational 
differences. In all chimeras, bending of the Pro-containing helices induces 
significant effects on the conformation of the two comprised extracellular loops 
(EL2 and EL3), the mobility of which slightly impacts also on the arrangement of 
the other two extracellular segments (i.e. NT and EL1) as seen in Figure 5.2.    
Table 5.2 reports some relevant geometrical and physicochemical properties for the 
modelled chimeras including the void volume of the binding cavity as computed by 
FPocket 
183
.  
The reported values suggest that bending of the Pro-containing helices induces an 
increase of solvent accessible surface area, an effect clearly understandable 
considering that the helix bending induces the overall opening of the TM bundle. 
When decomposing the surface area in polar and apolar components, one may note 
that the helix bending induces a substantial increase of the apolar surface, while the 
polar area remains roughly constant regardless of the bending. Such a behaviour 
can be explained considering the abundance of hydrophobic residues in both the 
external surface and in the accessible surface of the binding cavity the exposure of 
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which is necessarily increased by the TM bundle widening. When considering the 
apolar nature of the membrane environment, one may suppose that the reported 
increase of the apolar surface should not have destabilizing effects.   
 
 
 
 
Figure 5.2:  Superimposition of the 16 generated chimeras. It is evidencing the regions with the 
greatest structural differences as detailed in the right panel which maps the corresponding RMSD 
values. 
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Table 5.2 also shows that the opening of the TM bundle induces a clear 
enlargement of the binding cavities as described by their void volumes. In detail, 
the computed volumes allow the chimeras to be subdivided into three groups 
depending on the accessibility of their binding sites.  
The first group (volume < 3000 A3, 5 structures) is composed of the closed 
chimeras, the binding sites of which are completely surrounded by residues and 
rather inaccessible from the outside; M1β2 belongs to this closed group. 
The second group (3000 A
3
 < volume < 6000 A
3
, 6 structures) is composed of the 
intermediate chimeras, the binding sites of which are not so enlarged but open and 
accessible from the outside; M1 belongs to this intermediate group. The last 
group (volume > 6000 A
3
, 5 structures) is composed of the open chimeras, the 
binding sites of which are wide-open and accessible from the outside.  
The volumes of the cavities reveal that bending of the TM6-EL3-TM7 region plays 
the most significant role in determining the opening of the TM bundle, TM7 being 
the most effective helix.  
Finally, the RMSD values reported in Table 5.2 suggest that the arrangement of the 
TM bundle of M12 resembles that of the fully close SSSS chimera, while that of 
M1 appears to be similar to the arrangement of the SBSS chimera. This finding 
emphasizes that simulation of the helical bending should not be only seen as a way 
to reproduce the conformation of the more reliable M1 model but also as an 
approach to extensively simulate the receptor flexibility with a view to optimizing 
the ligand recognition.  
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Table 5.2:  Geometrical properties of the generated mAChR1 models.  a) Void volumes 
computed by FPocket  b) RMSD values as computed by considering the backbone atoms only.  
 
 
 
 
 
 
Model 
PSA 
(Å
2
) 
ASA 
(Å
2
) 
Area 
(Å
2
) 
Cavity 
Volume
a
 
(Å
3
) 
RMSD 
vs M1M3
b
 
(Å) 
RMSD 
vs M1
b 
(Å) 
M1b2 16861 32222 49083 2328 1.03 0.00 
M1M3 16805 33301 50106 7401 0.00 1.03 
SSSS 16861 31226 48787 1534 0.80 0.45 
BSSS 16705 32400 49105 4649 0.61 1.23 
SBSS 16685 32809 49494 1668 1.10 1.49 
SSBS 16837 33220 50057 5845 1.56 1.23 
SSSB 16641 32664 49305 5181 1.49 1.87 
SSBB 16655 32696 49352 7717 1.55 1.92 
BBSS 16672 32877 49550 1822 1.24 1.31 
SBBS 16716 32838 49554 5074 1.53 1.45 
BSSB 16632 32743 49375 2534 1.17 1.58 
BSBS 16821 33217 50038 4332 0.79 0.92 
SBSB 16454 34235 50689 6719 1.74 2.08 
SBBB 16604 34499 51103 4860 1.79 2.19 
BSBB 16623 34719 51343 7363 1.56 1.57 
BBSB 16563 34422 50984 6494 1.85 1.92 
BBBS 16718 34904 51621 2412 1.30 1.37 
BBBB 16433 34338 50771 8165 1.84 1.93 
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5.2.3.2   Preliminary correlative analysis 
Despite being unrelated to following virtual screening campaigns, a preliminary 
study involved the analysis of the linear correlations between the Plp95 scores 
(which were found to be the best performing ones, see below) and the pKi affinity 
(as computed by their r
2
 values, see Table 5.3).  
Such an analysis revealed some interesting correlations, although the exploited 
docking scores are directly derived from docking simulations without any 
complex’s refinement. Understandably, the M1M3 scores perform markedly better 
than the M12 scores, while the computed r
2
 values reveal significant differences 
among the considered chimeras, thus suggesting that the generated chimeras 
represent significantly different conformations compared to the starting homology 
model.  
Notably, the docking scores of some chimeras (e.g. SBSB) reveal promising 
correlations with the affinity values while showing a conformation significantly 
different compared with that of M1M3 (as encoded by the RMSD values, see Table 
5.2). In other words, the capacity to approximate the M1M3 model is not the key 
parameter when assessing the predictive power of a given chimera. Again, the five 
best performing chimeras (namely with an r
2
 value greater than 0.4) do not show 
common features neither with regard to the helix’s conformation nor with regard to 
the cavity volume.  
This suggests that there is not a structural element which determines the chimera’s 
performance, but the simulated chimeras represent relevant and distinct receptor 
states involved in the molecular recognition process and as such they may find 
fruitful applications in provisional studies regardless of their similarity to the 
starting homology models.  
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Table 5.3: Figures of merit for the performed virtual screening campaigns plus the r
2
 parameter for 
the correlation between the Plp95 docking scores and the experimental affinity values. 
 
 
 
 
 
 
 
 
 
Model 
r
2
 
Plp95 
vs pK 
EF 1% EF 2% EF 5% 
EF 
10% 
EF 
20% 
EF 
mean 
bottom 
50% 
Skew 
ness 
AUC 
ROC 
M1b2 0.31 0.00 2.87 3.44 3.71 2.86 2.58 20.00 1.80 0.74 
M1M3 0.47 2.87 2.87 3.45 4.58 3.00 3.35 5.71 3.18 0.81 
SSSS 0.42 2.87 2.87 4.02 4.86 3.29 3.58 2.86 2.78 0.82 
BSSS 0.47 0.00 1.44 4.6 4.00 2.57 2.52 5.71 1.86 0.78 
SBSS 0.35 0.00 0.00 1.15 2.86 3.15 1.43 8.57 2.04 0.77 
SSBS 0.28 0.00 5.74 5.17 4.86 3.29 3.81 2.86 2.45 0.83 
SSSB 0.31 0.00 2.87 4.6 4.29 3.00 2.95 17.14 1.84 0.76 
SSBB 0.32 0.00 2.87 4.6 4.29 2.72 2.90 17.14 2.24 0.76 
BBSS 0.21 0.00 4.31 4.6 4.86 3.43 3.44 8.57 2.64 0.82 
SBBS 0.36 0.00 0.00 1.15 2.86 3.00 1.40 8.57 2.20 0.77 
BSSB 0.35 5.74 4.31 5.17 4.58 3.15 4.59 14.29 2.73 0.78 
BSBS 0.36 0.00 1.44 5.17 4.29 3.15 2.81 5.71 2.57 0.8 
SBSB 0.42 0.00 0.00 3.45 2.57 2.57 1.72 17.14 2.07 0.74 
SBBB 0.41 0.00 4.31 3.45 3.15 2.29 2.64 11.43 2.24 0.74 
BSBB 0.40 0.00 4.31 4.6 4.00 2.86 3.15 8.57 1.85 0.77 
BBSB 0.29 2.87 2.87 2.87 4.00 2.72 3.07 14.29 2.62 0.76 
BBBS 0.11 0.00 2.87 4.02 4.29 3.29 2.89 8.57 2.20 0.8 
BBBB 0.31 2.87 1.44 4.02 4.00 2.86 3.04 14.29 2.20 0.76 
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5.2.3.3   Virtual screening campaigns 
As a preamble, it should be observed that the docking scores normalized per the 
ligand’s molecular weight perform vastly better than the total scores as witnessed 
by the overall enrichment mean of the normalized scores, which is about twice that 
of the total scores (2.88 vs 1.48, see Table 5.5). This result can be explained by 
considering that the normalized values indirectly account for the unavoidable 
differences between decoy set and active ligands
184
. Hence, most of the reported 
virtual screening results are focused on the normalized scores only.  
The preliminary analysis concerns the choice of the most effective docking score 
from among the three functions computed by PLANTS (ChemPlp, Plp and Plp95) 
using the M12 and M1 models as reference structures. Table 5.4 compares the 
enrichment factors obtained by using the normalized scores for the three 
implemented functions, and reveals that the Plp95 score produces significantly 
better results in both the M1 models. Consequently, the following virtual screening 
campaigns are performed by using the Plp95 function only. 
Table 5.3 compares the results obtained by virtual screening campaigns on each 
generated chimera and reports the enrichment factors as computed for different 
thresholds (1%, 2%, 5%, 10% and 20%), as well as the corresponding enrichment 
means. As expected, the M1 model performs remarkably better than the M12 
model. The greatest enrichment is observed in both models in the top 10%, while 
only the M1 model is able to place active compounds in the top 1%.    
Also with regard to virtual screening, the simulated chimeras show significantly 
different results even though there is no agreement between the above discussed r
2
 
values and the chimeras offering the highest enrichment factors. As examples, the 
chimera producing the highest enrichment mean (BSSB) gives average r
2
 value and 
that showing the second highest enrichment mean (SSBS) affords a very poor 
correlation.  
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For completeness, Table 5.5 compiles the enrichment factors as obtained by using 
the total Plp95 scores and as mentioned above shows that these scores perform 
vastly worse than the normalized values. Curiously, most chimeras shows EF top 
1% values greater than 0 probably due to 1 or 2 very large active molecules 
properly evaluated but then the following enrichment factors dramatically drop. 
The computed enrichment factors reveal that the most performing chimeras have 
cavities with intermediate volumes thus confirming that they show a satisfactory 
selectivity while possessing a suitable capacity to accommodate even large ligands. 
However, even the fully closed chimera shows remarkable results that can be 
explained by considering that this chimera is able to properly recognize small 
active ligands such as carbachole and metacholine. By contrast, chimeras  
 
 
Model score EF      
1% 
EF      
2% 
EF      
5% 
EF    
10% 
EF    
20% 
EF 
mean 
M1 Plp95 0.00 2.87 3.44 3.71 2.87 2.58 
M1 ChemPlp 0.00 0.00 3.44 2.87 2.29 1.72 
M1 Plp 0.00 0.00 3.44 3.44 2.29 1.83 
M1M3 Plp95 2.87 2.87 3.44 4.58 3.00 3.35 
M1M3 ChemPlp 0.00 1.15 3.44 2.87 2.29 1.95 
M1M3 Plp 0.00 1.15 2.27 2.87 2.29 1.72 
 
Table 5.4: Figures of merit for the preliminary virtual screening analyses performed on the M1M3 
and M1 models by testing all three implemented score functions. 
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Model EF 1% EF 2% EF 5% EF 10% EF 20% EF mean 
SSSS 0,00 1,43 0,57 0,86 1,29 0,83 
BSSS 2,87 1,43 2,29 1,43 1,14 1,83 
SBSS 2,87 2,87 2,29 1,43 1,14 2,12 
SSBS 0,00 0,00 1,15 1,43 0,86 0,69 
SSSB 2,87 2,87 1,15 0,86 0,43 1,64 
SSBB 2,87 1,43 0,57 0,57 0,43 1,17 
BBSS 0,00 2,87 2,29 1,71 2,00 1,77 
SBBS 5,74 4,30 2,87 1,43 1,14 3,10 
BSSB 2,87 1,43 0,57 0,57 0,29 1,15 
BSBS 2,87 4,30 2,29 1,43 1,43 2,46 
SBSB 2,87 1,43 0,57 0,57 0,43 1,17 
SBBB 0,00 0,00 0,57 1,14 1,00 0,54 
BSBB 2,87 1,43 1,15 0,57 0,86 1,38 
BBSB 2,87 1,43 0,57 0,57 0,43 1,17 
BBBS 2,87 1,43 1,72 0,86 0,86 1,55 
BBBB 2,87 1,43 0,57 0,29 0,57 1,15 
 
Table 5.5: Enrichment factors for the generated chimeras as generated by using the total Plp95 
scores. 
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5.2.3.4   Consensus Functions 
The last part of this analysis utilizes the above described script which combines 
more docking scores to maximize the corresponding enrichment factors.  
Table 5.6 lists the best performing equations as obtained by maximizing the EF top 
1% values. The first two equations (Eqs. 2 and 3) confirm the fruitful opportunity 
to combine more chimeras to improve the enrichment factors. Such an 
improvement appears to be significant even using the scores of only two different 
chimeras and becomes impressive when combining three chimeras. Even though 
the script could combine more scores (in theory even all sixteen chimeras), the 
developed equations include at most three variables to avoid overfitting conditions.  
Notably, Eq. 3 includes chimeras with intermediate cavities thus confirming the 
general applicability of these in-between chimeras.  
On the other hand, Eq. 4 includes chimeras differing in cavity volume probably 
because in this way they can recognize ligands proportionally differing in their size 
and shape. Stated differently, a single chimera recognizes heterogeneous ligands 
with difficulty and chimeras with intermediate cavities may represent an acceptable 
compromise to do this. However, vastly better results are obtained by combining 
different chimeras which are optimized to recognize small, intermediate and large 
ligands. 
The last two equations (Eqs. 5 and 6) combine docking scores with ligand-based 
descriptors and reveal very remarkable enrichment factors which emphasize the 
synergistic effect of combining heterogeneous parameters
185
. In detail, the study 
exploited a list of 20 well-known physicochemical and stereo-electronic parameters 
as computed by VEGA and semi-empirical calculations (see Appendix 4). 
Although consensus functions may be further enhanced by considering a richer set 
of ligand-based descriptors, such a preliminary analysis was aimed at giving a hint 
about the beneficial effects of combining diverse descriptors without stressing the 
study with an exaggeratedly rich list of descriptors.  
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The best performing equation (Eq. 4) includes two ligand-based descriptors and the 
score of one chimera while Eq. 5 includes the docking scores of two chimeras. The 
included ligand-based descriptors underline the key role of ligand size and polarity, 
while the chimeras included in Eq. 5 confirm the positive role of combining 
cavities of different capaciousness for suitably accommodating small and large 
ligands. 
 
 
N. Equation 
EF     
1% 
EF     
2% 
EF     
5% 
EF    
10% 
2 1.00 Plp95_SBBS - 0.77 Plp95_SBSB 7.94 5.29 6.35 3.95 
3 
1.00 Plp95_SSBS + 0.69 Plp95_SSBB - 
1.62 Plp95_SBBB 
26.45 14.55 6.35 4.74 
4 
1.00  Plp95_SSBS + 1.21 Radius of 
gyration  + 1.42  HbDon 
52.91 30.42 14.28 7.65 
5 
1.00 Plp95_SSSS - 0.25  Plp95_BBBB + 
0.24 HbDon 
42.35 27.77 13.75 7.37 
   
Table 5.6:  Enrichment factors for the optimized equations as obtained by combining the scores of 
more chimeras with ligand-based descriptors. 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 5 – Muscarinic Receptors  
222 
 
5.2.4   Discussion 
The above reported virtual screening campaigns were analysed by computing the 
corresponding enrichment factors, which indeed appear to be meaningful when 
comparing virtual screening campaigns performed by using the same dataset and 
different conformations of the same receptor (as in this study)
186
. Besides the 
arbitrariness of the defined thresholds, the use of enrichment factors has often been 
questioned, since they are focused on the top-ranking molecules and unavoidably 
ignore what happens in the remaining part of the ranking. Thus, Table 5.6 also 
compiles the percentage values of active ligands found in the lower half of the 
ranking. However, this parameter describes the abundance of false negatives but is 
unable to convey a clear picture concerning the distribution of active compounds 
throughout the ranking.  
Hence, Figure 5.3 shows the distributions for some illustrative models of the active 
compounds by subdividing the ranking into 100 bins (each composed of 25 
molecules). Ideally, the active compounds should be included in the first bins, 
gradually decrease in number in the following bins and be absent from the last bins. 
By contrast, a virtual screening which evenly distributes the active compounds 
throughout the ranking should be considered as ineffective regardless of how many 
active ligands are placed in the first bins.  
Figure 5.3 compares the virtual screening campaigns as performed on M12 (Fig. 
5.3-A) and M1 (Fig. 5.3-B) models and emphasizes that the latter, besides having 
markedly higher enrichment factors, also shows a more satisfactory distribution as 
confirmed by the percentage of active compounds in the bottom 50%. In detail, 
Figure 5.3-B shows a significant concentration of the active compounds in the top-
ranked 8 bins, while Figure 5.3-A shows an unsatisfactorily flat distribution of the 
active compounds until the 75
th
 bin.  
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The histograms can also be useful in analysing the modelled chimeras. Figure 5.3 
reports the two chimeras affording the highest enrichment factors (BSSB, Fig. 5.3-
C and SSBS, Fig. 5.3-D) and emphasizes that the former, while showing slightly 
higher enrichment factors, displays a clearly worse distribution which is reflected 
in the reported abundance in the bottom 50%.  
Besides a graphical support for the analysis of virtual screening campaigns, the 
proposed distributions can also be exploited to derive a novel metric, namely the 
skewness, which quantitatively describes how much the active compounds are 
focused on the first bins and thus which can be exploited to tackle the so-called 
“early recognition problem”.  
Table 5.3 compiles the skewness values for the performed virtual screening 
campaigns along with the AUC values of the ROC curves computed for easy 
comparison. Even though the chimeras with the highest enrichment means also 
show the largest skewness and AUC values, the reported skewness values reveal 
fair correlations with both the enrichment means (r = 0.54) and AUC values (r = 
0.65), thus emphasizing that they encode for additional information regarding both 
the complete reliability of a screening study and, more importantly, its ability to 
focus the active compounds on the best bins.  
Although skewness and AUC values show a similar correlation with the 
enrichment means, Figure 5.4 shows that the correlations of AUC values enhance 
when the number of the analysed top-ranked compounds is increased reaching their 
maximum with the Top 20% enrichment factors, while skewness values reveal 
their best relation with the Top 1% enrichment factor and then the relations roughly 
decrease with larger top-ranked enrichment factors. Notably, the same difference is 
noticeable for the correlations with the bottom 50% values.  These results confirm 
the well-known incapacity of ROC curves in early recognition and emphasize the 
fruitfulness of skewness as a simple metric to conveniently tackle this problem. 
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Figure 5.3:  Histogram distribution of the active molecules in the overall ranking as computed for 
the M1 (3A), M1 (3B), BSSB (3C) and SSBS (3D) models. 
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Figure 5.4:  Correlations (expressed by their Pearson coefficient) between enrichment factors and 
skewness values (blue bars) and AUC values (green bars). 
  
   
 
 
 
 
 
 
 Chapter 5 – Muscarinic Receptors  
226 
 
5.2.5   Conclusions 
As stated above, the primary objective of the study was to investigate the role of 
the Pro-containing helices in the GPCR conformational behaviour, by assessing the 
capacity of the simulated chimeras to enhance the predictive power of the 
corresponding homology models. The obtained virtual screening results emphasize 
that the chimeras are able to reach and surpass the predictive power of the more 
reliable M1 model, thus confirming the fruitful potentialities of such an approach 
in provisional studies. Nevertheless, the obtained results underline that the 
chimeras cannot be seen as a way to reproduce the M1 model, but their marked 
predictive efficacy can be ascribed to the capacity to represent relevant and distinct 
conformational states involved in the molecular recognition. On average, the 
chimeras showing the highest predictive power are endowed with binding pocket of 
intermediate size, and this is in agreement with experimental lines of evidence 
showing that the agonists bound GPCR structures appear to be intermediate 
structures which do not correspond to a fully-active state
187
. 
The best performing chimeras are not the same in correlative study (as seen in their 
r
2
 values) and virtual screening, but this finding is not very surprising and can find 
at least two possible explanations. On one hand, correlative analysis and virtual 
screening pursue different objectives; in the former, docking scores should 
parameterize the differences among the active ligands, while in the latter they 
should discriminate between active and inactive compounds. On the other hand, a 
good correlation can be developed only when the docking scores properly account 
for all considered compounds, and few badly predicted molecules are enough to 
pull down the statistics of a given equation. In contrast, virtual screening 
campaigns do not require that all active compounds are correctly top-ranked and 
the enrichment factors tolerate better few outliers (as seen in the bottom 50%). This 
concept is well clarified by chimeras with very restricted cavities (e.g. BBSS), 
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which properly recognize a set of small active ligands thus providing remarkable 
enrichment factors, even though their incapacity to harbour also the larger active 
compounds worsens their r
2
 value. 
Furthermore, the study describes and applies two new tools included as scripts in 
the VEGA suite of programs, and which can greatly support the virtual screening 
studies. The first tool allows both the analysis of the distribution of the active 
compounds throughout the ranking and the calculation of a parameter that 
corresponds to the skewness of the distribution, and which accounts for the 
abundance of the active compounds in the first selected bins thus successfully 
tackling the early recognition problem. The second and more powerful tool allows 
the enrichment factors to be maximized by developing fitting equations that 
linearly combine more docking scores (or ligand-based descriptors).  Even though 
this script should be validated by other tests, the obtained results confirm its 
relevant potentialities and give a glimpse of the manifold applications it can have.  
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5.3   Interaction features of 1,4-dioxane agonists at the 
Orthosteric Sites of  Muscarinic Receptors  
 
 
5.3.1   Setting the scene 
Numerous ACh analogues have been synthesized in an attempt to obtain 
therapeutically better muscarinic agents
188
 (see Figure 5.5). Among them, the cis-
N,N,N-trimethyl-(2-methyl-1,3-dioxolan-4-yl)methanaminiumiodide
189
, compound 
1, emerged as a potent agonist. Esatomic nuclei are also compatible with mAChR 
activity as recently demonstrated by 1,4-dioxane compounds which are effective 
muscarinic agonists
190
. Among these compounds, 2a, the higher homologue of 1, 
shows affinity and potency values similar to those of compound 1 ( 
Table 5.7).  
According to Ing’s rule of five, for maximal mAChR agonist activity, there should 
be no more than five atoms between the quaternary nitrogen atom and the terminal 
hydrogen of the acetyl mimicking chain. Moreover, it has been demonstrated that 
acetic acid esters of quaternary ammonium alcohols of greater length than choline 
have decreased mAChR activity, indicating that no more than two carbon atoms are 
tolerated between the nitrogen and the ether oxygen atoms
191
. 
The methyl group in position 2 of the 1,3-dioxolane nucleus of compound 1 has 
been demonstrated to be essential for the activation of the muscarinic receptors of 
the guinea pig ileum, since compound 13, its desmethyl analogue, is practically 
inactive in this tissue
192
. Indeed, only in the case of the 1,3-dioxolane 1 Ing’s rule is 
respected. Instead, compound 14, the desmethyl analogue of 2a, has been reported 
to be a potent muscarinic agonist
193
, but so far a complete pharmacological study at 
all mAChR subtypes has not been performed yet. Therefore, to verify whether the 
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methyl group of 1,4-dioxane 2a is essential for its potent mAChR activity and to 
understand the mode of interaction of 2a with the muscarinic receptors, compound 
14 was re-prepared and pharmacologically characterized.  
In a structure-activity relationship (SAR) study, in which the methyl group of 2a 
has alternatively or simultaneously been inserted in positions 5 and 6 of the 1,4-
dioxane nucleus in all combinations (compounds 3–12, Figure 5.5)194, we 
demonstrated that the presence of one methyl group in both positions 5 and 6 with 
a trans stereochemical relationship with each other (diastereomers 4 and 5) or the 
geminal dimethylation in position 6 (compound 8) favoured the selective activation 
of the M3 receptor subtype
194
. To extend such a SAR study the methyl group in 
position 6 of the 1,4-dioxane nucleus of 2a was moved to positions 2 and 3 
(compounds 15 and 16a,b, respectively).  
To get information about the recognition process of the 1,4-dioxane agonists, a 
retrospective computational study was performed involving the known derivatives 
2-14 and the novel derivatives 15 and 16 as compiled in Figure 5.5 and  
Table 5.7. Considering that the observed affinities can be due to the ligand capacity 
to assume an optimal bioactive conformation as well as to elicit the key 
interactions, the study involved two different approaches.  
In the first, a ligand-based correlative study was performed to reveal how the 
substituents can influence the puckering of the 1,4-dioxane ring and whether the so 
evidenced conformational differences can, in turn, affect the ligand binding to the 
mAChRs.  
To investigate the preferred binding modes for the examined 1,4-dioxanes, a 
second part of the study involved docking simulations on the recently resolved M2 
and M3 receptors
195,160
, which should allow the diverse affinity profiles to be 
rationalized.  
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Moreover, docking analyses involved the M2 receptor in both open and closed 
states to reveal how the ligand binding is influenced by receptor activation.  
 
 
 
 
Figure 5.5:  Chemical structures of compounds 1-16. 
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Comp. M2 M3 
Δ 
Energy 
Dipole 
Twist 
chair 
Dipole 
Chair 
Dipole 
average 
Δ 
Dipole 
Log PMLP 
Chair 
AD Electr  
Chair  
M2 open 
AD Electr 
Chair 
 M3 
AD VdW  
Twist 
M2 closed 
2a 5.80 5.12 2.67 6.80 8.05 7.43 1.25 -1.62 -0.66 -0.66 -6.54 
2b 5.31 4.45 1.81 7.17 7.17 7.17 0.00 -2.03 -0.53 -0.65 -6.24 
3a 4.95 4.18 1.57 7.95 7.08 7.52 0.86 -2.10 -0.59 -0.68 -6.50 
3b 4.76 4.35 1.49 7.62 7.69 7.65 0.07 -1.59 -0.51 -0.62 -6.46 
4 4.86 4.96 2.57 8.24 8.63 8.43 0.39 -1.56 -0.53 -0.5 -7.31 
5 4.78 <4 2.30 8.61 8.24 8.43 0.37 -1.61 -0.52 -0.62 -7.31 
6 4.05 <4 2.76 8.29 8.60 8.45 0.31 -1.56 -0.51 -0.54 -7.26 
7 4.70 <4 2.46 8.28 8.38 8.33 0.10 -1.56 -0.62 -0.66 -7.14 
8 4.74 4.67 2.88 7.59 7.88 7.73 0.29 -0.73 -0.60 -0.7 -7.02 
9 4.02 4.11 1.45 9.31 9.21 9.26 0.10 -0.01 -0.52 -0.67 -6.87 
10a 4.22 4.49 1.75 9.50 9.66 9.58 0.16 -0.08 -0.51 -0.56 -7.53 
10b 4.14 4.33 1.78 9.53 9.58 9.56 0.04 -0.07 -0.49 -0.61 -7.63 
11a 4.56 4.79 2.47 8.77 8.87 8.82 0.10 -0.28 -0.58 -0.66 -7.94 
11b 4.47 4.98 3.15 8.45 9.17 8.81 0.72 -0.26 -0.57 -0.56 -7.65 
12 4.33 4.39 2.94 9.58 9.95 9.76 0.37 1.22 -0.59 -0.58 -7.96 
14 5.76 4.57 2.43 6.18 6.21 6.21 0.03 -2.10 -0.60 -0.49 -6.67 
15 <4 <4 2.25 6.49 6.84 6.84 0.35 -1.65 -0.59 -0.42 -6.42 
16a <4 <4 2.64 6.96 6.97 6.97 0.01 -1.56 -0.64 -0.44 -6.55 
16b <4 <4 2.55 6.85 6.15 6.50 0.70 -0.92 -0.56 -0.35 -6.21 
 
Table 5.7:  Compounds, affinity values and descriptors used in the correlative analyses. ΔEnergy and the AutoDock (AD) scores are 
expressed in Kcal/mol, while dipole moments are expressed in Debye 
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5.3.2   Computational methods 
The simulated compounds were built by the VEGA suite of programs manually 
generating the favoured conformations (i.e. chair and twist-boat geometries) which 
were then optimized by PM7 semi-empirical calculations as implemented in 
MOPAC2012. The so minimized structures were used to compute the 
conformational energies and the dipole moments as compiled in Table 5.7 and were 
utilized in the following docking simulations.  
For each ligand, docking calculations involved separately chair and twist-boat 
geometries and were performed by using the recently resolved M2 in open and 
closed states and M3 structures (PDB Id: 3UON, 4MQS and 4DAJ, respectively). 
After removing the bound antagonist, the two structures were completed by adding 
hydrogen atoms, and the side-chains of Arg, Lys, Glu, and Asp were ionized to 
remain compatible with physiological pH values, while His and Cys residues were 
considered neutral by default. The structures so obtained were minimized, keeping 
the backbone fixed to preserve the experimental folding. The docking search was 
focused in a 12 Å radius sphere around the co-crystallized ligand. In detail, the 
resolution of the grid was 60×60×60 points with a grid spacing of 0.450 Å and each 
ligand was docked into this grid by the Lamarckian algorithm as implemented in 
AutoDock. The genetic-based algorithm ran 20 simulations per substrate with        
2000000 energy evaluations and a maximum number of generations of 27000. The 
crossover rate was increased to 0.8, and the number of individuals in each 
population to 150. All other parameters were left at the AutoDock default 
settings
196
. The selected complexes were finally minimized keeping fixed all atoms 
outside a 12 Å radius sphere around the docked ligand and then used to re-
calculated the AutoDock scores. 
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5.3.3   Results 
 
 
5.3.3.1   Ligand-based analyses: the role of ring conformations 
The conformational analysis of 1,4 dioxane ring showed that the more extended 
chair conformation is the preferred one for all considered derivatives even though 
the energy barrier separating the chair and the 2,5 twist-boat geometries can 
significantly vary depending on the arrangement of the methyl groups as compiled 
in  
Table 5.7. Briefly, a bird’s eye view of these energy gaps suggests that the methyl 
groups in position 5 reduce the energy barrier below 2.0 Kcal/mol, whereas the 
methyl groups in position 6 increase this energy barrier which shows its maximum 
values (around 3.0 Kcal) for the trimethyl analogue 11b and tetramethyl analogue 
12. Also for all novel derivatives, the chair geometry is the favored one with an 
energy barrier (about 2.5 Kcal/mol) in line with the previous data. This may 
suggest that the poor affinity of methyl derivatives 15 and 16a,b cannot be ascribed 
to distorted ring puckering, but it should be due to their incapacity to stabilize the 
required key contacts within the receptor binding sites because of the methyl 
hindrance (as examined below). 
With a view to investigating the influence of ring conformations on receptor 
binding, a correlative study involved all 1,4-dioxane derivatives by considering the 
above described energy gaps as well as some relevant physicochemical properties 
as computed for both chair and twist-boat geometries and the relative averages and 
differences (as compiled in  
Table 5.7). In analogy to docking simulations (see below), the correlative study was 
focused on M2 and M3 mAChRs only.  
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As a preamble, it should be noted that there is no correlation between energy gaps 
and ligand affinities for the M2 subtype, whereas there is a significant direct 
correlation between them for the M3 subtype (r
2
 = 0.55). Such a difference may 
suggest that the M2 receptor can conveniently recognize both geometries, while the 
M3 receptor recognizes preferentially (or almost exclusively, as suggested by 
docking results) the chair conformations and thus the affinity is linearly correlated 
to the relative stability of these latter. Such a hypothesis is in line with previous 
computational studies emphasizing the greater flexibility of the M2 binding 
site
197,198
. 
This hypothesis is further corroborated by the correlative study since Table 5.8 
shows that the best predictive equation derived for the M2 subtype (Eq. 1) involves 
the dipole averages and the corresponding difference as independent variables, 
while similar equations obtained using physicochemical properties as computed for 
chair or twist-boat conformations separately performed worst. On the other hand, 
Table 5.8 shows that the best relationship for the M3 subtype is derived by using 
the already discussed energy gaps plus the virtual logPMLP as computed for the 
chair geometries (Eq. 2), while the average values or the twist-boat properties 
afforded worst results. Overall, these results may further confirm that both ring 
conformations are recognized by the M2 binding site and thus the average values 
best encode the ligand properties, while the M3 subtype strongly prefers the 
energetically favoured chair conformations. Based on these preliminary correlative 
results, the following docking simulations involved the M2 and M3 subtypes 
considering both chair and twist-boat geometries. 
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Eq. Equation
 
Statistics 
1 pKM2 = 8.38 - 0.35 Dipole Average + 0.45 Dipole  
n = 16; r
2
 = 0.78; 
q
2
 = 0.59; SE = 0.27;  
F = 23.43; p < 0.001 
2 pKM3 = 344 + 0.45 Energy - 013 LogP_MLP_Chair  
n = 13; r
2
 = 0.71; 
q
2
 = 0.55; SE = 0.19;  
F = 12.37; p < 0.01 
3 pKM2 = 6.25 - 0.41 Dipole Average - 3.28 Electr Chair Open 
n = 16; r
2
 = 0.81; 
q
2
 = 0.68; SE = 0.25;  
F = 26.95; p < 0.001 
4 pKM2 = 8.34 - 0.55 Dipole Average – 0.14 vdW/HB Twist Close 
n = 16; r
2
 = 0.74; 
q
2
 = 0.64; SE = 0.29;  
F = 19.31; p < 0.001 
5 pKM3 = 3.87 + 0.41 Energy - 0.36 Electr Chair 
n = 13; r
2
 = 0.60; 
q
2
 = 0.47; SE = 0.23; 
F = 10.56; p < 0.01 
 
Table 5.8:   Best relationships developed in the study 
 
 
 
5.3.3.2   Docking studies on M2 receptor: comparison between open and closed 
states 
Regarding to the M2 subtype in its open inactive state, Figure 5.6 compares the key 
interactions stabilized by 2a in its chair (Figure 5.6-A) and twist-boat (Figure 5.6-
B) geometry. Remarkably, the key polar contacts are conserved in both complexes 
and involve: (1) ion-pair between the ligand ammonium head and Asp103; (2) 
charge transfer interactions involving the ammonium head and a set of surrounding 
aromatic residues (Trp400, Tyr403, Tyr426, Tyr430, plus Tyr104 not shown for 
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reasons of clarity); (3) H-bonds between O1 and Ser107 as well as between O4 and 
Asn404. 
The two complexes mainly differ in the accessibility of the ligand oxygen atoms, 
which influences the stability of the mentioned H-bonds, the chair conformation 
allowing a closer approach of Ser107 and Asn404. 
A second evident difference between the complexes involves the arrangement of 6-
methyl group which better approaches Ala194 when the dioxane ring assumes 
twist-boat conformation, even though the polar contacts appear to be here largely 
predominant as suggested by the following docking based correlative studies. 
Indeed, the best obtained equation (Eq. 3, Table 5.8) combines the dipole average 
(already used by Eq. 1) with electrostatic score as computed by AutoDock for the 
complexes with dioxane in chair conformation. This emphasizes that the chair 
conformations and the polar interactions play a key role in ligand recognition, even 
though the M2 binding site might accommodate both ring geometries. 
While the M2 receptor in its open state can suitably recognize both dioxane 
conformations but prefers the chair geometry (see above), docking simulations 
suggest that the closed active M2 state stabilizes significantly better complexes 
when interacting with the ligand in its twist-chair conformation, a results that can 
be ascribed to the markedly narrower binding cavity of the M2 active state which 
accommodates more conveniently the less hindered twist-chair geometry.  
Figure 5.6 compares the putative complexes for the derivative 2a in its chair 
(Figure 5.6-C) and twist-chair geometry (Figure 5.6-D) and evidence in both 
complexes a set of interactions almost superimposable to that observed in the M2 
open state. Nevertheless, Figure 5.6-C and 5.6-D reveal a significant difference 
between the two complexes since only the ligand assuming twist-chair geometry is 
able to elicit the key H-bond with Asn404, while the clashes exerted by the methyl 
group prevent a proper approaching of Asn404 when adopting the more hindered 
chair geometry.  
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Figure 5.6:  Main interactions stabilizing the compound 2a in its chair (A) and twist-boat (B) 
conformation within the M2 binding site in its open state as well as in its chair (C) and twist-boat 
(D) conformation within the M2 binding site in its closed state 
 
The role of twist-chair geometries in ligand recognition by the M2 closed state is 
corroborated by Eq. 4 (Table 5.8) which, despite showing worst statistics than Eq. 
3, allows some considerations to be made.  
First, Eq. 4 includes a score obtained by docking ligands in their twist-chair 
geometry, while docking scores derived by chair conformations did not afford 
satisfactory results.  
Second, the comparison of Eq. 3 and Eq. 4 confirms the role of dipole moment and 
evidences a notable difference since Eq. 4 includes a score encoding for H-bonds 
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and apolar contacts instead of an electrostatic score function as seen in Eq. 3. This 
may mean that well-defined ionic interactions are required for triggering receptor 
activation, while the binding to closed state is rather influenced by a precise fitting 
of the ligand within the narrower binding site stabilized by apolar contacts. 
 
 
 
 
Figure 5.7:   Main interactions stabilizing 14 in its chair conformation within the M2 binding site in 
its open state (A) as well as in its twist-chair conformation within the M2 binding site in its closed 
state (B). Comparison of the docked poses for compounds 1 (in blue) and 14 (in red) within the M2 
binding site in its open state (C) emphasizing (see the green circle) the remarkable overlapping 
between the methyl group of 1 and the 5-methylene group of 14. Main interactions stabilizing 16b 
in its chair conformation within the M2 binding site in its open state (D). 
C D 
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Concerning the here reported novel derivatives, Figure 5.7-A shows the complex as 
obtained for the most affine derivative 14 in its chair conformation within the M2 
binding site in its open state and evidences a set of key interactions in line with 
those reported in Figure 5.6-A. Similarly, Figure 5.7-B reports 14 in twist-chair 
conformation within the M2 binding site in the closed state and shows interactions 
almost identical to those displayed by Figure 5.6-D.  
In both cases, the major difference involves the arrangement of the dioxane ring 
because the absence of the methyl group allows the ring to be accommodated more 
superficially in a pose where it can maintain the crucial H-bonds with Ser107 and 
Asn404 and its carbon skeleton can conveniently approach Ala194, thus replacing 
the hydrophobic contacts stabilized by methyl groups in the previous analogues. 
When focusing the attention on the open state, the capacity of the dioxane ring of 
14 to replace the methyl substituents eliciting hydrophobic interactions with 
Ala194 and the surrounding residues is confirmed by the superimposition of the 
poses obtained for 1 and 14 (see Figure 5.7-C for M2 in the open state, 1 in blue and 
14 in red) and can explain the ability of 14 to obey Ing’s rule. Figure 5.7-C shows 
indeed the precise overlapping between the methyl substituent of 1 and the 5-
methylene group of the dioxane ring of 14, as evidenced by the green circle, thus 
confirming that the unsubstituted dioxane ring can elicit hydrophobic interactions 
similar to those afforded by the methyl dioxolanes regardless of ring conformation 
and receptor activation (as seen for 1). 
As illustrated in Figure 5.7-D for 16b, docking results can also explain the 
negligible affinity of methyl derivatives 15 and 16a,b, since even in the M2 open 
state the methyl group bumps against Trp400 plus Tyr403 which constrain the 
ligands in a more lateral pose where they lose some key contacts such as that with 
Ser107, thus justifying their lack of affinity.  
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5.3.3.3   Docking studies on the M3 receptor in its open state 
When docking both ligand geometries, completely different results are obtained for 
the M3 subtype which is considered in its open state (the only conformation 
hitherto resolved). Indeed, while chair and twist-boat conformations are stably 
retained within the M2 binding site even after complex minimization, the 
minimization of most twist-boat conformations within the M3 binding site leads to 
their conversion to chair geometries, thus indicating that the twist-boat 
conformations cannot be involved in ligand recognition by the M3 subtype. This 
difference can be rationalized by analyzing the minimized complex for the 
derivative 2a in its chair geometry as shown in Figure 5.8-A. The key stabilizing 
interactions involve: (1) ion-pair between the ligand ammonium head and Asp147; 
(2) charge transfer interactions involving the ligand ammonium head and a set of 
surrounding aromatic residues (Trp503, Tyr506, Tyr529, Tyr533, plus Tyr148 not 
shown for reasons of clarity); (3) H-bonds between O1 and Ser151 as well as O4 
and Asn507.  
 
 
 
Figure 5.8:  Main interactions stabilizing the compound 2a (A) and 15 (B) in their allowed chair 
conformations within the M3 binding site. 
A B 
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The comparison of this complex with the corresponding one for the M2 subtype 
reveals some remarkable differences, which can be summarized as follows: (1) the 
aromatic residues mostly contact the ammonium head in the M2 subtype while they 
completely surround the ligand in the M3 subtype, thus rendering the binding site 
more constrained and less flexible; (2) the H-bond between the conserved Ser151 
and the O1 atom appears to be weakened when compared to the corresponding 
contact within the M2 binding cavity; on one hand this underlines the greater 
relevance of the other H-bond involving the conserved Asn507 residue; on the 
other hand, this suggests that the surrounding tyrosine residues can be involved in 
additional H-bonds with the dioxane oxygen atoms but they can be conveniently 
approached only by the more accessible chair geometry; (3) similarly to what was 
observed for the M2 subtype, the methyl groups contact the conserved Ala238, but 
here these hydrophobic interactions are markedly influenced by the closeness of 
Trp199 which constrains this hydrophobic subpocket which can be suitably 
contacted only by the more extended chair geometries; notably, these steric 
requirements influence ligand conformation and receptor recognition regardless of 
position and configuration of the methyl groups. Indeed, only the trans 
diastereoisomers 2b and 3b are able to retain a distorted twist-boat conformation 
within the M3 binding cavity. 
The following correlative study confirms the key role of chair conformations since 
the best derived equation (Eq. 4, Table 5.8) includes the energy gaps between ring 
geometries and the electrostatic scores as computed by AutoDock. This result 
further underlines how the M3 affinity depends on the relative stability of the chair 
conformations and their ability to stabilize polar contacts within the M3 binding 
site. 
Docking simulations on the M3 subtype afford results in line with the previous ones 
and, as evidenced by the retrospective study, only chair conformations can be 
accommodated within its binding site. In detail, docking results show that the 
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methyl derivatives 15 and 16a,b are unable to be conveniently harboured due to the 
methyl group which bumps against Trp503 and Ser151, thus hampering the H-bond 
stabilized by this latter with the ligand O1 atom (as exemplified by Figure 5.8-B for 
15, Supporting Information).  
Similarly to what was observed for the M2 binding site, Figure 5.9 compares the 
computed poses of compounds 1 (red) and 14 (blue) within the binding cavity of 
M3 and shows an interaction pattern which is very similar to that observed for M2. 
One may note the remarkable overlapping between the methyl substituent of 1 and 
the 5-methylene group of the dioxane ring of 14, as evidenced by the green circle, 
and indeed both ligands stabilize apolar contacts with Ala235 and Ala238. This 
observation confirms that the dioxane ring can elicit hydrophobic interactions 
similar to those stabilized by methyl dioxolanes (as seen for 1), thus explaining 
why dioxane derivatives show similar affinity values regardless of the methyl 
substituent. 
 
 
 
 
Figure 5.9:  Comparison of the docked poses for compounds 1 (in blue) and 14 (in red) within the 
M3 binding site emphasizing (see the green circle) the remarkable overlapping between the methyl 
group of 1 and the 5-methylene group of 14. 
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5.3.4   Conclusions 
The present study completes a SAR study of 1,4-dioxane muscarinic agonists, and 
investigates their binding capacities by docking simulations as performed using the 
recently resolved human M2 and rat M3 crystal structures. On one hand, it should 
be observed that, to the best of our knowledge, this is one of the first studies which 
exploit such resolved GPCR structures to rationalize the affinity values of 
muscarinic ligands. On the other hand, one may imagine that the availability of 
resolved receptor structures can afford more reliable docking results, accounting 
also for very specific ligand features as here exemplified by the puckering of the 
dioxane ring.  
Indeed, the obtained docking results were able to reveal the key role played by 
often disregarded conformational profile of the 1,4-dioxane ring, thus underlining 
the already reported flexibility differences between the orthosteric binding sites of 
the M2 and M3 subtypes. Notably, the conformational profile of the 1,4-dioxane 
ring was found to play a key role also to second receptor activation and to optimize 
the ligand interactions as seen in the M2 closed state.  Moreover, the so obtained 
results evidence that the 1,4-dioxane compounds interact with muscarinic receptors 
in their orthosteric site similarly to their 1,3-dioxolane analogues. In the case of 
compound 14, the methylene group in position 5 of the 1,4-dioxane nucleus 
occupies the same lipophilic pocket as the methyl group of the potent muscarinic 
compounds 1 and 2a, thus explaining why 14 has a good affinity and obeys Ing’s 
rule.  
While considering the evidenced differences between the binding modes of the M2 
and M3 subtypes, docking results overall emphasize the remarkable similarity 
between the two binding pockets, thus justifying the difficulty of designing 
selective agonists as indeed confirmed by the here analysed ligands. Nevertheless, 
one may argue that the possibility of utilizing the resolved muscarinic structures 
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might provide ever deeper insights allowing the design of new agonists selectively 
targeting M2 and M3 mAChR subtypes. 
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5.4   Bitopic modulators of muscarinic receptors: a 
modelling study 
 
 
5.4.1   Setting the scene 
As mentioned in the Introduction, the main problem in the development of 
muscarinic agents is the high homology in their orthosteric binding site. This has 
hampered the development of drugs whose activity was associated to many adverse 
effects to have a concrete therapeutic role, arising from lack of selectivity
199,200
. 
The discovery of allosteric modulators has opened a new avenue in the 
development of selective drugs, since these compounds interact with binding sites 
which are less conserved within the five muscarinic receptors, thus allowing a 
selective modulation of only one subtypelindse
201,202
.  
New intriguing perspectives have been associated also to the discovery of 
dualsteric (bitopic) ligands, i.e. divalent compounds in which two pharmacophoric 
units, connected by a suitable spacer, are able to interact at the same time both with 
the orthosteric site and the allosteric binding areas, thus exploiting the favourable 
characteristics of both sites
203,204,205,206
. Originally divalent ligands have been 
designed to study receptor dimerization
206
, but in many instances the length of the 
linker allowed only the bridging of two neighboring interaction sites on the same 
protein. In principle, bitopic ligands may interact with the othosteric or the 
allosteric binding site, or with both, within a monomeric receptor; very recently it 
has been shown a bitopic interaction also within a dimeric receptor
207
. 
Several muscarinic homodivalent ligands, i.e. divalent compounds carrying two 
identical pharmacophoric units, have also been disclosed, such as the M2 selective 
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antagonist methoctramine
208,209
 or the dimers of agonists such as xanomeline
210
 or 
arecaidine propargyl ester (APE)
211
. These compounds displayed different range of 
potency, affinity and intrinsic activity, depending on the pharmacophoric structure 
and on the linker, as the pharmacophoric doubling not always resulted in an 
increased affinity or potency. In addition, homo or heterobivalent ligands carrying 
at least one agonist unit were not always endowed with receptor activation 
properties (see, for instance, refs
212,213
) 
On these bases the effect of homodimerization on carbachol, the well-known 
cholinergic agonist was here investigated. The idea underlying this approach 
concerned the possibility to bind two different sites in the same receptor, either 
orthosteric and allosteric, or two orthosteric sites in a dimeric receptor. Although 
carbachol itself does not display allosteric properties, the allosteric site of 
muscarinic receptors can bind compounds carrying choline residues as exemplified 
by gallamine. Therefore, a series of compounds where the two agonist units are 
symmetrically connected through a methylene chain of variable length were 
designed, linking the carbamic nitrogen atoms and considering both tertiary amines 
and ammonium derivatives. Ongoing biological analyses revealed that the tested 
compounds are able to occupy both orthosteric and allosteric binding sites, 
showing affinity values which increase with the linker length. Notably, all 
compounds lose the agonistic activity and show an antagonistic profile in all tested 
receptors. Again, the compounds, while remaining substantially unselective, show 
a clear preference for the M1/M3 subtypes, and this feature is completely different 
compared to the parent compound carbachol which, albeit unselective, is 
characterized by a known preference for M2/M4 subtypes. 
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5.4.3   Computational details 
Docking simulations involved the recently resolved structures of the hM2 subtype 
in complex with both the agonist iperoxo and the allosteric modulator LY2119620 
(PDB Id: 4MQT), as well as in complex with the antagonists QNB (PDB Id: 
3UON) The choice of the first hM2 structure is justified by the bound ligands 
which should assure that both binding cavities (allosteric and orthosteric sites) are 
finely optimized for ligand recognition. The second hM2 structure was selected to 
simulate receptor conditions similar to those experienced during the kinetic 
experiments.  
Again, docking studies involved the hM1 (Entry Id: P11229, Entry name: 
ACM1_HUMAN) homology model as generated by using the first hM2 structure as 
the template. Briefly, the homology modelling was performed by Modeller 9.10 
using the default parameters; among the 20 generated models, the best structure 
was selected according to the computed scores (i.e. DOPE and GA341), as well as 
to the percentage of residues falling in the allowed regions of the Ramachandran 
(91.2 %) and chi plots (95.8%). The completed model was carefully checked to 
avoid unphysical occurrences such as cis peptide bonds, wrong configurations, 
improper bond lengths, non-planar aromatic rings or colliding side-chains.  
The so obtained hM1 and hM2 structures were then completed by adding hydrogen 
atoms and to remain compatible with physiological pH, Asp, Glu, Lys and Arg 
residues were considered in their ionized form while His and Cys were maintained 
neutral by default. Finally, the structures were optimized by a minimization made 
up by two phases: a first minimization without constraints until RMS = 0.1 kcal 
mol-1Å-1 and then a second minimization with backbone fixed until RMS = 0.01 
kcal mol-1Å-1 to preserve their folding.  
All ligands were simulated in their protonated state, since this is involved in 
receptor recognition. The conformational profile was investigated by MonteCarlo 
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simulations (as implemented in the VEGA program), which produced 1000 
minimized conformations by randomly rotating the rotatable bonds, and the so 
computed lowest energy structure underwent docking simulations. 
Docking simulations were carried out using PLANTS with default settings and 
without geometric constraints. The search within the first hM2 structure and the 
hM1 homology model was focused on a region obtained combining a 10.0 Å radius 
sphere around Asp105 (hM1) or Asp103 (hM2) plus a 10.0 Å radius sphere around 
Tyr179 (hM1) or Tyr177 (hM2), thus completely encompassing both binding 
cavities. In contrast, the search within the second hM2 structure was focused on a 
region obtained combining a 10.0 Å radius sphere around Tyr177, keeping the 
bound QNB antagonist. For each ligand, speed 1 was used and 10 poses were 
generated and scored using the ChemPlp function. The so obtained best complexes 
were finally optimized by a minimization keeping all atoms fixed apart from those 
included within a 10.0 Å radius sphere around the bound ligand. 
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5.4.3   Results 
 
5.4.3.1   Docking results on hM2 in its closed state 
To rationalize the results of binding and functional experiments, docking studies 
were performed on the recently resolved hM2 structure in complex with the agonist 
iperoxo and the allosteric modulator LY2119620 , for both ammounium derivatives 
and ammines in the protonated form; since both classes interact in a similar way, 
only the methiodides are discussed here.  
In detail, the short-chain derivatives (n = 3 or 5) can assume two distinct binding 
modes. In the first pose (as shown in Figure 5.10-A, n=3), the ligands are 
completely accommodated in the orthosteric cavity, where they stabilize the 
following set of interactions: (i) one ammonium head is engaged in the key ion-
pairing with Asp103, reinforced by a set of charge transfer interactions with 
surrounding aromatic residues (e.g., Tyr80, Trp99, Tyr426, Tyr430); (ii) the two 
carbamate moieties elicit clear H-bonds with Tyr104, Ser107 and Tyr403 and (iii) 
the second ammonium head approaches Asn108, Phe195, Trp400, and Asn404. 
In the second binding mode, the ligands assume a central pose by which they 
contact both the orthosteric and the allosteric sites. Specifically, both ammonium 
heads are engaged in ion-pairs, one with Asp103 in the orthosteric cavity and the 
other with Glu172 and Glu175 in the allosteric site, the latter being further 
reinforced by charge transfer interactions with Tyr177. The two carbamate moieties 
elicit again H-bond interactions, but with Tyr426 and Asn419 in the orthosteric and 
the allosteric sites, respectively. For the short-chain derivatives, the first binding 
mode is markedly favoured in terms of both calculated docking scores and relative 
abundance among the computed poses.  
When extending the linker, the first binding mode becomes progressively less 
favoured to disappear for n = 6 due to obvious steric hindrance. As exemplified in  
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Figure 5.10:  Docking poses of selected ligands into the hM1 and hM2 receptors. A: n =3 within the 
orthosteric cavity of hM2. B: n = 9 docked between the orthosteric and allosteric sites of hM2.  
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Figure 5.10-B, the long-chain analogues show only the second binding mode and 
assume a deeper pose compared to that shown by short-chain derivatives, by which 
the dimethylaminoethylcarbamate moiety within the orthosteric cavity contacts 
Asn404, while retaining the already mentioned interactions with Asp103 plus the 
surrounding aromatic residues. The type of interactions established by the second 
carbachol unit, which are accommodated in the allosteric site, are similar to those 
already seen for the short-chain analogues, consisting in ion pairing between the 
ammonium moiety and Glu172 and Glu175, reinforced by a set of H-bonds with 
Tyr83, Tyr177, Asn419. However, it is worth noting that all derivatives, when 
assuming this second binding mode, are unable to insert the carbachol unit into the 
orthosteric cavity in a pose comparable to that shown by CCh. As a matter of fact, 
the linker constrains the dimethylaminoethylcarbamate moiety in an inverted 
arrangement which prevents the carbamate group to contact Asn404. In such a 
second binding mode the linker is inserted in a constrained channel lined by 
aromatic residues.  
Taken together, these results can provide an explanation for the antagonistic 
activity of the long-chain derivatives, since they do achieve a rich interaction 
pattern while being unable to elicit the key contacts usually established by the 
agonists within the orthosteric site. 
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5.4.3.2   Docking results on the hM1 homology model 
Since the compounds show higher affinity for the hM1 receptor, compared to hM2 
subtype, docking simulations were also performed on an hM1 homology model as 
generated by using the above mentioned recently resolved hM2 structure as the 
template. Also on this subtype, docking studies suggest significant differences on 
the binding mode of the compounds, depending on the length of the linker.  
In detail, the short-chain derivatives tend to remain in the allosteric site where one 
carbachol moiety elicits ionic interactions with Glu397 plus a set of H-bonds with 
Tyr85, Tyr179, Gln177, while the second carbachol group approaches the 
orthosteric site without reaching it. On the contrary, as shown in Figure 5.11-A, the 
long-chain derivatives assume a central pose by which they occupy both the 
orthosteric and the allosteric sites. Such a pose brings to mind that previously 
described for the hM2 subtype, although these ligands appear to be more fittingly 
accommodated in the hM1 receptor. In fact, while the key contacts within the 
allosteric cavity are similar in both subtypes, the carbachol moiety within the 
orthosteric site assumes an optimal orientation being able to elicit the same key 
interactions established by CCh, namely the ammonium head with Asp105 plus the 
surrounding aromatic residues and the carbamate moiety with Asn382. Moreover, 
the alkyl linker appears to be suitably inserted in a tight channel completely lined 
by aliphatic residues, which can form a rich set of apolar contacts with the ligand.  
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Figure 5.11:  Docking poses of selected ligands into the hM1 and hM2 receptors. A: n = 9, docked 
between the orthosteric and allosteric sites of hM1. B: n = 9 into the allosteric site of the QNB-
occupied hM2 receptor.   
 
 
 
 
 
A 
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5.4.3.3   Docking results on hM2 in its open state and in complex with QNB 
Docking simulations were repeated by using the M2 resolved structure in complex 
with the QNB antagonist in order to mimic an experimental condition comparable 
with the kinetic binding studies. The obtained results reveal that all compounds 
with two carbachol units are conveniently accommodated in the allosteric binding 
cavity regardless of the length of the linker. Thus, Figure 5.11-B depicts the 
putative complex for n= 5. The ligand is completely harboured in the allosteric site 
where it can elicit a rich set of polar contacts.  
In detail, (i) one ammonium head is engaged in the key ion-pairing with Glu175 
reinforced by charge transfer interactions with surrounding aromatic residues (e.g., 
Tyr83 and Tyr88); (ii) the second ammonium head elicits only charge transfer 
interactions with Tyr177 and Phe181; (iii) both carbamate moieties are involved in 
several H-bonds with Tyr80, Thr187, Tyr403, Asn419, Thr423, and Tyr426; (iv) 
the linker elicits hydrophobic contacts with Trp422. All examined ligands show a 
very similar binding mode, permitted by their folding degree which increases with 
the length of the linker. Notably, some tyrosine residues which normally belong to 
the orthosteric site (i.e. Tyr403 and Tyr426) are here slightly shifted due to the 
presence of the antagonist and can participate to the interaction in the allosteric site, 
thus suggesting that these aromatic residues act as a watershed to divide the two 
considered binding sites. 
 
 
5.4.4   Conclusions 
As mentioned above, preliminary biological data revealed that affinity increases 
with the linker’s length, even though the increase is not smooth, and a “jump” in 
the affinity values can be seen going from the compounds with n ≤ 5 to those with 
n ≥ 7. Although the beneficial effect of the linker length can be rationalized by 
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considering a direct contribution of this moiety, probably by hydrophobic 
interactions, such a discontinuous behaviour may be explained by a change in the 
binding mode of the compounds, which allows a better fit within the receptor, as if, 
for instance, a gap could be bridged between the binding sites accommodating the 
two pharmacophoric units.  
Indeed, docking simulations, performed on the recently resolved hM2 structure, 
revealed significant differences between the simulated compounds depending on 
the length of their linker, suggesting a change in binding mode for n = 6. While 
short compounds (n ≤5) may interact within the orthosteric binding site or between 
the orthosteric and allosteric sites, by increasing the length of the linker only the 
bitopic interaction is possible due to steric hindrance.  
The comparison of the docking results obtained for hM1 and hM2 allows some 
considerations which correlate with the outcomes of equilibrium binding studies. 
First, in both receptors the binding mode depends on the length of the linker and 
only the long-chain analogues are able to occupy both binding sites. Second, the 
short-chain derivatives reveal significant differences between the two receptor 
subtypes: in fact, when docked on hM2 receptor they tend to be completely 
harboured within the orthosteric site while on the hM1 subtype they remain in the 
allosteric cavity. This different behaviour is easily explained by considering that 
the hM2 orthosteric pocket is larger and more flexible than the one in hM1, as 
demonstrated by previous studies. Third, while assuming comparable pose, the 
long-chain derivatives are predicted to elicit a more favourable pattern of 
interactions on hM1 receptors compared to hM2. This difference is due to the 
contacts established by the carbachol moiety within the orthosteric site as well as to 
the hydrophobic interactions stabilized by the linker. 
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Appendix 1: Physicochemical properties 
 
MOE CODE DESCRIPTION 
AM1_dipole The dipole moment calculated using the AM1 Hamiltonian 
AM1_E 
The total SCF energy (kcal/mol) calculated using the AM1 
Hamiltonian 
AM1_Eele 
The electronic energy (kcal/mol) calculated using the AM1 
Hamiltonian 
AM1_HF 
The heat of formation (kcal/mol) calculated using the AM1 
Hamiltonian 
AM1_HOMO 
The energy (eV) of the Highest Occupied Molecular Orbital 
calculated using the AM1 Hamiltonian 
AM1_IP 
The ionization potential (kcal/mol) calculated using the AM1 
Hamiltonian 
AM1_LUMO 
The energy (eV) of the Lowest Unoccupied Molecular Orbital 
calculated using the AM1 Hamiltonian 
ASA 
Water accessible surface area calculated using a radius of 1.4 A 
for the water molecule. A polyhedral representation is used for 
each atom in calculating the surface area. 
ASA_H Water accessible surface area of all hydrophobic (|qi|<0.2) atoms. 
ASA_P Water accessible surface area of all polar (|qi|>=0.2) atoms. 
DASA Absolute value of the difference between ASA+ and ASA-. 
DCASA Absolute value of the difference between CASA+ and CASA-. 
dens 
Mass density: molecular weight divided by van der Waals volume 
as calculated in the vol descriptor. 
dipole 
Dipole moment calculated from the partial charges of the 
molecule. 
E 
Value of the potential energy. The state of all term enable flags 
will be honored (in addition to the term weights). This means that 
the current potential setup accurately reflects what will be 
calculated. 
E_ang 
Angle bends potential energy. In the Potential Setup panel, the 
term enable (Bonded) flag is ignored, but the term weight is 
applied. 
E_ele 
Electrostatic component of the potential energy. In the Potential 
Setup panel, the term enable flag is ignored, but the term weight is 
applied. 
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E_nb 
Value of the potential energy with all bonded terms disabled. The 
state of the non-bonded term enable flags will be honored (in 
addition to the term weights). 
E_oop 
Out-of-plane potential energy. In the Potential Setup panel, the 
term enable (Bonded) flag is ignored, but the term weight is 
applied. 
E_sol Solvation energy. 
E_stb Bond stretch-bend cross-term potential energy. 
E_str Bond stretch potential energy. 
E_strain 
Local strain energy: the current energy minus the value of the 
energy at a near local minimum. The current energy is calculated 
as for the E descriptor. The local minimum energy is the value of 
the E descriptor after first performing an energy minimization. 
E_tor Torsion (proper and improper) potential energy. 
E_vdw Van der Waals component of the potential energy. 
FASA_H Fractional ASA_H calculated as ASA_H / ASA. 
FASA_P Fractional ASA_P calculated as ASA_P / ASA. 
glob 
Globularity or inverse condition number (smallest eigenvalue 
divided by the largest eigenvalue) of the covariance matrix of 
atomic coordinates. A value of 1 indicates a perfect sphere while a 
value of 0 indicates a two- or one-dimensional object. 
MNDO_dipol
e The dipole moment calculated using the MNDO Hamiltonian. 
MNDO_E 
The total SCF energy (kcal/mol) calculated using the MNDO 
Hamiltonian. 
MNDO_Eele 
The electronic energy (kcal/mol) calculated using the MNDO 
Hamiltonian. 
MNDO_HF 
The heat of formation (kcal/mol) calculated using the MNDO 
Hamiltonian. 
MNDO_HO
MO 
The energy (eV) of the Highest Occupied Molecular Orbital 
calculated using the MNDO Hamiltonian. 
MNDO_IP 
The ionization potential (kcal/mol) calculated using the MNDO 
Hamiltonian. 
MNDO_LUM
O 
The energy (eV) of the Lowest Unoccupied Molecular Orbital 
calculated using the MNDO Hamiltonian. 
npr1 Normalized PMI ratio pmi1/pmi3. 
npr2 Normalized PMI ratio pmi2/pmi3. 
PM3_dipole The dipole moment calculated using the PM3 Hamiltonian. 
PM3_E 
The total SCF energy (kcal/mol) calculated using the PM3 
Hamiltonian. 
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PM3_Eele 
The electronic energy (kcal/mol) calculated using the PM3 
Hamiltonian. 
PM3_HF 
The heat of formation (kcal/mol) calculated using the PM3 
Hamiltonian. 
PM3_HOMO 
The energy (eV) of the Highest Occupied Molecular Orbital 
calculated using the PM3 Hamiltonian. 
PM3_IP 
The ionization potential (kcal/mol) calculated using the PM3 
Hamiltonian. 
PM3_LUMO 
The energy (eV) of the Lowest Unoccupied Molecular Orbital 
calculated using the PM3 Hamiltonian. 
pmi Principal moment of inertia. 
pmi1 First diagonal element of diagonalized moment of inertia tensor. 
pmi2 Second diagonal element of diagonalized moment of inertia tensor. 
pmi3 Third diagonal element of diagonalized moment of inertia tensor. 
rgyr Radius of gyration. 
std_dim1 
Standard dimension 1: the square root of the largest eigenvalue of 
the covariance matrix of the atomic coordinates. A standard 
dimension is equivalent to the standard deviation along a principal 
component axis. 
std_dim2 
Standard dimension 2: the square root of the second largest 
eigenvalue of the covariance matrix of the atomic coordinates. A 
standard dimension is equivalent to the standard deviation along a 
principal component axis. 
std_dim3 
Standard dimension 3: the square root of the third largest 
eigenvalue of the covariance matrix of the atomic coordinates. A 
standard dimension is equivalent to the standard deviation along a 
principal component axis. 
vol 
Van der Waals volume calculated using a grid approximation 
(spacing 0.75 A). 
VSA 
Van der Waals surface area. A polyhedral representation is used 
for each atom in calculating the surface area. 
vsurf_A Amphiphilic moment. 
vsurf_CP Critical packing parameter. 
vsurf_CW1 Capacity factor (1). 
vsurf_CW2 Capacity factor (2). 
vsurf_CW3 Capacity factor (3). 
vsurf_CW4 Capacity factor (4). 
vsurf_CW5 Capacity factor (5). 
vsurf_CW6 Capacity factor (6). 
vsurf_CW7 Capacity factor (7). 
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vsurf_CW8 Capacity factor (8). 
vsurf_D1 Hydrophobic volume (1). 
vsurf_D2 Hydrophobic volume (2). 
vsurf_D3 Hydrophobic volume (3). 
vsurf_D4 Hydrophobic volume (4). 
vsurf_D5 Hydrophobic volume (5). 
vsurf_D6 Hydrophobic volume (6). 
vsurf_D7 Hydrophobic volume (7). 
vsurf_D8 Hydrophobic volume (8). 
vsurf_DD12 Contact distances of vsurf_DDmin (12). 
vsurf_DD13 Contact distances of vsurf_DDmin (13). 
vsurf_DD23 Contact distances of vsurf_DDmin (23). 
vsurf_DW12 Contact distances of vsurf_EWmin (12). 
vsurf_DW13 Contact distances of vsurf_EWmin (13). 
vsurf_DW23 Contact distances of vsurf_EWmin (23). 
vsurf_EDmin
1 Lowest hydrophobic energy (1). 
vsurf_EDmin
2 Lowest hydrophobic energy (2). 
vsurf_EDmin
3 Lowest hydrophobic energy (3). 
vsurf_EWmin
1 Lowest hydrophilic energy (1). 
vsurf_EWmin
2 Lowest hydrophilic energy (2). 
vsurf_EWmin
3 Lowest hydrophilic energy (3). 
vsurf_G Surface globularity. 
vsurf_HB1 H-bond donor capacity (1). 
vsurf_HB2 H-bond donor capacity (2). 
vsurf_HB3 H-bond donor capacity (3). 
vsurf_HB4 H-bond donor capacity (4). 
vsurf_HB5 H-bond donor capacity (5). 
vsurf_HB6 H-bond donor capacity (6). 
vsurf_HB7 H-bond donor capacity (7). 
vsurf_HB8 H-bond donor capacity (8). 
vsurf_HL1 Hydrophilic-Lipophilic (1). 
vsurf_HL2 Hydrophilic-Lipophilic (2). 
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vsurf_ID1 Hydrophobic integy moment (1). 
vsurf_ID2 Hydrophobic integy moment (2). 
vsurf_ID3 Hydrophobic integy moment (3). 
vsurf_ID4 Hydrophobic integy moment (4). 
vsurf_ID5 Hydrophobic integy moment (5). 
vsurf_ID6 Hydrophobic integy moment (6). 
vsurf_ID7 Hydrophobic integy moment (7). 
vsurf_ID8 Hydrophobic integy moment (8). 
vsurf_IW1 Hydrophilic integy moment (1). 
vsurf_IW2 Hydrophilic integy moment (2). 
vsurf_IW3 Hydrophilic integy moment (3). 
vsurf_IW4 Hydrophilic integy moment (4). 
vsurf_IW5 Hydrophilic integy moment (5). 
vsurf_IW6 Hydrophilic integy moment (6). 
vsurf_IW7 Hydrophilic integy moment (7). 
vsurf_IW8 Hydrophilic integy moment (8). 
vsurf_R Surface rugosity. 
vsurf_S Interaction field surface area. 
vsurf_V Interaction field volume. 
vsurf_W1 Hydrophilic volume (1). 
vsurf_W2 Hydrophilic volume (2). 
vsurf_W3 Hydrophilic volume (3). 
vsurf_W4 Hydrophilic volume (4). 
vsurf_W5 Hydrophilic volume (5). 
vsurf_W6 Hydrophilic volume (6). 
vsurf_W7 Hydrophilic volume (7). 
vsurf_W8 Hydrophilic volume (8). 
vsurf_Wp1 Polar volume (1). 
vsurf_Wp2 Polar volume (2). 
vsurf_Wp3 Polar volume (3). 
vsurf_Wp4 Polar volume (4). 
vsurf_Wp5 Polar volume (5). 
vsurf_Wp6 Polar volume (6). 
vsurf_Wp7 Polar volume (7). 
vsurf_Wp8 Polar volume (8). 
ASA+ 
Water accessible surface area of all atoms with positive partial 
charge (strictly greater than 0). 
ASA- Water accessible surface area of all atoms with negative partial 
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charge (strictly less than 0). 
CASA+ 
Positive charge weighted surface area, ASA+ times max { qi > 0 } 
[Stanton 1990]. 
CASA- 
Negative charge weighted surface area, ASA- times max { qi < 0 } 
[Stanton 1990]. 
FASA+ Fractional ASA+ calculated as ASA+ / ASA. 
FASA- Fractional ASA- calculated as ASA- / ASA. 
FCASA+ Fractional CASA+ calculated as CASA+ / ASA. 
FCASA- Fractional CASA- calculated as CASA- / ASA. 
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Appendix 2: Purinergic inhibitors 
 
ID Diaminopyrimidines (DAP) P2X3 pIC50 P2X2/3 pIC50 
25_19 
N
NNH
2
NH
2
O
CH
3
O
CH
3
CH
3
CH
3  
7.3 6.8 
28_19 
N
NNH
2
NH
2
O
CH
O
CH
3
CH
3
CH
3  
8.2 7.9 
30_19 N
NNH
2
NH
2
O
Cl
O
CH
3
CH
3
CH
3  
7.6 7.0 
31_19 N
NNH
2
NH
2
O
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O
CH
3
CH
3
CH
3  
7.7 7.1 
 Appendix  
268 
 
32_19  N
NNH
2
NH
2
O
I
O
CH
3
CH
3
CH
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ID Arylamidic derivates (SAA) P2X3 pIC50 
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Appendix 3: Compound descriptors for QSAR models 
 
DESCRIPTOR DESCRIPTION 
COSTITUTIVE 
Angles Number of bond angles 
Atoms Number of atoms  
Bonds Number of bonds 
ChiralAtm  Number of chiral atoms 
EzBonds Number of atoms with E/Z geometric isomerism  
FlexTorsion Number of flexible torsions  
HbAcc Number of H-bond acceptors atoms 
HbDon  Number of H-bond donors atoms 
HbTot 
Number of H-bond acceptors and donors atoms 
(HbAcc + HbDon) 
Impropers 
Number of improper angles (out of plane or 
pyramidal angles)  
Torsion Number of torsions 
STRUCTURAL 
Gyrrad Gyration radius in Å 
Mass  Mass in Daltons 
MassMi  Monoisotopic mass in Daltons 
Ovality  
Ovality of the molecule (if it’s one, the molecule 
has a spherical shape) 
PSA Polar surface area in Å
2
 
SAS Solvent accessible surface in Å
2 
ASA Apolar surface area in Å
2
 
Surface  Surface area in Å
2
 
Sdiam 
Surface diameter (diameter of the sphere having 
the same surface of the molecule) 
Vdiam 
Volume diameter (diameter of the sphere having 
the same volume of the molecule) 
Volume  Molecular volume in A
3
 
PHYSICO-CHEMICAL 
Charge  Total charge 
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Dipole  Dipole moment  
Lipole 
Lipophilic moment (it indicates the lipophilic 
distribution of the molecule) 
VlogP Bernard Testa’s Virtual LogP 
DOCKING  SCORES  
PLANTS docking score  PLP95 score before the complex minimization 
CHEMPLP CHEMPLP score after the complex minimization 
PLP PLP score after the complex minimization 
PLP95  PLP95 score after the complex minimization 
CHEMPLP_NORM_H_ATM 
CHEMPLP normalized by the number of heavy 
atoms 
PLP_NORM_H_ATM PLP normalized by the number of heavy atoms 
PLP95_NORM_H_ATM PLP95 normalized by the number of heavy atoms 
MLPinS 
Molecular Lipophilicity Potential Interaction 
Score: it indicates the hydro/lipophilic 
complementarity between the ligand and the 
receptor 
MLPinS2 
Like MLPinS but take in account the square 
distance between the interacting atoms 
MLPinS3 
Like MLPinS but take in account the cubic 
distance between the interacting atoms 
MLPinS 
Like MLPinS but uses the Fermi equation to 
establish the effect of the distance between the 
interacting atoms 
VdW + Hbond + Desolv 
Interaction energy calculated by AutoDock 4 as 
sum the contributes of Van der Waals, hydrogen 
bonds and desolvatation energy 
CHARMM R6-R12 
Non-bond interaction energy calculated by 
CHARMM 22 force field 
Electr Coulomb electrostatic interaction energy 
ElectrDD 
Distance-dependent electrostatic interaction 
energy  
Ki 
Ki of the minimized complex calculated by 
AutoDock 4 
APBS  
Electrostatic binding energy calculated using the 
Poisson-Botzman model implemented in APBS 
software 
HMScore 
Hydrophobic match score calculated by X-Score 
software 
HSScore Steric score calculated by X-Score software 
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HPScore 
Hydrophobic pair score calculated by X-Score 
software 
Average 
Average score calculated by X-Score ((HPScore 
+ HMScore + HSScore) / 3) 
Binding Energy  X-score binding energy 
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Appendix 4: Compound descriptors for consensus 
functions 
 
L
ig
a
n
d
-b
a
s
e
d
 d
e
s
c
ri
p
to
rs
 
V
E
G
A
 
Atoms number of atoms 
HeavyAtoms number of heavy atoms 
Gyrrad radius of gyration 
HbAcc number of H-bond acceptor atoms 
HbDon number of H-bond donor atoms 
HbTot number of H-bonding atoms 
Rotors number of flexible dihedral angles 
Impropers 
number of unsaturations taken from the improper 
angles 
Lipole lipophilicity moment 
Mass molecular weight 
Ovality molecular ovality 
Psa polar surface area 
Asa apolar surface area 
VirtualLogP logP calculated by the MLP approach 
M
O
P
A
C
 Heat of formation 
parameters obtained by PM7 semi-empirical 
optimization  
Dipole 
Homo energy 
Lumo energy 
Cosmo area 
Cosmo volume 
D
o
c
k
in
g
 
s
c
o
re
s
 
P
L
A
N
T
S
 
 
docking scores calculated by PLANTS 
Plp95 
Plp95Normalized 
 
(SW stands for the utilized software).  
 
Type SW Name Description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibliography 
 
1.  Strömbergsson H. Chemogenomics : Models of Protein-Ligand Interaction Space.; 
2009. doi:citeulike-article-id:7989621. 
2.  Bender A, Glen RC. Molecular similarity: a key technique in molecular 
informatics. Org Biomol Chem. 2004;2(22):3204-3218. doi:10.1039/b409813g. 
3.  van Westen GJP, Wegner JK, IJzerman AP, van Vlijmen HWT, Bender  a. 
Proteochemometric modeling as a tool to design selective compounds and for 
extrapolating to novel targets. Medchemcomm. 2011;2(1):16. 
doi:10.1039/c0md00165a. 
4.  Kauvar LM. Affinity fingerprinting. Biotechnology (N Y). 1995;13(9):965-966. 
doi:10.1038/nbt0995-965. 
5.  Cortés-Ciriano I, Ain QU, Subramanian V, et al. Polypharmacology modelling 
using proteochemometrics (PCM): recent methodological developments, 
applications to target families, and future prospects. Med Chem Commun. 
2015;6(1):24-50. doi:10.1039/C4MD00216D. 
6.  Mestres J, Gregori-Puigjané E, Valverde S, Solé R V. The topology of drug-target 
interaction networks: implicit dependence on drug properties and target families. 
Mol Biosyst. 2009;5(9):1051-1057. doi:10.1039/b905821b. 
7.  Prusis P, Muceniece R, Andersson P, Post C, Lundstedt T, Wikberg JES. PLS 
modeling of chimeric MS04/MSH-peptide and MC1/MC3-receptor interactions 
reveals a novel method for the analysis of ligand-receptor interactions. Biochim 
Biophys Acta - Protein Struct Mol Enzymol. 2001;1544(1-2):350-357. 
doi:10.1016/S0167-4838(00)00249-1. 
8.  Weill N, Rognan D. Development and validation of a novel protein-ligand 
fingerprint to mine chemogenomic space: Application to G protein-coupled 
receptors and their ligands. J Chem Inf Model. 2009;49(4):1049-1062. 
doi:10.1021/ci800447g. 
9.  Bock JR, Gough DA. Virtual screen for ligands of orphan G protein-coupled 
receptors. J Chem Inf Model. 2005;45(5):1402-1414. doi:10.1021/ci050006d. 
10.  Strömbergsson H, Kryshtafovych A, Prusis P, et al. Generalized modeling of 
enzyme-ligand interactions using proteochemometrics and local protein 
substructures. Proteins Struct Funct Genet. 2006;65(3):568-579. 
doi:10.1002/prot.21163. 
11.  Cortés-Ciriano I, van Westen GJP, Bouvier G, et al. Improved large-scale 
 Bibliography  
280 
 
prediction of growth inhibition patterns using the NCI60 cancer cell line panel. 
Bioinformatics. 2015. doi:10.1093/bioinformatics/btv529. 
12.  Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol. 
2007;152(1):38-52. doi:10.1038/sj.bjp.0707307. 
13.  Kubinyi H, Hamprecht FA, Mietzner T. Three-dimensional quantitative similarity-
activity relationships (3D QSiAR) from SEAL similarity matrices. J Med Chem. 
1998;41(14):2553-2564. doi:10.1021/jm970732a. 
14.  Pastor M, Cruciani G, McLay I, Pickett S, Clementi S. GRid-INdependent 
descriptors (GRIND): A novel class of alignment-independent three-dimensional 
molecular descriptors. J Med Chem. 2000;43(17):3233-3243. 
doi:10.1021/jm000941m. 
15.  Rogers D, Hahn M. Extended-connectivity fingerprints. JCheInformModel. 
2010;50(5):742-754. doi:10.1021/ci100050t. 
16.  Laeeq S, Sirbaiya AK, Siddiqui HH, Mehdi S, Zaidi H. An overview of the 
computer aided drug designing. 2014;3(5):963-994. 
17.  MOE. https://www.chemcomp.com/MOE-Molecular_Operating_Environment.htm. 
18.  Berenger F, Voet A, Lee XY, Zhang KYJ. A rotation-translation invariant 
molecular descriptor of partial charges and its use in ligand-based virtual screening. 
J Cheminform. 2014;6(1). doi:10.1186/1758-2946-6-23. 
19.  Ballester PJ, Richards WG. Ultrafast shape recognition for similarity search in 
molecular databases. Proc R Soc A Math Phys Eng Sci. 2007;463(2081):1307-1321. 
doi:10.1098/rspa.2007.1823. 
20.  Awale M, Jin X, Reymond J-L. Stereoselective virtual screening of the ZINC 
database using atom pair 3D-fingerprints. J Cheminform. 2015;7(1):1-15. 
doi:10.1186/s13321-014-0051-5. 
21.  Carhart RE, Smith DH, Venkataraghavan R. Atom pairs as molecular features in 
structure-activity studies: definition and applications. J Chem Inf Comput Sci. 
1985;25(2):64-73. doi:10.1021/ci00046a002. 
22.  Awale M, Reymond JL. Atom pair 2D-fingerprints perceive 3D-molecular shape 
and pharmacophores for very fast virtual screening of ZINC and GDB-17. J Chem 
Inf Model. 2014;54:1892-1907. doi:10.1021/ci500232g. 
23.  Sheridan RP, Miller MD, Underwood DJ, Kearsley SK. Chemical Similarity Using 
Geometric Atom Pair Descriptors. J Chem Inf Model. 1996;36(1):128-136. 
doi:10.1021/ci950275b. 
24.  Van Westen GJP, Wegner JK, Bender A, IJzerman AP, Van Vlijmen HWT. Mining 
protein dynamics from sets of crystal structures using “consensus structures.” 
Protein Sci. 2010;19(4):742-752. doi:10.1002/pro.350. 
25.  Hvidsten TR, Kryshtafovych A, Komorowski J, Fidelis K. A novel approach to fold 
 Bibliography  
281 
 
recognition using sequence-derived properties from sets of structurally similar local 
fragments of proteins. In: Bioinformatics. Vol 19. ; 2003. 
doi:10.1093/bioinformatics/btg1064. 
26.  van Westen GJ, Swier RF, Wegner JK, Ijzerman AP, van Vlijmen HW, Bender A. 
Benchmarking of protein descriptor sets in proteochemometric modeling (part 1): 
comparative study of 13 amino acid descriptor sets. J Cheminf. 2013;5(1):41. 
doi:10.1186/1758-2946-5-41. 
27.  Fourches D, Muratov E, Tropsha  a. Trust but verify: on the importance of chemical 
structure curation in chemoinformatics and QSAR modeling research. J Chem Inf 
Model. 2010;50(7):1189-1204. 
28.  Tropsha  a, Gramatica P, Gombar VK. The importance of being earnest: Validation 
is the absolute essential for successful application and interpretation of QSPR 
models. Qsar Comb Sci. 2003;22(1):69-77. doi:10.1002/qsar.200390007. 
29.  Eklund M, Norinder U, Boyer S, Carlsson L. Choosing feature selection and 
learning algorithms in QSAR. J Chem Inf Model. 2014;54(3):837-843. 
doi:10.1021/ci400573c. 
30.  Wegner JK, Fröhlich H, Zell A. Feature selection for descriptor based classification 
models. 1. Theory and GA-SEC algorithm. J Chem Inf Comput Sci. 
2004;44(3):921-930. doi:10.1021/ci0342324. 
31.  Cortes-Ciriano I, Van Westen GJP, Lenselink EB, Murrell DS, Bender A, Malliavin 
T. Proteochemometric modeling in a Bayesian framework. J Cheminform. 
2014;6(1):1-16. doi:10.1186/1758-2946-6-35. 
32.  Park Y, Marcotte EM. Flaws in evaluation schemes for pair-input computational 
predictions. Nat Methods. 2012;9(12):1134-1136. doi:10.1038/nmeth.2259. 
33.  Krstajic D, Buturovic LJ, Leahy DE, Thomas S. Cross-validation pitfalls when 
selecting and assessing regression and classification models. J Cheminform. 
2014;6(1):1-15. doi:10.1186/1758-2946-6-10. 
34.  Golbraikh A, Tropsha A. Beware of q
2
! J Mol Graph Model. 2002;20(4):269-276. 
http://www.ncbi.nlm.nih.gov/pubmed/11858635. 
35.  Di L. The role of drug metabolizing enzymes in clearance. Expert Opin Drug 
Metab Toxicol. 2014;10(3):379-393. doi:10.1517/17425255.2014.876006. 
36.  Testa B, Balmat AL, Long A, Judson P. Predicting drug metabolism - An 
evaluation of the expert system METEOR. Chem Biodivers. 2005;2(7):872-885. 
doi:10.1002/cbdv.200590064. 
37.  Kola I, Landis J. Opinion: Can the pharmaceutical industry reduce attrition rates? 
Nat Rev Drug Discov. 2004;3(8):711-716. doi:10.1038/nrd1470. 
38.  Wunberg T, Hendrix M, Hillisch A, et al. Improving the hit-to-lead process: data-
driven assessment of drug-like and lead-like screening hits. Drug Discov Today. 
2006;11(3-4):175-180. doi:10.1016/S1359-6446(05)03700-1. 
 Bibliography  
282 
 
39.  Gleeson MP, Hersey A, Hannongbua S. In-silico ADME models: a general 
assessment of their utility in drug discovery applications. Curr Top Med Chem. 
2011;11(4):358-381. doi:10.2174/156802611794480927. 
40.  Kirchmair J, Göller AH, Lang D, et al. Predicting drug metabolism: experiment 
and/or computation? Nat Rev Drug Discov. 2015;(April). doi:10.1038/nrd4581. 
41.  Testa B, Krämer SD. The Biochemistry of Drug Metabolism – An Introduction. 
Chem Biodivers. 2006;3(10):1053-1101. doi:10.1002/cbdv.200690111. 
42.  Kirchmair J, Williamson MJ, Tyzack JD, et al. Computational Prediction of 
Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms. J 
Chem Inf Model. 2012;52(3):617-648. doi:10.1021/ci200542m. 
43.  Faust K, Croes D, van Helden J. Prediction of metabolic pathways from genome-
scale metabolic networks. BioSystems. 2011;105(2):109-121. 
doi:10.1016/j.biosystems.2011.05.004. 
44.  Testa B, Pedretti A, Vistoli G. Reactions and enzymes in the metabolism of drugs 
and other xenobiotics. Drug Discov Today. 2012;17(11-12):549-560. 
doi:10.1016/j.drudis.2012.01.017. 
45.  Oda S, Fukami T, Yokoi T, Nakajima M. A comprehensive review of UDP-
glucuronosyltransferase and esterases for drug development. Drug Metab 
Pharmacokinet. 2015;30(1):30-51. doi:10.1016/j.dmpk.2014.12.001. 
46.  Lévesque E, Turgeon D, Carrier JS, Montminy V, Beaulieu M, Bélanger  a. 
Isolation and characterization of the UGT2B28 cDNA encoding a novel human 
steroid conjugating UDP-glucuronosyltransferase. Biochemistry. 2001;40(13):3869-
3881. doi:10.1021/bi002607y. 
47.  Mackenzie PI, Gonzalez FJ, Owens IS. Cloning and characterization of DNA 
complementary to rat liver UDP-glucuronosyltransferase mRNA. J Biol Chem. 
1984;259(19):12153-12160. 
48.  Mackenzie PI, Owens IS, Burchell B, et al. The UDP glycosyltransferase gene 
superfamily: recommended nomenclature update based on evolutionary divergence. 
Pharmacogenetics. 1997;7(4):255-269. doi:10.1097/00008571-199708000-00001. 
49.  Stoffel W, Bosio A. Myelin glycolipids and their functions. Curr Opin Neurobiol. 
1997;7(5):654-661. doi:10.1016/S0959-4388(97)80085-2. 
50.  Mackenzie PI, Bock KW, Burchell B, et al. Nomenclature update for the 
mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet 
Genomics. 2005;15(10):677-685. doi:10.1097/01.fpc.0000173483.13689.56. 
51.  Lairson LL, Henrissat B, Davies GJ, Withers SG. Glycosyltransferases: structures, 
functions, and mechanisms. Annu Rev Biochem. 2008;77(February):521-555. 
doi:10.1146/annurev.biochem.76.061005.092322. 
52.  Offen W, Martinez-Fleites C, Yang M, et al. Structure of a flavonoid 
glucosyltransferase reveals the basis for plant natural product modification. EMBO 
 Bibliography  
283 
 
J. 2006;25(6):1396-1405. doi:10.1038/sj.emboj.7600970. 
53.  Brazier-Hicks M, Offen WA, Gershater MC, et al. Characterization and engineering 
of the bifunctional N- and O-glucosyltransferase involved in xenobiotic metabolism 
in plants. Proc Natl Acad Sci U S A. 2007;104(51):20238-20243. 
doi:10.1073/pnas.0706421104. 
54.  Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, Redinbo 
MR. Crystal Structure of the Cofactor-Binding Domain of the Human Phase II 
Drug-Metabolism Enzyme UDP-Glucuronosyltransferase 2B7. J Mol Biol. 
2007;369(2):498-511. doi:10.1016/j.jmb.2007.03.066. 
55.  Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO. Influence of N-
terminal domain histidine and proline residues on the substrate selectivities of 
human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab 
Dispos. 2009;37(9):1948-1955. doi:10.1124/dmd.109.028225. 
56.  Kato Y, Izukawa T, Oda S, et al. Human UDP-glucuronosyltransferase (ugt) 2b10 
in drug n-glucuronidation: Substrate screening and comparison with UGT1A3 and 
UGT1A4. Drug Metab Dispos. 2013;41(7):1389-1397. 
doi:10.1124/dmd.113.051565. 
57.  Testa B, Krämer SD. The biochemistry of drug metabolism - An introduction: Part 
4. Reactions of conjugation and their enzymes. Chem Biodivers. 2008;5(11):2171-
2336. doi:10.1002/cbdv.200890199. 
58.  Testa B, D. Kramer S. The Biochemistry of Drug Metabolism: Volume 2: 
Conjugations, Consequences of Metabolism, Influencing Factors (v. 2). Wiley-
VCH; 2010. 
59.  Miners JO, Knights KM, Houston JB, Mackenzie PI. In vitro-in vivo correlation for 
drugs and other compounds eliminated by glucuronidation in humans: pitfalls and 
promises. Biochem Pharmacol. 2006;71(11):1531-1539. 
doi:10.1016/j.bcp.2005.12.019. 
60.  Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. Predicting human 
drug glucuronidation parameters: application of in vitro and in silico modeling 
approaches. Annu Rev Pharmacol Toxicol. 2004;44:1-25. 
doi:10.1146/annurev.pharmtox.44.101802.121546. 
61.  Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Miners JO. The 
Glucuronidation of ⌬ 4 -3-Keto C19- and C21-Hydroxysteroids by Human Liver 
Microsomal and Recombinant Hydroxyprogesterone Are Selective Substrates for 
UGT2B7 ABSTRACT : Pharmacology. 2007;35(3):363-370. 
doi:10.1124/dmd.106.013052.2B15. 
62.  Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. Selectivity of substrate 
(trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, 
hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “probes” for 
human udp-glucuronosyltransferases. Drug Metab Dispos. 2006;34(3):449-456. 
 Bibliography  
284 
 
doi:10.1124/dmd.105.007369. 
63.  Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO. 
Quantitative prediction of in vivo inhibitory interactions involving glucuronidated 
drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. 
Br J Clin Pharmacol. 2006;61(4):427-439. doi:10.1111/j.1365-2125.2006.02588.x. 
64.  P I Mackenzie, D A Gardner-Stephen  and JOM. Comprehensive Toxicology. Vol 4. 
second. (Elsevier, ed.).; 2010. 
65.  Vore M, Hadd H, Slikker W. Ethynylestradiol-17 beta D-ring glucuronide 
conjugates are potent cholestatic agents in the rat. Life Sci. 1983;32(26):2989-2993. 
http://www.ncbi.nlm.nih.gov/pubmed/6865644. Accessed November 27, 2015. 
66.  Boelsterli UA. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-
reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr 
Drug Metab. 2002;3(4):439-450. http://www.ncbi.nlm.nih.gov/pubmed/12093359. 
Accessed November 27, 2015. 
67.  Southwood HT, DeGraaf YC, Mackenzie PI, Miners JO, Burcham PC, Sallustio 
BC. Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing 
human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and 
glycation pathways. Chem Res Toxicol. 2007;20(10):1520-1527. 
doi:10.1021/tx700188x. 
68.  Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML. Randomized 
placebo-controlled trial of the activity of the morphine glucuronides. Clin 
Pharmacol Ther. 2000;68(6):667-676. doi:10.1067/mcp.2000.111934. 
69.  Curley RW, Abou-Issa H, Panigot MJ, Repa JJ, Clagett-Dame M, Alshafie G. 
Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-
glucuronides against breast cancer development and growth. Anticancer Res. 
16(2):757-763. http://www.ncbi.nlm.nih.gov/pubmed/8687125. Accessed 
November 27, 2015. 
70.  Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, 
pharmacology, and continued development of the camptothecins. Clin Cancer Res. 
2002;8(3):641-661. http://www.ncbi.nlm.nih.gov/pubmed/11895891. Accessed 
November 27, 2015. 
71.  Gagné J-F, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. 
Common human UGT1A polymorphisms and the altered metabolism of irinotecan 
active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol. 
2002;62(3):608-617. http://www.ncbi.nlm.nih.gov/pubmed/12181437. Accessed 
November 27, 2015. 
72.  Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase 
gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 
2000;60(24):6921-6926. http://www.ncbi.nlm.nih.gov/pubmed/11156391. 
73.  Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/pharmacodynamics 
 Bibliography  
285 
 
and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. 
Pharmacogenet Genomics. 2007;17(7):497-504. 
doi:10.1097/FPC.0b013e328014341f. 
74.  Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. 
Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes 
on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 
1A substrates. Pharmacogenet Genomics. 2007;17(12):1017-1029. 
doi:10.1097/FPC.0b013e328256b1b6. 
75.  Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and 
UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma 
risk. Cancer Res. 2001;61(9):3566-3569. 
http://www.ncbi.nlm.nih.gov/pubmed/11325819. Accessed November 28, 2015. 
76.  Hubner RA, Muir KR, Liu J-F, et al. Genetic variants of UGT1A6 influence risk of 
colorectal adenoma recurrence. Clin Cancer Res. 2006;12(21):6585-6589. 
doi:10.1158/1078-0432.CCR-06-0903. 
77.  Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, Marquet P. Identification of the 
UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II 
metabolism. Drug Metab Dispos. 2005;33(1):139-146. 
doi:10.1124/dmd.104.001651. 
78.  Chung J-Y, Cho J-Y, Yu K-S, et al. Effect of the UGT2B15 genotype on the 
pharmacokinetics, pharmacodynamics, and drug interactions of intravenous 
lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005;77(6):486-494. 
doi:10.1016/j.clpt.2005.02.006. 
79.  Court MH, Hao Q, Krishnaswamy S, et al. UDP-glucuronosyltransferase (UGT) 
2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major 
determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther. 
2004;310(2):656-665. doi:10.1124/jpet.104.067660. 
80.  Wanibuchi F, Konishi T, Harada M, et al. Pharmacological studies on novel 
muscarinic agonists, 1-oxa-8-azaspiro[4.5]decane derivatives, YM796 and YM954. 
Eur J Pharmacol. 1990;187(3):479-486. 
http://www.ncbi.nlm.nih.gov/pubmed/1963596. Accessed November 26, 2015. 
81.  Gaganis P, Miners JO, Brennan JS, Thomas A, Knights KM. Human renal cortical 
and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical 
localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-
naproxen glucuronidation. J Pharmacol Exp Ther. 2007;323(2):422-430. 
doi:10.1124/jpet.107.128603. 
82.  Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-
glucuronosyltransferase substrates: a pharmacokinetic explanation for typically 
observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 
2004;32(11):1201-1208. doi:10.1124/dmd.104.000794. 
 Bibliography  
286 
 
83.  Court MH, Krishnaswamy S, Hao Q, et al. Evaluation of 3-azido-3-
deoxythymidine, morphine, and codeine as probe substrates for udp-
glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: Specificity 
and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 
2003;31(9):1125-1133. doi:10.1124/dmd.31.9.1125. 
84.  Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi A a, Miners JO. In 
vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of 
codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and 
methadone in humans. J Pharmacol Exp Ther. 2010;334(2):609-618. 
doi:10.1124/jpet.110.167916. 
85.  Miners JO, Valente L, Lillywhite KJ, et al. Preclinical prediction of factors 
influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new 
anticancer drug. CANCER Res. 1997;57(2):284-289. 
86.  Innocenti F, Iyer L, Ramírez J, Green MD, Ratain MJ. Epirubicin glucuronidation 
is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos. 
2001;29(5):686-692. 
87.  Mano Y, Usui T, Kamimura H. The UDP-glucuronosyltransferase 2B7 isozyme is 
responsible for gemfibrozil glucuronidation in the human liver. Drug Metab 
Dispos. 2007;35(11):2040-2044. doi:10.1124/dmd.107.017269. 
88.  Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic 
acid cloning and expression of a human liver uridine diphosphate-
glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J 
Pharmacol Exp Ther. 1993;264(1):475-479. 
http://www.ncbi.nlm.nih.gov/pubmed/8423545. 
89.  Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO. S-
naproxen and desmethylnaproxen glucuronidation by human liver microsomes and 
recombinant human UDP-glucuronosyltransferases (UGT): Role of UGT2B7 in the 
elimination of naproxen. Br J Clin Pharmacol. 2005;60(4):423-433. 
doi:10.1111/j.1365-2125.2005.02446.x. 
90.  Jin CJ, Mackenzie PI, Miners JO. The regio- and stereo-selectivity of C19 and C21 
hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem 
Biophys. 1997;341(2):207-211. doi:10.1006/abbi.1997.9949. 
91.  Breton C, Šnajdrová L, Jeanneau C, Koča J, Imberty A. Structures and mechanisms 
of glycosyltransferases. Glycobiology. 2006;16(2):29-37. 
doi:10.1093/glycob/cwj016. 
92.  Shao H, He X, Achnine L, Blount JW, Dixon RA, Wang X. Crystal structures of a 
multifunctional triterpene/flavonoid glycosyltransferase from Medicago truncatula. 
Plant Cell. 2005;17(11):3141-3154. doi:10.1105/tpc.105.035055. 
93.  Chau N, Elliot DJ, Lewis BC, et al. Morphine glucuronidation and glucosidation 
represent complementary metabolic pathways that are both catalyzed by UDP-
 Bibliography  
287 
 
glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. J 
Pharmacol Exp Ther. 2014;349(1):126-137. doi:10.1124/jpet.113.212258. 
94.  Lewis BC, Mackenzie PI, Miners JO. Homodimerization of UDP-
glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative 
dimerization domain by protein homology modeling. Biochem Pharmacol. 
2011;82(12):1-8. doi:10.1016/j.bcp.2011.09.007. 
95.  Rocha J, Popescu AO, Borges P, et al. Structure of Burkholderia cepacia UDP-
Glucose Dehydrogenase (UGD) BceC and Role of Tyr10 in Final Hydrolysis of 
UGD Thioester Intermediate. J Bacteriol. 2011;193(15):3978-3987. 
doi:10.1128/JB.01076-10. 
96.  MOPAC. http://openmopac.net/. 
97.  Plants. http://www.tcd.uni-konstanz.de/research/plants.php. 
98.  NAMD. http://www.ks.uiuc.edu/Research/namd/. 
99.  Md tools. http://www.ks.uiuc.edu/Development /MDTools/sodium/. 
100.  Uniprot. http://www.uniprot.org/. 
101.  VEGA ZZ. http://nova.disfarm.unimi.it/vegazz. 
102.  JChem Suite. https://www.chemaxon.com/download/jchem-suite/. 
103.  Chemaxon Software Company. https://www.chemaxon.com/. 
104.  RStudio. https://www.rstudio.com/. 
105.  Java. https://java.com/it/. 
106.  Pubmed. http://www.ncbi.nlm.nih.gov/pubmed. 
107.  Clustal Omega. http://www.clustal.org/omega/. 
108.  Python. https://www.python.org/. 
109.  pycharm. https://www.jetbrains.com/pycharm/. 
110.  Pandas. http://pandas.pydata.org/index.html. 
111.  scikit-learn. http://scikit-learn.org/stable/. 
112.  Ganganwar V. An overview of classification algorithms for imbalanced datasets. 
Int J Emerg Technol Adv Eng. 2012;2(4):42-47. 
http://www.ijetae.com/files/Volume2Issue4/IJETAE_0412_07.pdf. 
113.  scikit learn RFC. http://scikit-
learn.org/stable/modules/generated/sklearn.ensemble.RandomForestClassifier.html. 
114.  class weight warning. https://github.com/scikit-learn/scikit-learn/issues/3928. 
115.  Longadge R, Dongre S, Malik L. Class Imbalance Problem in Data Mining : 
Review. 2013;2(1). 
 Bibliography  
288 
 
116.  Galar M, Fern A, Barrenechea E, Bustince H. Hybrid-Based Approaches. 2011:1-
22. 
117.  Kawashima S, Ogata H, Kanehisa M. AAindex: Amino Acid Index Database. 
Nucleic Acids Res. 1999;27(1):368-369. 
118.  Sahigara F. Defining the Applicability Domain of QSAR models : An overview. 
Mol Descriptors - Free online Resour. 2007;Tutorial 7:1-6. 
119.  Safety CP. REVIEW OF METHODS FOR ASSESSING THE APPLICABILTY 
DOMAINS OF SARS AND QSARS Review of methods for applicability domain 
estimation. 1853;2004(September 2004):1-5. 
120.  Nikolova-Jeliazkova N, Jaworska J. An approach to determining applicability 
domains for QSAR group contribution models: An analysis of SRC KOWWIN. 
ATLA Altern to Lab Anim. 2005;33(5):461-470. 
121.  Holton P. The liberation of adenosine triphosphate on antidromic stimulation of 
sensory nerves. J Physiol. 1959;145(3):494-504. 
doi:10.1113/jphysiol.1959.sp006157. 
122.  Burnstock G. Purinergic nerves. Pharmacol Rev. 1972;24(3):509-581. 
http://www.ncbi.nlm.nih.gov/pubmed/4404211. 
123.  Kawate T, Michel JC, Birdsong WT, Gouaux E. Crystal structure of the ATP-gated 
P2X(4) ion channel in the closed state. Nature. 2009;460(7255):592-598. 
doi:10.1038/nature08198. 
124.  Hattori M, Gouaux E. Molecular mechanism of ATP binding and ion channel 
activation in P2X receptors. Nature. 2012;485(7397):207-212. 
doi:10.1038/nature11010. 
125.  Browne LE. Structure of P2X receptors. Wiley Interdiscip Rev Membr Transp 
Signal. 2012;1(1):56-69. doi:10.1002/wmts.24. 
126.  Jiang R, Taly A, Grutter T. Moving through the gate in ATP-activated P2X 
receptors. Trends Biochem Sci. 2013;38(1):20-29. doi:10.1016/j.tibs.2012.10.006. 
127.  Chaumont S, Jiang L-H, Penna A, North RA, Rassendren F. Identification of a 
trafficking motif involved in the stabilization and polarization of P2X receptors. J 
Biol Chem. 2004;279(28):29628-29638. doi:10.1074/jbc.M403940200. 
128.  North RA. Molecular Physiology of P2X Receptors. Physiol Rev. 2002;82(4):1013-
1067. doi:10.1152/physrev.00015.2002. 
129.  Ford AP. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and 
afferent sensitization. Purinergic Signal. 2012;8(S1):3-26. doi:10.1007/s11302-
011-9271-6. 
130.  Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, Stojilkovic SS. Activation and 
Regulation of Purinergic P2X Receptor Channels. Pharmacol Rev. 2011;63(3):641-
683. doi:10.1124/pr.110.003129. 
 Bibliography  
289 
 
131.  Wu G, Whiteside GT, Lee G, et al. A-317491, a selective P2X3/P2X2/3 receptor 
antagonist, reverses inflammatory mechanical hyperalgesia through action at 
peripheral receptors in rats. Eur J Pharmacol. 2004;504(1-2):45-53. 
doi:10.1016/j.ejphar.2004.09.056. 
132.  Gever JR, Soto R, Henningsen RA, et al. AF-353, a novel, potent and orally 
bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010;160(6):1387-
1398. doi:10.1111/j.1476-5381.2010.00796.x. 
133.  Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in 
refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 
study. Lancet (London, England). 2015;385(9974):1198-1205. doi:10.1016/S0140-
6736(14)61255-1. 
134.  Fauman EB, Rai BK, Huang ES. Structure-based druggability assessment--
identifying suitable targets for small molecule therapeutics. Curr Opin Chem Biol. 
2011;15(4):463-468. doi:10.1016/j.cbpa.2011.05.020. 
135.  Le Guilloux V, Schmidtke P, Tuffery P. Fpocket: An open source platform for 
ligand pocket detection. BMC Bioinformatics. 2009;10(1):168. doi:10.1186/1471-
2105-10-168. 
136.  Di Domizio A, Vitriolo A, Vistoli G, Pedretti A. SPILLO-PBSS: detecting hidden 
binding sites within protein 3D-structures through a flexible structure-based 
approach. J Comput Chem. 2014;35(27):2005-2017. doi:10.1002/jcc.23714. 
137.  Borrelli KW, Vitalis A, Alcantara R, Guallar V. PELE:  Protein Energy Landscape 
Exploration. A Novel Monte Carlo Based Technique. J Chem Theory Comput. 
2005;1(6):1304-1311. doi:10.1021/ct0501811. 
138.  Madadkar-Sobhani A, Guallar V. PELE web server: atomistic study of 
biomolecular systems at your fingertips. Nucleic Acids Res. 2013;41(Web Server 
issue):W322-W328. doi:10.1093/nar/gkt454. 
139.  Modeller. https://salilab.org/modeller/. 
140.  PROCHECK. http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/. 
141.  Ballini E, Virginio C, Medhurst SJ, et al. Characterization of three 
diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 
receptors with in vivo efficacy in a pain model. Br J Pharmacol. 2011;163(6):1315-
1325. doi:10.1111/j.1476-5381.2011.01322.x. 
142.  Carter DS, Alam M, Cai H, et al. Identification and SAR of novel 
diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) 
antagonist for the treatment of pain. Bioorg Med Chem Lett. 2009;19(6):1628-1631. 
doi:10.1016/j.bmcl.2009.02.003. 
143.  Jahangir A, Alam M, Carter DS, et al. Identification and SAR of novel 
diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual 
P2X(3)/P2X(2/3) antagonist for the treatment of pain. Bioorg Med Chem Lett. 
 Bibliography  
290 
 
2009;19(6):1632-1635. doi:10.1016/j.bmcl.2009.01.097. 
144.  Ford AP, Undem BJ. The therapeutic promise of ATP antagonism at P2X3 
receptors in respiratory and urological disorders. Front Cell Neurosci. 2013;7:267. 
doi:10.3389/fncel.2013.00267. 
145.  DUD. http://dud.docking.org/. 
146.  PLANTS. http://www.tcd.uni-konstanz.de/research/plants.php. 
147.  Korb O, Stützle T, Exner TE. Empirical scoring functions for advanced protein-
ligand docking with PLANTS. J Chem Inf Model. 2009;49(1):84-96. 
doi:10.1021/ci800298z. 
148.  PELE online server. https://pele.bsc.es/. 
149.  Topiol S. X-ray structural information of GPCRs in drug design: what are the 
limitations and where do we go? Expert Opin Drug Discov. 2013;8(6):607-620. 
doi:10.1517/17460441.2013.783815. 
150.  Tehan BG, Bortolato A, Blaney FE, Weir MP, Mason JS. Unifying family A GPCR 
theories of activation. Pharmacol Ther. 2014;143(1):51-60. 
doi:10.1016/j.pharmthera.2014.02.004. 
151.  Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. 
Molecular signatures of G-protein-coupled receptors. Nature. 2013;494(7436):185-
194. doi:10.1038/nature11896. 
152.  Costanzi S. Modeling G protein-coupled receptors and their interactions with 
ligands. Curr Opin Struct Biol. 2013;23(2):185-190. doi:10.1016/j.sbi.2013.01.008. 
153.  Deupi X. Relevance of rhodopsin studies for GPCR activation. Biochim Biophys 
Acta. 2014;1837(5):674-682. doi:10.1016/j.bbabio.2013.09.002. 
154.  Deupi X. Quantification of structural distortions in the transmembrane helices of 
GPCRs. Methods Mol Biol. 2012;914:219-235. doi:10.1007/978-1-62703-023-
6_13. 
155.  Bettinelli I, Graziani D, Marconi C, Pedretti A, Vistoli G. The approach of 
conformational chimeras to model the role of proline-containing helices on GPCR 
mobility: the fertile case of Cys-LTR1. ChemMedChem. 2011;6(7):1217-1227. 
doi:10.1002/cmdc.201100037. 
156.  Kruse AC, Hu J, Kobilka BK, Wess J. Muscarinic acetylcholine receptor X-ray 
structures: potential implications for drug development. Curr Opin Pharmacol. 
2014;16:24-30. doi:10.1016/j.coph.2014.02.006. 
157.  Fisher A. Cholinergic modulation of amyloid precursor protein processing with 
emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of 
Alzheimer’s disease. J Neurochem. 2012;120 Suppl :22-33. doi:10.1111/j.1471-
4159.2011.07507.x. 
158.  Dean B. Selective activation of muscarinic acetylcholine receptors for the treatment 
 Bibliography  
291 
 
of schizophrenia. Curr Pharm Biotechnol. 2012;13(8):1563-1571. 
http://www.ncbi.nlm.nih.gov/pubmed/22283751. Accessed November 26, 2015. 
159.  Davie BJ, Christopoulos A, Scammells PJ. Development of M1 mAChR allosteric 
and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. 
ACS Chem Neurosci. 2013;4(7):1026-1048. doi:10.1021/cn400086m. 
160.  Kruse AC, Hu J, Pan AC, et al. Structure and dynamics of the M3 muscarinic 
acetylcholine receptor. Nature. 2012;482(7386):552-556. doi:10.1038/nature10867. 
161.  Cherezov V, Rosenbaum DM, Hanson MA, et al. High-resolution crystal structure 
of an engineered human beta2-adrenergic G protein-coupled receptor. Science. 
2007;318(5854):1258-1265. doi:10.1126/science.1150577. 
162.  Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, Sali A. Comparative 
protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct. 
2000;29:291-325. doi:10.1146/annurev.biophys.29.1.291. 
163.  Bas DC, Rogers DM, Jensen JH. Very fast prediction and rationalization of pKa 
values for protein-ligand complexes. Proteins. 2008;73(3):765-783. 
doi:10.1002/prot.22102. 
164.  Wilman HR, Shi J, Deane CM. Helix kinks are equally prevalent in soluble and 
membrane proteins. Proteins. 2014;82(9):1960-1970. doi:10.1002/prot.24550. 
165.  Pedretti A, Villa L, Vistoli G. VEGA: a versatile program to convert, handle and 
visualize molecular structure on Windows-based PCs. J Mol Graph Model. 
2002;21(1):47-49. http://www.ncbi.nlm.nih.gov/pubmed/12413030. Accessed 
November 26, 2015. 
166.  Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J 
Comput Chem. 2005;26(16):1781-1802. doi:10.1002/jcc.20289. 
167.  Vistoli G, Pedretti A, Dei S, Scapecchi S, Marconi C, Romanelli MN. Docking 
analyses on human muscarinic receptors: unveiling the subtypes peculiarities in 
agonists binding. Bioorg Med Chem. 2008;16(6):3049-3058. 
doi:10.1016/j.bmc.2007.12.036. 
168.  Sullivan NR, Leventhal L, Harrison J, et al. Pharmacological characterization of the 
muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-
bicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic 
pain. J Pharmacol Exp Ther. 2007;322(3):1294-1304. 
doi:10.1124/jpet.106.118604. 
169.  Watt ML, Schober DA, Hitchcock S, et al. Pharmacological characterization of 
LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric 
agonist. J Pharmacol Exp Ther. 2011;338(2):622-632. 
doi:10.1124/jpet.111.182063. 
170.  Tecle H, Barrett SD, Lauffer DJ, et al. Design and synthesis of m1-selective 
muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3’-
 Bibliography  
292 
 
methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective 
muscarinic agonist. J Med Chem. 1998;41(14):2524-2536. 
doi:10.1021/jm960683m. 
171.  Avlani VA, Langmead CJ, Guida E, et al. Orthosteric and allosteric modes of 
interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. 
Mol Pharmacol. 2010;78(1):94-104. doi:10.1124/mol.110.064345. 
172.  Verspohl EJ, Tacke R, Mutschler E, Lambrecht G. Muscarinic receptor subtypes in 
rat pancreatic islets: binding and functional studies. Eur J Pharmacol. 
1990;178(3):303-311. http://www.ncbi.nlm.nih.gov/pubmed/2187704. Accessed 
November 26, 2015. 
173.  Wienrich M, Meier D, Ensinger HA, et al. Pharmacodynamic profile of the M1 
agonist talsaclidine in animals and man. Life Sci. 2001;68(22-23):2593-2600. 
http://www.ncbi.nlm.nih.gov/pubmed/11392631. Accessed November 26, 2015. 
174.  Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer’s disease--
an update. Curr Alzheimer Res. 2007;4(5):577-580. 
http://www.ncbi.nlm.nih.gov/pubmed/18220527. Accessed November 26, 2015. 
175.  Mei L, Lai J, Yamamura HI, Roeske WR. Pharmacologic comparison of selected 
agonists for the M1 muscarinic receptor in transfected murine fibroblast cells 
(B82). J Pharmacol Exp Ther. 1991;256(2):689-694. 
http://www.ncbi.nlm.nih.gov/pubmed/1704434. Accessed November 26, 2015. 
176.  Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J. In vivo 
muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 
antagonist in vitro. Psychopharmacology (Berl). 1998;137(3):233-240. 
http://www.ncbi.nlm.nih.gov/pubmed/9683000. Accessed November 26, 2015. 
177.  Michal P, El-Fakahany EE, Dolezal V. Muscarinic M2 receptors directly activate 
Gq/11 and Gs G-proteins. J Pharmacol Exp Ther. 2007;320(2):607-614. 
doi:10.1124/jpet.106.114314. 
178.  ChemBridge website. www.hit2lead.com. 
179.  Kukol A. Consensus virtual screening approaches to predict protein ligands. Eur J 
Med Chem. 2011;46(9):4661-4664. doi:10.1016/j.ejmech.2011.05.026. 
180.  Plewczynski D, Łaźniewski M, von Grotthuss M, Rychlewski L, Ginalski K. 
VoteDock: consensus docking method for prediction of protein-ligand interactions. 
J Comput Chem. 2011;32(4):568-581. doi:10.1002/jcc.21642. 
181.  Guvenir HA, Kurtcephe M. Ranking Instances by Maximizing the Area under ROC 
Curve. IEEE Trans Knowl Data Eng. 2013;25(10):2356-2366. 
doi:10.1109/TKDE.2012.214. 
182.  Hooke R, Jeeves TA. `` Direct Search’' Solution of Numerical and Statistical 
Problems. J ACM. 1961;8(2):212-229. doi:10.1145/321062.321069. 
183.  Schmidtke P, Le Guilloux V, Maupetit J, Tufféry P. fpocket: online tools for 
 Bibliography  
293 
 
protein ensemble pocket detection and tracking. Nucleic Acids Res. 2010;38(Web 
Server issue):W582-W589. doi:10.1093/nar/gkq383. 
184.  Wallach I, Jaitly N, Nguyen K, Schapira M, Lilien R. Normalizing molecular 
docking rankings using virtually generated decoys. J Chem Inf Model. 
2011;51(8):1817-1830. doi:10.1021/ci200175h. 
185.  Wilson GL, Lill MA. Integrating structure-based and ligand-based approaches for 
computational drug design. Future Med Chem. 2011;3(6):735-750. 
doi:10.4155/fmc.11.18. 
186.  Truchon J-F, Bayly CI. Evaluating virtual screening methods: good and bad metrics 
for the “early recognition” problem. J Chem Inf Model. 47(2):488-508. 
doi:10.1021/ci600426e. 
187.  Deupi X, Standfuss J, Schertler G. Conserved activation pathways in G-protein-
coupled receptors. Biochem Soc Trans. 2012;40(2):383-388. 
doi:10.1042/BST20120001. 
188.  Broadley KJ, Kelly DR. Muscarinic Receptor Agonists and Antagonists. Molecules. 
2001;6(3):142-193. doi:10.3390/60300142. 
189.  Ridley HF, Chatterjee SS, Moran JF, Triggle DJ. Studies on the cholinergic 
receptor. IV. The synthesis and muscarinic activity of 3,7-dimethyl-2,4-dioxo-7-
azaspiro[3.4]octane methiodide. J Med Chem. 1969;12(5):931-933. 
http://www.ncbi.nlm.nih.gov/pubmed/5812223. Accessed November 27, 2015. 
190.  Piergentili A, Quaglia W, Giannella M, et al. Dioxane and oxathiane nuclei: 
suitable substructures for muscarinic agonists. Bioorg Med Chem. 2007;15(2):886-
896. doi:10.1016/j.bmc.2006.10.040. 
191.  Takayanagi I, Harada M, Koike K. A difference in receptor mechanisms for 
muscarinic full and partial agonists. Jpn J Pharmacol. 1991;56(1):23-31. 
http://www.ncbi.nlm.nih.gov/pubmed/1880983. Accessed November 27, 2015. 
192.  Triggle DJ, Belleau B. STUDIES ON THE CHEMICAL BASIS FOR 
CHOLINOMIMETIC AND CHOLINOLYTIC ACTIVITY: PART I. THE 
SYNTHESIS AND CONFIGURATION OF QUATERNARY SALTS IN THE 1,3-
DIOXOLANE AND OXAZOLINE SERIES. Can J Chem. 1962;40(6):1201-1215. 
doi:10.1139/v62-183. 
193.  Fourneau JP, Rybak B. Mise au point d’une nouvelle technique de titration sur 
coeur ouvert de mammifere des effets muscariniques a partir d'une nouvelle serie de 
composes parasympathomimetiques. Life Sci. 1962;1(5):185-193. 
doi:10.1016/0024-3205(62)90016-4. 
194.  Piergentili A, Quaglia W, Del Bello F, et al. Properly substituted 1,4-dioxane 
nucleus favours the selective M3 muscarinic receptor activation. Bioorg Med Chem. 
2009;17(24):8174-8185. doi:10.1016/j.bmc.2009.10.027. 
195.  Haga K, Kruse AC, Asada H, et al. Structure of the human M2 muscarinic 
 Bibliography  
294 
 
acetylcholine receptor bound to an antagonist. Nature. 2012;482(7386):547-551. 
doi:10.1038/nature10753. 
196.  Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a 
Lamarckian genetic algorithm and an empirical binding free energy function. J 
Comput Chem. 1998;19(14):1639-1662. doi:10.1002/(SICI)1096-
987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B. 
197.  Pedretti A, Vistoli G, Marconi C, Testa B. Muscarinic receptors: A comparative 
analysis of structural features and binding modes through homology modelling and 
molecular docking. Chem Biodivers. 2006;3(5):481-501. 
doi:10.1002/cbdv.200690052. 
198.  Vistoli G, Pedretti A, Testa B, Matucci R. The conformational and property space 
of acetylcholine bound to muscarinic receptors: an entropy component accounts for 
the subtype selectivity of acetylcholine. Arch Biochem Biophys. 2007;464(1):112-
121. doi:10.1016/j.abb.2007.04.022. 
199.  Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective 
muscarinic receptor agonist, on cognitive function and behavioral symptoms in 
Alzheimer disease. Arch Neurol. 1997;54(4):465-473. 
http://www.ncbi.nlm.nih.gov/pubmed/9109749. Accessed November 27, 2015. 
200.  Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of 
muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9(2):159-186. 
http://www.ncbi.nlm.nih.gov/pubmed/12847557. Accessed November 27, 2015. 
201.  Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of 
muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 
2009;30(3):148-155. doi:10.1016/j.tips.2008.12.002. 
202.  Melancon BJ, Hopkins CR, Wood MR, et al. Allosteric modulation of seven 
transmembrane spanning receptors: theory, practice, and opportunities for central 
nervous system drug discovery. J Med Chem. 2012;55(4):1445-1464. 
doi:10.1021/jm201139r. 
203.  Mohr K, Schmitz J, Schrage R, Tränkle C, Holzgrabe U. Molecular alliance-from 
orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled 
receptors. Angew Chem Int Ed Engl. 2013;52(2):508-516. 
doi:10.1002/anie.201205315. 
204.  Mohr K, Tränkle C, Kostenis E, Barocelli E, De Amici M, Holzgrabe U. Rational 
design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol. 
2010;159(5):997-1008. doi:10.1111/j.1476-5381.2009.00601.x. 
205.  Valant C, Robert Lane J, Sexton PM, Christopoulos A. The best of both worlds? 
Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. Annu Rev 
Pharmacol Toxicol. 2012;52:153-178. doi:10.1146/annurev-pharmtox-010611-
134514. 
206.  Portoghese PS. From Models to Molecules:  Opioid Receptor Dimers, Bivalent 
 Bibliography  
295 
 
Ligands, and Selective Opioid Receptor Probes †. J Med Chem. 2001;44(14):2259-
2269. doi:10.1021/jm010158+. 
207.  Steinfeld T, Mammen M, Smith JAM, Wilson RD, Jasper JR. A novel multivalent 
ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic 
receptor. Mol Pharmacol. 2007;72(2):291-302. doi:10.1124/mol.106.033746. 
208.  Bock A, Merten N, Schrage R, et al. The allosteric vestibule of a seven 
transmembrane helical receptor controls G-protein coupling. Nat Commun. 
2012;3:1044. doi:10.1038/ncomms2028. 
209.  Lane JR, Donthamsetti P, Shonberg J, et al. A new mechanism of allostery in a G 
protein–coupled receptor dimer. Nat Chem Biol. 2014;10(9):745-752. 
doi:10.1038/nchembio.1593. 
210.  Melchiorre C, Cassinelli A, Quaglia W. Differential blockade of muscarinic 
receptor subtypes by polymethylene tetraamines. Novel class of selective 
antagonists of cardiac M-2 muscarinic receptors. J Med Chem. 1987;30(1):201-204. 
http://www.ncbi.nlm.nih.gov/pubmed/3806594. Accessed November 27, 2015. 
211.  Christopoulos A, Grant MK, Ayoubzadeh N, et al. Synthesis and pharmacological 
evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp 
Ther. 2001;298(3):1260-1268. http://www.ncbi.nlm.nih.gov/pubmed/11504829. 
Accessed November 27, 2015. 
212.  Rajeswaran WG, Cao Y, Huang XP, et al. Design, synthesis, and biological 
characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole 
derivatives as selective muscarinic agonists. J Med Chem. 2001;44(26):4563-4576. 
http://www.ncbi.nlm.nih.gov/pubmed/11741475. Accessed November 27, 2015. 
213.  Moser U, Gubitz C, Galvan M, Immel-Sehr A, Lambrecht G, Mutshcler E. 
Aliphatic and heterocyclic analogues of arecaidine propargyl ester. Structure-
activity relationships of mono- and bivalent ligands at muscarinic M1 (M4), M2 
and M3 receptor subtypes. Arzneimittelforschung. 1995;45(4):449-455. 
http://www.ncbi.nlm.nih.gov/pubmed/7779140. 
 
   
296 
 
 
